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1The plasma proteome is among the most challenging bio-logical matrices to analyze.1 An untargeted proteomics 
approach results in oversampling of abundant proteins, leav-
ing peptides from low abundant proteins undetected.2 The 
selectivity of multiple reaction monitoring (MRM) on the 
triple quadrupole (QqQ) mass spectrometer (MS) ensures 
that lower abundant proteins can be targeted using stable 
isotope-labeled standards (SIS) for absolute quantification.3,4 
MRM has been used as the gold standard in small molecule 
quantification for decades5 and has recently been explored 
for measuring plasma proteins.6–10 Other MS approaches for 
plasma proteomics have also been described, including Stable 
Isotope Standards and Capture by Anti-Peptide Antibodies6 
and data-independent acquisition,7 but these can add sev-
eral steps to the work flow and increase data analysis time, 
limiting the application for epidemiological studies. Instead, 
throughput and costs are critical considerations for applica-
tions in clinical research. The latest high sensitive QqQ MS 
combined with high-performance liquid chromatography 
(HPLC) offers the potential to eliminate the need for protein 
enrichment or fractionation, which limits throughput and also 
introduces technical variability.7,11–14 A recent study demon-
strated robust analytic performance for MRM analyses across 
laboratories and instrument platforms,15 a prerequisite for the 
advancement of MS-based protein quantification for routine 
clinical applications.
See Clinical Perspective
Among the numerous potential biomarkers cited in the 
proteomics literature, only few have obtained regulatory 
approval.16 Several clinical studies using targeted plasma pro-
teomics have been published, including both nanoflow8,17 and 
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standard-flow methods,9,18,19 but the sample numbers are low 
(<100). Currently, the preferred high-sensitivity proteomics 
workflows use nanoflow LC, which is slow in nature and ham-
pered by poor robustness during continuous operation. A pre-
vious comparison of standard-flow and nanoflow LC-MRM 
was limited to 30 samples.10 The need for validating the appli-
cability of standard-flow MRM method to larger cohorts is 
apparent.3,20
In this study, we have applied a standard-flow LC-MS 
method to quantify 100 proteins in plasma samples from the 
community-based, prospective Bruneck cohort (n=668 sam-
ples, >1500 injections), which is, to our knowledge, the largest 
targeted proteomics study on human plasma samples to date.
Methods
The data, analytic methods, and study materials will not be made 
available to other researchers for purposes of reproducing the re-
sults or replicating the procedure because of the limited availability 
of plasma samples. However, the raw files (a subset of 44 samples) 
and transition list from both nanoflow and standard-flow platforms 
were deposited into the PeptideAtlas SRM Experiment Library (Data 
set Identifier: PASS00949). The MRM data are also deposited into 
Panorama Public: https://panoramaweb.org/labkey/plasmadive1.url 
(MacCoss Laboratory Software).
Human Plasma Samples
The human plasma samples were from the year 2000 evaluation of 
the prospective, community-based Bruneck Study.21,22 The Bruneck 
Study protocol conformed to the Declaration of Helsinki and was 
approved by the Local Ethics Committee (Bolzano, Italy). All par-
ticipants provided their written informed consent before entering the 
study. Blood samples were drawn after an overnight fast and 12 hours 
of abstinence from smoking. Citrate plasma samples were divided 
into aliquots and stored at −80°C. In this study, the plasma samples 
(n=668) were used for observation purposes only. The serotransferrin 
(TRFE) clinical measurement was conducted using a Behring BNA II 
nephelometer system immediately after the plasma sample collection.
Sample Preparation Using PlasmaDive
Plasma samples were analyzed using the PlasmaDive MRM Panel 
(beta test version; Biognosys AG, CH). Sample processing was semi-
automated on a Bravo liquid handling system (Agilent Technologies). 
In brief, 10 μL of plasma was denatured, reduced, and alkylated ac-
cording to the manufacturer’s instruction, followed by spiking-in of 
SIS peptides and an in-solution digestion overnight using trypsin 
(Thermo Fisher Scientific). After solid-phase extraction cleanup with 
a 96-well C18 spin plate (Harvard apparatus), the eluted peptides were 
dried using a SpeedVac (Thermo Fisher Scientific) and resuspended 
in 40 μL of LC solution with addition of indexed retention time (RT) 
peptides (Biognosys, CH) to adjust the RT variability across differ-
ent LC-MS runs. A pooled sample was used as quality control (QC) 
sample with repeated injections during continuous operation.
Nanoflow HPLC-MRM
On the nanoflow platform (Thermo U3000 RSLCnano; Thermo 
Fisher Scientific), 2 μL of digested sample was directly injected 
onto a 15-cm column (Acclaim PepMap 100, C18, 15 cm×75 µm, 3 
µm, 100 Å) and separated over a 32-minute gradient at 300 nL/min 
(0–30 min, 5%–35% B; 30–32 min, 35%–99% B; 32–40 min, 99% 
B; 40–70 min, 2% B; A=1% acetonitrile, 0.1% formic acid; B=97% 
acetonitrile, 0.1% formic acid). The nanoflow HPLC was interfaced 
to a TSQ Vantage MS (Thermo Fisher Scientific). Analysis was per-
formed using the following parameters: Q1 resolution 0.7 Th, Q2 
collision gas pressure 1 mTorr, Q3 resolution 0.7 Th. Eight hundred 
fifty transitions were exported from SpectroDive software version 6 
(Biognosys AG, CH) and scheduled with a cycle time of 3 s and a RT 
window of 4 minutes. The transition list is shown in Table I in the 
Data Supplement. The SIS peptides were labeled with heavy lysine 
(+8 Da) or arginine (+10 Da), and the cysteines were carbamidometh-
ylated (+57 Da).
Standard-Flow HPLC-MRM
The same samples were also analyzed on a standard-flow platform 
(Agilent 1290 Infinity II LC). Ten microliters of digest was directly 
injected onto a 25-cm column (AdvanceBio Peptide Mapping, C18, 
2.1 mm×250 mm, 2.7um, 120 Å) and separated over a 23-minute gra-
dient at 350 μL/min (0–0.5 min, 5%–7.5% B; 0.5–18 min, 7.5%–28% 
B; 18–20 min, 28%–95% B; 20–23 min, 95% B; 23–27 min, 5% B; 
A=0.1% formic acid in H2O; B=0.1% formic acid in acetonitrile) at 
50°C. The standard-flow LC was interfaced to an Agilent 6495 QqQ 
MS, and both were controlled by MassHunter Workstation soft-
ware (version B.08.00). Both Q1 and Q3 were set at unit resolution 
(0.7 Th), and the following parameters were used: Delta EMV 350, 
Frag 380 V, Cell Acc 4 V, Gas Temp 200°C, Gas Flow 11 L/min, 
Nebulizer 35 psi, Sheath Gas Heater 250°C, Sheath Gas Flow 12 L/
min, Capillary 4 kV, VCharging 300, Ion Funnel Pos High-Pressure 
RF 180 V, and Pos Low-Pressure RF 90 V. Seven hundred sixty-five 
transitions were scheduled using Dynamic MRM with a cycle time of 
0.5 s and a RT window of 0.8 minutes. The transition list is provided 
in Table II in the Data Supplement.
PlasmaDive MRM Data Analysis
The data were analyzed using SpectroDive, and protein concentra-
tions were calculated using the light/heavy ratio and the concentra-
tion of spiked-in SIS peptides. The data with a Q value <0.01 were 
included in the final results.
Sample Preparation for Standard Curve
Pooled human plasma was digested using the PlasmaDive protocol 
(Biognosys, CH) without SIS peptides. Then 2 pools were made: pool 
1, 90 µL of digested plasma +30 µL of SIS peptides; and pool 2, 450 
µL of digested plasma+100 µL of LC solution (5% acetonitrile, 0.1% 
formic acid)+50 µL of 10x iRT standard (Biognosys, CH). Pool 1 rep-
resents 1× SIS in plasma matrix, and pool 2 is the background plasma 
matrix. Serial dilutions of SIS peptides were performed in plasma 
matrix (1:10, 1:100, 1:1000, 1:10 000, 1:100 000). The same proce-
dure was followed to make serial dilutions of SIS peptides in LC solu-
tion (5% acetonitrile, 0.1% formic acid) only. On the nanoflow HPLC 
system, the injection volume was 3 µL. On the standard-flow HPLC 
system, the injection volume was 15 µL. The limit of detection was 
calculated by using the mean response of the blank samples+3×SD. 
The limit of quantification was calculated by using the mean response 
of the blank samples+10×SD.
Enzyme-Linked Immunosorbent Assays
The levels of platelet factor 4 (PLF4) were measured using the 
DuoSet ELISA Development kits (DY795) and the DuoSet Ancillary 
Reagent Kit 2 (DY008, R&D Systems, Minneapolis) according to the 
manufacturer’s instructions. Absorbance at 450 nm was measured on 
a Tecan Infinite 200 Pro plate reader (Tecan Group Ltd, Männedorf, 
Switzerland) using 570 nm as a reference wavelength. Results were 
calculated using a 4-parameter logistic fit.
PeptiQuant MRM Assay Biomarker Assessment Kit 
(BAK-76, MRM Proteomics)
The plasma samples were processed according to the manufacturer’s 
instruction. In brief, the individual plasma samples were diluted 1:10 
using 25 mmol/L ammonium bicarbonate first, and pooled plasma 
was used as reference sample. Thirty microliters of diluted plasma 
sample or pooled plasma (×4 wells) was mixed with 177 μL of 25 
mmol/L ammonium bicarbonate and 37 μL of 10% sodium deoxy-
cholate to denature proteins. The proteins were reduced by 5 mmol/L 
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tris(2-carboxyethyl) phosphine and alkylated by 10 mmol/L iodo-
acetamide. The remaining iodoacetamide was quenched by adding 
10 mmol/L dithiothreitol. Trypsin solution (23.3 μL; 0.9 mg/mL; 
Affymetrix) was added and the samples incubated at 37°C for 16 
hours. Six dilutions (from 0.5 to 250 fmol/μL) of the SIS peptide mix-
ture for reference samples were prepared for the reference samples. 
Fifty microliters of the SIS peptide mixture for reference samples was 
added to 227 μL pooled reference plasma digest and 277 μL of 1% 
formic acid. Next, 227 μL of each plasma digest was mixed with 50 
μL of 25 fmol/μL SIS peptide mixture for the experimental samples 
and 277 μL of 1% formic acid. After centrifugation at 12 000g for 
10 minutes, 444 μL of peptide supernatant was desalted and con-
centrated by solid phase extraction (Oasis HLB Extraction Cartridge, 
Waters). The eluted peptides were freeze-dried and resuspended in 
100 μL of 0.1% formic acid. Each reference sample (standard A–F) 
was injected 3× using 15 μL per injection, and each experimental 
sample was injected once using 15 μL per sample. The samples 
were run on the standard-flow platform (Agilent 1290 Infinity II LC 
with 6495 QqQ MS) and analyzed using MassHunter Quantitative 
Analysis (Agilent) and Qualis-SIS (University of Victoria, Canada) 
following the manufacturer’s instructions.
Milliplex Map Human Apolipoprotein Magnetic 
Bead Panel Kit
Apolipoproteins (apo) were measured using Milliplex Map Human 
Apolipoprotein Magnetic Bead Panel Kit, 96-well plate assay (Cat No. 
APOMAG-62K, Millipore) following the manufacturer’s instructions. 
In brief, plasma samples were diluted 1:4000 in the assay buffer in 
duplicate, and 10 μL of diluted plasma was used per well. One hun-
dred fifty microliters of each antibody-immobilized bead for apoA1, 
apoA2, apoC2, apoC3, and apoE was mixed and topped up to 3 mL 
with Bead diluent. QC1, QC2, and the apolipoprotein calibrator cock-
tail were reconstituted with 250 μL deionized water and mixed thor-
oughly. The calibrator was further diluted to 1:5, 1:25, 1:125, 1:625, 
1:3125, 1:15 625, in Assay buffer. After washing and drying the plate, 
65 μL of Assay buffer, 10 μL of Assay buffer/serial dilution of cali-
brators/QC1/QC2/diluted samples, and 25 μL of the premixed beads 
were added to each well before the plate was sealed, wrapped in foil, 
and incubated at 700 rpm for 1 hour at room temperature. A handheld 
magnetic plate was used to gently remove well contents, and the plate 
was washed 3× using the Washing buffer. Subsequently, 50 μL of de-
tection antibodies mixture was added to each well, and the plate was 
incubated at 700 rpm for 30 minutes at room temperature. The wash 
step was repeated before adding 50 μL of streptavidin–phycoerythrin 
per well for a final incubation of 30 minutes. After a third wash step, 
the plate was prepared for analysis on FlexMap 3D by resuspending 
the beads in 100 μL of sheath fluid on a plate shaker for 5 minutes. The 
median fluorescent intensity data were analyzed to calculate apolipo-
protein concentrations in the samples. A dilution factor of 4000 was 
applied to the concentrations to correct for the sample dilution, and an 
average of the 2 technical replicates of each sample was calculated.
Statistics
Agreement of nanoflow and standard-flow measurements for all pro-
teins measured was described graphically by overlaying 95% data 
ellipses on the x=y line indicating perfect agreement. Agreement of 
nanoflow and standard-flow measurements with independent refer-
ence measurements for 2 exemplary proteins (TRFE and PLF4) was 
analyzed by means of Bland–Altman plots,23 and the dependence 
of measurement difference on measurement mean was summa-
rized by ordinary least squares regression lines. Both proteins were 
log transformed toward normality beforehand. Agreement between 
PlasmaDive, PeptiQuant BAK-76, and Luminex measurements was 
analyzed using scatter plots, Pearson correlation, and Deming regres-
sion, which in contrast to ordinary least squares regression consid-
ers error in both x and y. Comparative performance of nanoflow and 
standard-flow methodology in a clinical context was evaluated by 
comparing associations with the same clinical variables of measure-
ments produced by either method. Significance of association was 
derived from Pearson correlation analysis, except for the categorical 
clinical variables sex and diabetes mellitus, for which Student t tests 
were used. Analyses were conducted using R 3.3.2.
Results
Plasma Proteomics in a Community-Based Cohort
MRM-MS was applied to plasma samples of the prospective, 
community-based Bruneck study (n=668, year 2000 evalua-
tion) using nanoflow LC-MS (Ultimate3000 RSLCnano inter-
faced to a TSQ Vantage QqQ MS; Thermo Fisher Scientific) 
as recommended by the manufacturer (PlasmaDive; Biogno-
sys, CH). The raw files were analyzed using SpectroDive soft-
ware, which calculated concentrations for the majority of the 
100 proteins.
When using the nanoflow LC-MS platform, each sample 
required a 32-minute gradient for separation of the peptides 
and a further 38 minutes for washing and reequilibrating the 
column. The total run time for the entire cohort (n=668) was 2 
months because of the inherent complications of nanoflow LC, 
for example, blockage of column or spray emitter, prolonged 
purging/calibration of the nanoflow pump, and shifts in RT.
To further the application of plasma proteomics to larger 
cohorts, we transferred the nanoflow LC-MS method onto 
a standard-flow platform consisting of an Agilent 1290 
Infinity II HPLC interfaced to an Agilent 6495 QqQ MS. 
A 27-minute LC method was successfully established to 
measure the same 200 peptides (light and heavy peptides 
for 100 proteins) with a minimum of 3 transitions for each 
peptide. The lower limit of detection and the lower limit of 
quantification were evaluated on both the nanoflow and the 
standard-flow platform (Table III in the Data Supplement 
and Figure I in the Data Supplement). To obtain a similar 
sensitivity to the nanoflow method, 5× more sample vol-
ume (10 μL) had to be injected using the standard-flow 
approach compared with nanoflow (2 μL). With the larger 
sample load, a similar detection range could be achieved 
despite the switch to standard-flow LC-MS with higher ion 
suppression. When using the nanoflow system, median SIS 
peptide intensities in plasma samples were only decreased 
by one third compared with the intensities in the LC solu-
tion (Figure II in the Data Supplement). Using the standard-
flow system, the median lower limit of detection was about 
2-fold higher in the SIS diluted with plasma than with LC 
solution (Table III in the Data Supplement).
Among the proteins quantified by both methods, the results 
showed a high correlation (r=0.998) in all 668 samples (Figure 1 
and Table IV in the Data Supplement) apart from few notable 
exceptions: for β-2-glycoprotein 1 (APOH_HUMAN) because 
of chromatography issues with the SIS peptide after digestion, 
for fibrinogen β chain (FIBB_HUMAN) and for serum paraox-
onase/arylesterase 1 (PON1_HUMAN) because of a RT window 
error, and for α-2-macroglobulin (A2MG_HUMAN) because of 
a manufacturing error with a missing SIS peptide.
To demonstrate that both high and less abundant pro-
teins were measured reliably, we selected TRFE and PLF4 as 
examples to be compared with a reference measurement from 
a routine clinical assay for TRFE or ELISA for PLF4. The 
high abundant TRFE displayed similar agreement with the 
reference measurement for both the nanoflow and standard-
flow LC-MS measurements (Figure 2A). For less abundant 
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PLF4, standard-flow LC-MS displayed closer agreement with 
the reference measurement, whereas nanoflow LC-MS mea-
sured higher values than the reference measurement in the 
low concentration range and lower values in the high concen-
tration range, resulting in higher overall deviation from the 
reference measurement compared with standard-flow method 
(Figure 2B).
To evaluate the performance of the 2 LC-MS platforms, a 
pooled QC sample was injected periodically during continu-
ous operation while analyzing hundreds of samples on both 
platforms. For the peptides quantified on both platforms, the 
relative SD of the light or heavy peptide peak area on the 
nanoflow platform was much higher (light 38.07%–83.80%, 
heavy 37.92%–80.88%) compared with the standard-flow 
platform (light 5.12%–28.51%, heavy 5.59%–28.14%) with P 
<0.001. After adjustment to heavy peptides, the variations of 
the light:heavy ratio in both platforms were more comparable 
(nanoflow 1.68%–16.56%, standard flow 1.34%–18.52%; 
P=0.651; Figure 3). Nonetheless, the nanoflow LC-MS sys-
tem showed higher variation for the absolute signal intensities 
between different runs.
When comparing the stability of the RT, in the nanoflow 
system, the SIS peptides eluted from 3.62 to 27.56 min-
utes. The SD of the RT of each peptide ranged from 0.26 to 
0.44 minutes over 700 injections (Figure 4A). The standard 
peptides eluted in the standard-flow system from 3.22 to 19.99 
minutes but with substantially less variation: the SD range 
was within 0.003 to 0.05 minutes (Figure 4B).
Comparison of Commercial MRM Kits for Plasma 
Proteomics
A different MRM kit (PeptiQuant MRM Assay Biomarker 
Assessment Kit BAK-76, MRM Proteomics) was used to com-
pare the apolipoprotein measurements with the PlasmaDive 
(Biognosys, CH) results (n=44). The plasma samples were 
processed and analyzed on the standard-flow platform with 15 
µL injection volume according to the manufacturer’s instruc-
tions. The target peptide concentrations were calculated 
using both single-point calibration and relative response–
relative concentration standard curve. The results derived 
from the single-point calibration for apolipoprotein measure-
ments were compared with the PlasmaDive (Biognosys, CH) 
method (Figure 5). In general, the results were highly cor-
related between the 2 commercial kits when using the same 
proteotypic peptide (apo(a) r=0.928, apoC2 r=0.922, apoE 
r=0.930). For the same protein with different proteotypic pep-
tides, the MRM-based measurements still showed good cor-
relation (r>0.7). However, the absolute concentrations varied 
between the 2 kits with extreme ratios for apo(a) (6.01) and 
apoB (3.22). In both kits, a peptide (GTYSTTVTGR) within 
the Kringle repeat was selected for the measurement of apo(a) 
(APOA_HUMAN). The number of Kringle repeats, however, 
greatly varies between individuals.24,25 Although the peptide 
is readily detectable in plasma digests, this peptide is not a 
suitable target for measuring apo(a) concentrations. Instead, 
both commercial MRM kits provide a readout for Kringle size 
(Kringle mass). For this reason, apo(a) was excluded from the 
final version of the PlasmaDive kit (Biognosys, CH).
Comparison to Antibody-Based Assays
Next, to evaluate the compatibility of MS-based methods 
with the traditional antibody-based method, we compared 
PlasmaDive (n=44) with an antibody-based Luminex assay 
(Milliplex MAP Human Apolipoprotein Magnetic Bead Panel 
kit, Millipore) for 5 apolipoproteins (apoA1, apoA2, apoC2, 
apoC3, and apoE). The PlasmaDive and the Luminex results 
showed very high correlation for apoC2 (r=0.917), apoC3 
(r=0.944), and apoE (r=0.886; Figure 6). However, the MRM 
measurements returned lower concentrations compared with 
the antibody-based analysis. This difference was particu-
larly pronounced for apoA2: the concentration of apoA2 was 
≈27.7% of that of apoA1 using the Luminex kit. The MRM 
data, however, estimated apoA2 concentration to be just 3.7% 
of that of apoA1 (Figure III in the Data Supplement).
Association of Protein Measurements With Clinical 
Variables
Figure 7 shows the associations of protein measures with 
clinical variables. As expected, most proteins showed a simi-
lar strength of association when using either the nanoflow or 
standard-flow method, and the measurements of apoA1 and 
apoB were strongly associated with HDL-C and LDL-C, 
respectively (Figure IV in the Data Supplement). Nonethe-
less, 51.1% of comparisons returned lower P values with the 
Figure 1. Comparison between nanoflow and standard-flow 
liquid chromatography (LC) method. Plasma samples from the 
Bruneck Study (year 2000 evaluation, n=668) were digested, and 
100 proteins were measured using multiple reaction monitoring 
(MRM) with stable isotope-labeled standards (SIS) peptides as 
spike-in standards. Samples were denatured, reduced, alkylated, 
and digested with trypsin using PlasmaDive MRM Panel kit (Biog-
nosys, CH) on an automated liquid handling robot (BRAVO, Agi-
lent) following the manufacturer’s instruction. The SIS peptides 
were spiked-in before tryptic digestion. The digested peptides 
were purified and analyzed on both nanoflow high-performance 
liquid chromatography (HPLC) mass spectrometry (MS) and stan-
dard-flow HPLC-MS. The results were analyzed using Spectro-
Dive software (Biognosys, CH). Protein concentrations measured 
by nanoflow and standard-flow LC-MS are highly correlated with 
the exception of β-2-glycoprotein 1 (APOH_HUMAN) because of 
a splitting of the chromatographic peak for the reference peptide.
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standard-flow method, but this was not significant (P=0.5 with 
t test und P=0.4 with Wilcoxon test). Importantly, there was 
less interference with the MRM transitions in the standard-
flow method. The most discordant protein measurements are 
highlighted in Figure V in the Data Supplement.
Discussion
In this study, we have developed a standard-flow LC-MS 
workflow to analyze 100 proteins in plasma samples from a 
community-based, prospective cohort (n=668 samples, >1500 
injections). The optimized standard-flow LC-MS method 
Figure 2. Comparison for high and low abundant plasma proteins. For the high abundant plasma protein TRFE, the nanoflow and stan-
dard-flow results were similar when compared with traditional measurements (A). For the less abundant plasma protein PLF4, nanoflow 
measurements are higher at low concentration end and lower at high concentration end compared with traditional measurements. The 
standard-flow measurements showed lower variation than nanoflow liquid chromatography (LC) mass spectrometry (MS; B). In the Bland–
Altman plots, x axis is the mean of log-transformed protein concentration of subject-wise multiple reaction monitoring (MRM) and clinical 
measurement; y axis is the difference between these 2 measurements.
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improved reproducibility, robustness, and throughput in com-
parison to the traditional proteomics method using nanoflow 
LC. Using the standard-flow LC-MS method, the Bruneck 
cohort (n=668) could be analyzed in just over 2 weeks rather 
than 2 months without the need for enrichment, protein deple-
tion, or fractionation of peptides.
The PlasmaDive LC-MS method recommended by the manu-
facturer is based on a nanoflow LC method, and the protocol 
requires minimal user optimization. For large cohorts, however, 
analysis time becomes prohibitive. For example, for the samples 
of the Bruneck study, the total run time extended to 2 months 
because of the inherent complications that arose from nanoflow 
LC applications. The extended run time also required clean-
ing and calibration of the QqQ MS in between. Thus, nanoflow 
LC-based workflows did not allow the throughput required for 
clinical research applications. On the other hand, standard-flow 
LC offers greater stability and robustness and thus less variability 
but has only been described in small-scale studies.6–10,17 By apply-
ing MRM-MS to a community-based cohort, we demonstrate the 
advantages of shifting from a nanoflow LC to a standard-flow LC 
method, ideally suited to epidemiological studies: The HPLC run 
time was shortened from 70 minutes in nanoflow LC-MS to 27 
minutes. Accordingly, the cycle time was reduced to 0.5 s, and 3 
transitions per peptide were used to accommodate the 200 peptides 
into the narrower peak width (0.2 minutes) and maintain a reason-
able peak shape (≈15 data points). Because of the different ioniza-
tion properties between the nanospray source and Jet Stream ESI 
source, the most abundant precursor charge state of some peptides 
had to be changed to get the best signal intensity. These transitions 
were also optimized independently using a quadrupole time-of-
flight MS/MS (Agilent) system, which confirmed that the selec-
tion of the 3 transitions did not decrease the accuracy or sensitivity 
for reliable MRM quantification (data not shown). In fact, some 
of the peptide measurements were even improved by removal of 
transitions with a saturated peak or of an interfering peak.
Reduced sensitivity and increased ion suppression are the 
main limitations of standard-flow LC compared with nanoflow 
LC.26,27 We have tested the limit of detection and ion suppression 
on both platforms. With the increased injection volume (5×), 
the standard-flow LC system reached the same sensitivity as the 
nanoflow LC system. However, this may also be in part because 
of the better sensitivity of the QqQ MS coupled to standard LC. 
The increased injection volume on the standard-flow platform 
is not problematic when the sample source is plasma, as the 
high protein concentration means that only a small volume (10 
µL) is required to perform the analysis. Our ion suppression 
test revealed that some of the SIS peptides have a lower limit of 
quantification in LC solution compared with plasma, whereas 
others are not influenced as much. The ion suppression depends 
in part on the ionization properties of the peptides and coeluting 
abundant peptides. For low abundant proteins, the effects of ion 
suppression can be compensated by increasing the concentra-
tions of spike-in SIS peptides as long as they remain with simi-
lar concentration to the target peptides.
Once the standard-flow LC-MS method was optimized, 
we analyzed 668 samples plus regular QCs, back-to-back 
with a total run time of 15 days. Overall, we demonstrate the 
advantages of shifting from a nanoflow LC to a standard-flow 
LC method. This is because of 2 main reasons:
1. The 2.1 mm inner diameter column had no blockages 
during continuous operation for a few months.
2. The better RT stability means smaller and less overlap-
ping RT windows in a scheduled MRM, therefore, longer 
Figure 3. Comparison of relative SD (RSD) between nanoflow 
and standard-flow liquid chromatography (LC). The quality con-
trol samples on the nanoflow and standard-flow system showed 
similar RSD of the light/heavy ratio, but the light or heavy peptide 
peak area showed a higher variation on the nanoflow system.
Figure 4. Comparison of retention time (RT) between nanoflow 
and standard-flow liquid chromatography (LC). The RT of each 
peptide showed higher variation across 668 samples using nano-
flow LC (A) compared with standard-flow LC (B).
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dwell times for each transition resulting in better signal 
intensities and less missing data.
We have recently applied this standard-flow method to com-
pare the associations of the different apolipoproteins with car-
diovascular risk.22 We also measured the same apolipoproteins 
in an intervention study using antisense therapy for apoC3. 
Plasma apoC3 levels were decreased by 75%, whereas apoC2 
and apoE levels showed a 50% drop on antisense treatment. 
These apolipoproteins are predominantly associated with 
very-low-density lipoproteins, and there is increasing evi-
dence for a role of very-low-density lipoproteins in addition 
to low-density lipoproteins in atherosclerosis.28
MRM Versus Alternative MS Quantification 
Methodologies
Different MS approaches for plasma proteomics have been 
described in recent years. Stable Isotope Standards and Capture 
by Anti-Peptide Antibodies uses antipeptide antibodies to enrich 
peptides of interest after addition of stable isotope-labeled inter-
nal peptide standards to the protein digest. Light and heavy pep-
tides are enriched simultaneously, resulting in a sensitive and 
accurate quantification of the peptides of interest.29,30 Data-inde-
pendent acquisition analysis offers a hypothesis-free approach 
and allows the analysis of a larger number of proteins. The sam-
ples are converted into digital archive as all detectable peptides 
in the samples are fragmented and MS/MS spectra are acquired. 
However, sensitivity and dynamic range are limited in nonde-
pleted plasma samples. In a subcohort of the UK Twin registry 
(n=232), 342 plasma proteins could be analyzed by Sequential 
Windowed Acquisition of All Theoretical Fragment Ion Mass 
Spectra analysis, but essential steps including depletion of the 
14 most abundant proteins and fractionation into 6 fractions 
were needed.7 Complicated analytic workflows or demanding 
data analysis will limit the wider application of proteomics in 
epidemiology. Throughput and costs are critical considerations 
for applications in clinical research. Thus, we focused on a stan-
dard-flow LC-MRM method for plasma proteomics to meet the 
requirements for epidemiological studies in terms of reducing 
costs and increasing throughput. Further improvements may 
include parallel reaction monitoring with comparable linearity, 
dynamic range and precision compared with MRM,31,32 and less 
method development time for new targets as only the accurate 
precursor masses of the target peptides are required. For all MS-
based methods, the choice of the proteotypic peptide is critical 
for meaningful quantification of a protein and must not only be 
based on criteria for LC-MS analysis, such as peptide length, 
uniqueness, post-translational modifications, physiochemi-
cal properties, and abundance, but also biological function as 
exemplified by the reference peptide selected for apo(a).
LC-MRM-MS Versus Antibody-Based Protein 
Measurements
Antibody-based methods require lower investment in equip-
ment and offer automation and high throughput. Compared 
with LC-MS, however, immunoassays rely on the specificity 
and selectivity of the binders. The necessity of good antibodies 
results in high running costs, gives rise to batch to batch incon-
sistencies, and limits the multiplexing capability. Moreover, 
Figure 5. Comparison between multiple reaction monitoring (MRM)–based kits from 2 different vendors. When comparing the concentra-
tion of the same apolipoproteins measured by PlasmaDive (PD) and PeptiQuant BAK-76 (MRM), we observed a high correlation between 
the 2 kits, especially for those apolipoproteins measured using the same peptide (apo(a) r=0.928, apoC2 r=0.922, apoE r=0.930). How-
ever, the absolute concentrations varied between 2 kits with extreme ratios for apo(a) (6.01) and apoB (3.22). The linear regression formula 
is shown as PD=a+MRM×b on top of each graph.
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only external standard but no internal standards are used. 
LC-MS has a higher initial cost for instrumentation and mainte-
nance and offers a lower throughput at this moment. However, 
LC-MS methods are faster and cheaper to develop; they offer 
high multiplexing capability within a dynamic range for the 
simultaneous detection of low and high abundant analytes over 
4 to 5 orders of magnitude; and stable isotope-labeled internal 
standards reduce variability while increasing robustness.3
Both MRM- and antibody-based absolute quantification 
methods rely on the accuracy of the standard. In general, lower 
concentrations were detected by the MRM method than the 
antibody-based method. We have investigated the digestion 
efficiency by measuring known amount of human TRFE in a 
fetal bovine serum background using the PlasmaDive kit. The 
PlasmaDive results returned about 88% of the spike-in concen-
tration when the transferrin concentration is high and dropped 
to 60% when the concentration is low (data not shown). These 
differences may come from the weighting error, the incomplete 
digestion, the peptide loss during the experiment procedure, 
and the ion suppression especially when measuring at low con-
centrations. An inherent risk of using peptide standards in a 
relatively low concentration is that every sample preparation 
step may cause losses, that is, because of the hydrophobic pep-
tides binding to the surface of plastic ware.33 This may also 
be the reason for the variation of the late eluting peptides (eg, 
VSFLSALEEYTK from apoA1). Ideally, SIS proteins should 
be used instead of SIS peptides for MRM-based measure-
ments. Stable isotope-labeled proteins, however, are signifi-
cantly more expensive than using SIS peptides.34 On the other 
hand, ELISA kits tend to use protein standards in physiologi-
cal buffers or in reference samples but without the biological 
matrix of the actual sample. Differences in the matrix between 
samples may interfere with the binding of the antibody to the 
antigen and thus influence the results. With MRM-MS, pro-
teins can be measured directly and the multiplexing capabil-
ity allows for measurements of biomarker panels in a single 
run. Although MRM-MS is routinely applied clinically for 
measuring small molecules,35–37 the use of MRM-MS could be 
expanded to protein measurements in future.
Conclusions
For large epidemiological studies, experimental variation 
has to be well controlled. We have successfully applied a 
standard-flow LC-MRM method to obtain tens of thousands 
of protein measurements in a community-based cohort. The 
standard-flow LC-MRM method resulted in significant time 
savings and offered higher precision and better reproducibil-
ity. Although the limitations of antibodies are well recognized, 
questions should also be raised about discordance between 
peptide measurements using LC-MS and the true protein con-
centration. For absolute quantification, protein standards may 
be required to adjust for tryptic digestion efficiency and to 
account for peptide losses, which might not always be similar 
for spike-in SIS and endogenous peptides.
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CLINICAL PERSPECTIVE
Despite the ongoing genetic sequencing efforts, the impact of most genetic variation on cardiovascular disease is still poorly 
understood. Attention has shifted to postgenomic technologies, including proteomics and lipidomics, to refine the cardiovas-
cular disease phenotypes at a molecular level. For omics measurements in epidemiological cohorts, experimental variation 
has to be well controlled to assure data comparability over time and between studies. We have successfully applied mass 
spectrometry to obtain plasma protein measurements in a community-based cohort using a standard-flow liquid chroma-
tography method. The standard-flow method resulted in significant time savings and offered higher precision and better 
reproducibility. The multiplexing capability of mass spectrometry combined with the standard-flow liquid chromatography 
method increased throughput and reduced the costs of large-scale protein measurements in epidemiological cohorts. For 
example, apolipoproteins can be measured with high specificity and precision using mass spectrometry. Our study dem-
onstrates the use of mass spectrometry for simultaneously measuring a broader panel of apolipoproteins than the current 
antibody-based apolipoprotein measurements used in the clinic.
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Supplemental	 Figure	 1.	 The	 standard	 curve	 of	 13	 apolipoproteins.	 The	 standard	 curve	 of	
apolipoproteins	using	both	nanoflow	system	with	3ul	injection	volume	(left)	and	standard	flow	system	






Supplemental	 Figure	 3.	 The	 ApoA1	 and	 ApoA2	 concentrations	 showed	 different	 ratios	 when	
measured	using	different	methods.	The	scatter	plot	using	the	PlasmaDiveTM	measurements	estimated	
























The	LOD/LOQ	were	expressed	as	ug/mL	and	were	calculated	based	on	3ul	 injection	volume	 in	 the	
nanoflow	 system	 and	 15ul	 injection	 volume	 in	 the	 standard	 flow	 system.	 Please	 note	 that	
APOA_HUMAN	 (with	 grey	 background)	 was	 removed	 and	 ALS_HUMAN	 was	 added	 in	 the	 final	
PlasmaDiveTM	panel.	
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Precursor	m/z Fragment	m/z CE Start	RT	(min) Stop	RT	(min) Polarity Comment
556.7666 302.1347 22.2 13.3 17.3 Positive A1AG1_HUMAN.SDVVYTDWK.2
556.7666 712.3301 22.2 13.3 17.3 Positive A1AG1_HUMAN.SDVVYTDWK.2
556.7666 910.4669 22.2 13.3 17.3 Positive A1AG1_HUMAN.SDVVYTDWK.2
556.7666 811.3985 22.2 13.3 17.3 Positive A1AG1_HUMAN.SDVVYTDWK.2
560.7737 720.3443 22.4 13.3 17.3 Positive A1AG1_HUMAN.SDVVYTDWK.2
560.7737 819.4127 22.4 13.3 17.3 Positive A1AG1_HUMAN.SDVVYTDWK.2
560.7737 918.4811 22.4 13.3 17.3 Positive A1AG1_HUMAN.SDVVYTDWK.2
560.7737 302.1347 22.4 13.3 17.3 Positive A1AG1_HUMAN.SDVVYTDWK.2
617.8564 869.5356 24.3 14.3 18.3 Positive A1AG2_HUMAN.EHVAHLLFLR.2
617.8564 968.6040 24.3 14.3 18.3 Positive A1AG2_HUMAN.EHVAHLLFLR.2
617.8564 548.3555 24.3 14.3 18.3 Positive A1AG2_HUMAN.EHVAHLLFLR.2
617.8564 798.4985 24.3 14.3 18.3 Positive A1AG2_HUMAN.EHVAHLLFLR.2
622.8610 879.5440 24.5 14.3 18.3 Positive A1AG2_HUMAN.EHVAHLLFLR.2
622.8610 978.6130 24.5 14.3 18.3 Positive A1AG2_HUMAN.EHVAHLLFLR.2
622.8610 808.5070 24.5 14.3 18.3 Positive A1AG2_HUMAN.EHVAHLLFLR.2
622.8610 558.3640 24.5 14.3 18.3 Positive A1AG2_HUMAN.EHVAHLLFLR.2
508.3109 415.2607 20.6 16.3 20.3 Positive A1AT_HUMAN.SVLGQLGITK.2
508.3109 829.5142 20.6 16.3 20.3 Positive A1AT_HUMAN.SVLGQLGITK.2
508.3109 716.4301 20.6 16.3 20.3 Positive A1AT_HUMAN.SVLGQLGITK.2
508.3109 418.2660 20.6 16.3 20.3 Positive A1AT_HUMAN.SVLGQLGITK.2
512.3180 426.2802 20.7 16.3 20.3 Positive A1AT_HUMAN.SVLGQLGITK.2
512.3180 724.4443 20.7 16.3 20.3 Positive A1AT_HUMAN.SVLGQLGITK.2
512.3180 419.2678 20.7 16.3 20.3 Positive A1AT_HUMAN.SVLGQLGITK.2
512.3180 837.5284 20.7 16.3 20.3 Positive A1AT_HUMAN.SVLGQLGITK.2
632.8302 762.4145 24.8 14.7 18.7 Positive A1BG_HUMAN.SGLSTGWTQLSK.2
632.8302 819.4359 24.8 14.7 18.7 Positive A1BG_HUMAN.SGLSTGWTQLSK.2
632.8302 920.4836 24.8 14.7 18.7 Positive A1BG_HUMAN.SGLSTGWTQLSK.2
632.8302 1007.5156 24.8 14.7 18.7 Positive A1BG_HUMAN.SGLSTGWTQLSK.2
636.8373 928.4978 25.0 14.7 18.7 Positive A1BG_HUMAN.SGLSTGWTQLSK.2
636.8373 770.4287 25.0 14.7 18.7 Positive A1BG_HUMAN.SGLSTGWTQLSK.2
636.8373 1015.5298 25.0 14.7 18.7 Positive A1BG_HUMAN.SGLSTGWTQLSK.2
636.8373 827.4501 25.0 14.7 18.7 Positive A1BG_HUMAN.SGLSTGWTQLSK.2
395.2289 529.2980 16.8 13.3 17.3 Positive A2AP_HUMAN.LFGPDLK.2
395.2289 676.3665 16.8 13.3 17.3 Positive A2AP_HUMAN.LFGPDLK.2
395.2289 375.2238 16.8 13.3 17.3 Positive A2AP_HUMAN.LFGPDLK.2
395.2289 472.2766 16.8 13.3 17.3 Positive A2AP_HUMAN.LFGPDLK.2
399.2360 537.3122 16.9 13.3 17.3 Positive A2AP_HUMAN.LFGPDLK.2
399.2360 684.3807 16.9 13.3 17.3 Positive A2AP_HUMAN.LFGPDLK.2
399.2360 383.2380 16.9 13.3 17.3 Positive A2AP_HUMAN.LFGPDLK.2
399.2360 480.2908 16.9 13.3 17.3 Positive A2AP_HUMAN.LFGPDLK.2
495.2800 890.4843 20.2 11.8 15.8 Positive A2GL_HUMAN.VAAGAFQGLR.2
495.2800 620.3515 20.2 11.8 15.8 Positive A2GL_HUMAN.VAAGAFQGLR.2
495.2800 748.4100 20.2 11.8 15.8 Positive A2GL_HUMAN.VAAGAFQGLR.2
495.2800 819.4472 20.2 11.8 15.8 Positive A2GL_HUMAN.VAAGAFQGLR.2
500.2841 630.3597 20.3 11.8 15.8 Positive A2GL_HUMAN.VAAGAFQGLR.2
500.2841 829.4554 20.3 11.8 15.8 Positive A2GL_HUMAN.VAAGAFQGLR.2
500.2841 758.4183 20.3 11.8 15.8 Positive A2GL_HUMAN.VAAGAFQGLR.2
500.2841 900.4925 20.3 11.8 15.8 Positive A2GL_HUMAN.VAAGAFQGLR.2
473.5372 560.2100 24.1 8.6 12.6 Positive A2MG_HUMAN.HYDGSYSTFGER.3
473.5372 609.2991 24.1 8.6 12.6 Positive A2MG_HUMAN.HYDGSYSTFGER.3
473.5372 361.1830 24.1 8.6 12.6 Positive A2MG_HUMAN.HYDGSYSTFGER.3
473.5372 508.2514 24.1 8.6 12.6 Positive A2MG_HUMAN.HYDGSYSTFGER.3
476.8733 560.2100 24.3 8.6 12.6 Positive A2MG_HUMAN.HYDGSYSTFGER.3
476.8733 619.3074 24.3 8.6 12.6 Positive A2MG_HUMAN.HYDGSYSTFGER.3
476.8733 371.1913 24.3 8.6 12.6 Positive A2MG_HUMAN.HYDGSYSTFGER.3
476.8733 518.2597 24.3 8.6 12.6 Positive A2MG_HUMAN.HYDGSYSTFGER.3
531.2975 300.1554 21.4 16.2 20.2 Positive AACT_HUMAN.EIGELYLPK.2
531.2975 633.3970 21.4 16.2 20.2 Positive AACT_HUMAN.EIGELYLPK.2
531.2975 357.2496 21.4 16.2 20.2 Positive AACT_HUMAN.EIGELYLPK.2
531.2975 819.4611 21.4 16.2 20.2 Positive AACT_HUMAN.EIGELYLPK.2
535.3046 827.4753 21.5 16.3 20.3 Positive AACT_HUMAN.EIGELYLPK.2
535.3046 365.2638 21.5 16.3 20.3 Positive AACT_HUMAN.EIGELYLPK.2
535.3046 641.4112 21.5 16.3 20.3 Positive AACT_HUMAN.EIGELYLPK.2
535.3046 300.1554 21.5 16.3 20.3 Positive AACT_HUMAN.EIGELYLPK.2
807.4072 779.4046 30.8 18.8 22.8 Positive ABCF1_HUMAN.IGFFNQQYAEQLR.2
807.4072 907.4632 30.8 18.8 22.8 Positive ABCF1_HUMAN.IGFFNQQYAEQLR.2
807.4072 1149.5647 30.8 18.8 22.8 Positive ABCF1_HUMAN.IGFFNQQYAEQLR.2
807.4072 616.3413 30.8 18.8 22.8 Positive ABCF1_HUMAN.IGFFNQQYAEQLR.2
812.4110 1159.5740 30.9 18.7 22.7 Positive ABCF1_HUMAN.IGFFNQQYAEQLR.2
812.4110 917.4720 30.9 18.7 22.7 Positive ABCF1_HUMAN.IGFFNQQYAEQLR.2
812.4110 626.3500 30.9 18.7 22.7 Positive ABCF1_HUMAN.IGFFNQQYAEQLR.2
812.4110 789.4130 30.9 18.7 22.7 Positive ABCF1_HUMAN.IGFFNQQYAEQLR.2
811.8538 1335.5885 30.9 11.8 15.8 Positive AFAM_HUMAN.AESPEVC[CAM]FNEESPK.2
811.8538 1109.4932 30.9 11.8 15.8 Positive AFAM_HUMAN.AESPEVC[CAM]FNEESPK.2
811.8538 1010.4248 30.9 11.8 15.8 Positive AFAM_HUMAN.AESPEVC[CAM]FNEESPK.2
811.8538 850.3941 30.9 11.8 15.8 Positive AFAM_HUMAN.AESPEVC[CAM]FNEESPK.2
815.8609 858.4083 31.1 11.8 15.8 Positive AFAM_HUMAN.AESPEVC[CAM]FNEESPK.2
815.8609 1117.5074 31.1 11.8 15.8 Positive AFAM_HUMAN.AESPEVC[CAM]FNEESPK.2
815.8609 1343.6027 31.1 11.8 15.8 Positive AFAM_HUMAN.AESPEVC[CAM]FNEESPK.2
815.8609 1018.4390 31.1 11.8 15.8 Positive AFAM_HUMAN.AESPEVC[CAM]FNEESPK.2
464.2504 651.3461 19.1 12.7 16.7 Positive ALBU_HUMAN.YLYEIAR.2
464.2504 764.4301 19.1 12.7 16.7 Positive ALBU_HUMAN.YLYEIAR.2
464.2504 359.2401 19.1 12.7 16.7 Positive ALBU_HUMAN.YLYEIAR.2
464.2504 488.2827 19.1 12.7 16.7 Positive ALBU_HUMAN.YLYEIAR.2
469.2545 661.3543 19.3 12.7 16.7 Positive ALBU_HUMAN.YLYEIAR.2
469.2545 774.4384 19.3 12.7 16.7 Positive ALBU_HUMAN.YLYEIAR.2
469.2545 369.2484 19.3 12.7 16.7 Positive ALBU_HUMAN.YLYEIAR.2
469.2545 498.2910 19.3 12.7 16.7 Positive ALBU_HUMAN.YLYEIAR.2
607.3397 1013.5561 24.0 13.7 17.7 Positive AMBP_HUMAN.TVAAC[CAM]NLPIVR.2
607.3397 871.4818 24.0 13.7 17.7 Positive AMBP_HUMAN.TVAAC[CAM]NLPIVR.2
607.3397 942.5189 24.0 13.7 17.7 Positive AMBP_HUMAN.TVAAC[CAM]NLPIVR.2
607.3397 711.4512 24.0 13.7 17.7 Positive AMBP_HUMAN.TVAAC[CAM]NLPIVR.2
612.3438 881.4901 24.1 13.7 17.7 Positive AMBP_HUMAN.TVAAC[CAM]NLPIVR.2
612.3438 952.5272 24.1 13.7 17.7 Positive AMBP_HUMAN.TVAAC[CAM]NLPIVR.2
612.3438 1023.5643 24.1 13.7 17.7 Positive AMBP_HUMAN.TVAAC[CAM]NLPIVR.2
612.3438 721.4595 24.1 13.7 17.7 Positive AMBP_HUMAN.TVAAC[CAM]NLPIVR.2
634.8823 600.4079 24.9 17.4 21.4 Positive ANGT_HUMAN.ALQDQLVLVAAK.2
634.8823 1084.6361 24.9 17.4 21.4 Positive ANGT_HUMAN.ALQDQLVLVAAK.2
634.8823 956.5775 24.9 17.4 21.4 Positive ANGT_HUMAN.ALQDQLVLVAAK.2
634.8823 713.4920 24.9 17.4 21.4 Positive ANGT_HUMAN.ALQDQLVLVAAK.2
638.8894 721.5062 25.0 17.4 21.4 Positive ANGT_HUMAN.ALQDQLVLVAAK.2
638.8894 964.5917 25.0 17.4 21.4 Positive ANGT_HUMAN.ALQDQLVLVAAK.2
638.8894 1092.6503 25.0 17.4 21.4 Positive ANGT_HUMAN.ALQDQLVLVAAK.2
638.8894 608.4221 25.0 17.4 21.4 Positive ANGT_HUMAN.ALQDQLVLVAAK.2
695.3816 623.3334 27.0 22.5 26.5 Positive ANT3_HUMAN.EVPLNTIIFMGR.2
695.3816 951.5080 27.0 22.5 26.5 Positive ANT3_HUMAN.EVPLNTIIFMGR.2
695.3816 837.4651 27.0 22.5 26.5 Positive ANT3_HUMAN.EVPLNTIIFMGR.2
695.3816 736.4174 27.0 22.5 26.5 Positive ANT3_HUMAN.EVPLNTIIFMGR.2
700.3857 633.3416 27.1 22.5 26.5 Positive ANT3_HUMAN.EVPLNTIIFMGR.2
700.3857 847.4734 27.1 22.5 26.5 Positive ANT3_HUMAN.EVPLNTIIFMGR.2
700.3857 746.4257 27.1 22.5 26.5 Positive ANT3_HUMAN.EVPLNTIIFMGR.2
700.3857 961.5163 27.1 22.5 26.5 Positive ANT3_HUMAN.EVPLNTIIFMGR.2
521.7618 533.3042 21.1 6.0 10.0 Positive APOA_HUMAN.GTYSTTVTGR.2
521.7618 333.1881 21.1 6.0 10.0 Positive APOA_HUMAN.GTYSTTVTGR.2
521.7618 634.3519 21.1 6.0 10.0 Positive APOA_HUMAN.GTYSTTVTGR.2
521.7618 721.3839 21.1 6.0 10.0 Positive APOA_HUMAN.GTYSTTVTGR.2
526.7613 543.3031 21.2 6.0 10.0 Positive APOA_HUMAN.GTYSTTVTGR.2
526.7613 343.1870 21.2 6.0 10.0 Positive APOA_HUMAN.GTYSTTVTGR.2
526.7613 644.3508 21.2 6.0 10.0 Positive APOA_HUMAN.GTYSTTVTGR.2
526.7613 731.3828 21.2 6.0 10.0 Positive APOA_HUMAN.GTYSTTVTGR.2
693.8612 940.4622 26.9 23.5 27.5 Positive APOA1_HUMAN.VSFLSALEEYTK.2
693.8612 1053.5463 26.9 23.5 27.5 Positive APOA1_HUMAN.VSFLSALEEYTK.2
693.8612 853.4302 26.9 23.5 27.5 Positive APOA1_HUMAN.VSFLSALEEYTK.2
693.8612 782.3931 26.9 23.5 27.5 Positive APOA1_HUMAN.VSFLSALEEYTK.2
697.8683 790.4073 27.0 23.6 27.6 Positive APOA1_HUMAN.VSFLSALEEYTK.2
697.8683 861.4444 27.0 23.6 27.6 Positive APOA1_HUMAN.VSFLSALEEYTK.2
697.8683 948.4764 27.0 23.6 27.6 Positive APOA1_HUMAN.VSFLSALEEYTK.2
697.8683 1061.5605 27.0 23.6 27.6 Positive APOA1_HUMAN.VSFLSALEEYTK.2
471.2869 571.3814 19.3 13.1 17.1 Positive APOA2_HUMAN.EQLTPLIK.2
471.2869 684.4654 19.3 13.1 17.1 Positive APOA2_HUMAN.EQLTPLIK.2
471.2869 373.2809 19.3 13.1 17.1 Positive APOA2_HUMAN.EQLTPLIK.2
471.2869 470.3337 19.3 13.1 17.1 Positive APOA2_HUMAN.EQLTPLIK.2
475.2940 579.3956 19.5 13.1 17.1 Positive APOA2_HUMAN.EQLTPLIK.2
475.2940 692.4796 19.5 13.1 17.1 Positive APOA2_HUMAN.EQLTPLIK.2
475.2940 381.2951 19.5 13.1 17.1 Positive APOA2_HUMAN.EQLTPLIK.2
475.2940 478.3479 19.5 13.1 17.1 Positive APOA2_HUMAN.EQLTPLIK.2
492.2796 589.2940 20.1 11.6 15.6 Positive APOA4_HUMAN.LAPLAEDVR.2
492.2796 518.2569 20.1 11.6 15.6 Positive APOA4_HUMAN.LAPLAEDVR.2
492.2796 799.4308 20.1 11.6 15.6 Positive APOA4_HUMAN.LAPLAEDVR.2
492.2796 702.3781 20.1 11.6 15.6 Positive APOA4_HUMAN.LAPLAEDVR.2
497.2838 599.3023 20.2 11.6 15.6 Positive APOA4_HUMAN.LAPLAEDVR.2
497.2838 528.2652 20.2 11.6 15.6 Positive APOA4_HUMAN.LAPLAEDVR.2
497.2838 809.4391 20.2 11.6 15.6 Positive APOA4_HUMAN.LAPLAEDVR.2
497.2838 712.3863 20.2 11.6 15.6 Positive APOA4_HUMAN.LAPLAEDVR.2
937.5304 1372.7947 35.2 26.2 30.2 Positive APOB_HUMAN.FSVPAGIVIPSFQALTAR.2
937.5304 990.5367 35.2 26.2 30.2 Positive APOB_HUMAN.FSVPAGIVIPSFQALTAR.2
937.5304 1103.6208 35.2 26.2 30.2 Positive APOB_HUMAN.FSVPAGIVIPSFQALTAR.2
937.5304 1202.6892 35.2 26.2 30.2 Positive APOB_HUMAN.FSVPAGIVIPSFQALTAR.2
942.5298 1212.6881 35.4 26.2 30.2 Positive APOB_HUMAN.FSVPAGIVIPSFQALTAR.2
942.5298 1382.7936 35.4 26.2 30.2 Positive APOB_HUMAN.FSVPAGIVIPSFQALTAR.2
942.5298 1000.5356 35.4 26.2 30.2 Positive APOB_HUMAN.FSVPAGIVIPSFQALTAR.2
942.5298 1113.6197 35.4 26.2 30.2 Positive APOB_HUMAN.FSVPAGIVIPSFQALTAR.2
526.7484 776.3785 21.2 9.2 13.2 Positive APOC1_HUMAN.EFGNTLEDK.2
526.7484 391.1823 21.2 9.2 13.2 Positive APOC1_HUMAN.EFGNTLEDK.2
526.7484 504.2664 21.2 9.2 13.2 Positive APOC1_HUMAN.EFGNTLEDK.2
526.7484 605.3141 21.2 9.2 13.2 Positive APOC1_HUMAN.EFGNTLEDK.2
530.7555 784.3927 21.4 9.2 13.2 Positive APOC1_HUMAN.EFGNTLEDK.2
530.7555 399.1965 21.4 9.2 13.2 Positive APOC1_HUMAN.EFGNTLEDK.2
530.7555 512.2806 21.4 9.2 13.2 Positive APOC1_HUMAN.EFGNTLEDK.2
530.7555 613.3283 21.4 9.2 13.2 Positive APOC1_HUMAN.EFGNTLEDK.2
519.2667 666.3457 21.0 6.2 10.2 Positive APOC2_HUMAN.TAAQNLYEK.2
519.2667 439.2187 21.0 6.2 10.2 Positive APOC2_HUMAN.TAAQNLYEK.2
519.2667 794.4043 21.0 6.2 10.2 Positive APOC2_HUMAN.TAAQNLYEK.2
519.2667 865.4414 21.0 6.2 10.2 Positive APOC2_HUMAN.TAAQNLYEK.2
523.2738 873.4556 21.1 6.2 10.2 Positive APOC2_HUMAN.TAAQNLYEK.2
523.2738 447.2329 21.1 6.2 10.2 Positive APOC2_HUMAN.TAAQNLYEK.2
523.2738 674.3599 21.1 6.2 10.2 Positive APOC2_HUMAN.TAAQNLYEK.2
523.2738 802.4185 21.1 6.2 10.2 Positive APOC2_HUMAN.TAAQNLYEK.2
598.8009 854.4254 23.7 18.2 22.2 Positive APOC3_HUMAN.GWVTDGFSSLK.2
598.8009 953.4938 23.7 18.2 22.2 Positive APOC3_HUMAN.GWVTDGFSSLK.2
598.8009 638.3508 23.7 18.2 22.2 Positive APOC3_HUMAN.GWVTDGFSSLK.2
598.8009 753.3777 23.7 18.2 22.2 Positive APOC3_HUMAN.GWVTDGFSSLK.2
602.8080 646.3650 23.8 18.2 22.2 Positive APOC3_HUMAN.GWVTDGFSSLK.2
602.8080 961.5080 23.8 18.2 22.2 Positive APOC3_HUMAN.GWVTDGFSSLK.2
602.8080 862.4396 23.8 18.2 22.2 Positive APOC3_HUMAN.GWVTDGFSSLK.2
602.8080 761.3919 23.8 18.2 22.2 Positive APOC3_HUMAN.GWVTDGFSSLK.2
615.8381 1003.5419 24.3 13.3 17.3 Positive APOD_HUMAN.NILTSNNIDVK.2
615.8381 890.4578 24.3 13.3 17.3 Positive APOD_HUMAN.NILTSNNIDVK.2
615.8381 789.4101 24.3 13.3 17.3 Positive APOD_HUMAN.NILTSNNIDVK.2
615.8381 341.2183 24.3 13.3 17.3 Positive APOD_HUMAN.NILTSNNIDVK.2
619.8452 341.2183 24.4 13.3 17.3 Positive APOD_HUMAN.NILTSNNIDVK.2
619.8452 1011.5561 24.4 13.3 17.3 Positive APOD_HUMAN.NILTSNNIDVK.2
619.8452 898.4720 24.4 13.3 17.3 Positive APOD_HUMAN.NILTSNNIDVK.2
619.8452 797.4243 24.4 13.3 17.3 Positive APOD_HUMAN.NILTSNNIDVK.2
749.4046 898.4741 28.8 12.6 16.6 Positive APOE_HUMAN.AATVGSLAGQPLQER.2
749.4046 1155.6117 28.8 12.6 16.6 Positive APOE_HUMAN.AATVGSLAGQPLQER.2
749.4046 827.4370 28.8 12.6 16.6 Positive APOE_HUMAN.AATVGSLAGQPLQER.2
749.4046 642.3570 28.8 12.6 16.6 Positive APOE_HUMAN.AATVGSLAGQPLQER.2
754.4088 837.4453 29.0 12.6 16.6 Positive APOE_HUMAN.AATVGSLAGQPLQER.2
754.4088 908.4824 29.0 12.6 16.6 Positive APOE_HUMAN.AATVGSLAGQPLQER.2
754.4088 1165.6199 29.0 12.6 16.6 Positive APOE_HUMAN.AATVGSLAGQPLQER.2
754.4088 652.3652 29.0 12.6 16.6 Positive APOE_HUMAN.AATVGSLAGQPLQER.2
751.8928 999.5582 28.9 19.8 23.8 Positive APOH_HUMAN.VC[CAM]PFAGILENGAVR.2
751.8928 758.4155 28.9 19.8 23.8 Positive APOH_HUMAN.VC[CAM]PFAGILENGAVR.2
751.8928 1243.6793 28.9 19.8 23.8 Positive APOH_HUMAN.VC[CAM]PFAGILENGAVR.2
751.8928 928.5211 28.9 19.8 23.8 Positive APOH_HUMAN.VC[CAM]PFAGILENGAVR.2
756.8970 938.5293 29.0 20.1 24.1 Positive APOH_HUMAN.VC[CAM]PFAGILENGAVR.2
756.8970 1009.5664 29.0 20.1 24.1 Positive APOH_HUMAN.VC[CAM]PFAGILENGAVR.2
756.8970 768.4238 29.0 20.1 24.1 Positive APOH_HUMAN.VC[CAM]PFAGILENGAVR.2
756.8970 1253.6876 29.0 20.1 24.1 Positive APOH_HUMAN.VC[CAM]PFAGILENGAVR.2
815.8996 804.3846 31.1 10.1 14.1 Positive APOL1_HUMAN.VTEPISAESGEQVER.2
815.8996 933.4272 31.1 10.1 14.1 Positive APOL1_HUMAN.VTEPISAESGEQVER.2
815.8996 1091.4964 31.1 10.1 14.1 Positive APOL1_HUMAN.VTEPISAESGEQVER.2
815.8996 1301.6332 31.1 10.1 14.1 Positive APOL1_HUMAN.VTEPISAESGEQVER.2
820.9037 1101.5046 31.2 10.1 14.1 Positive APOL1_HUMAN.VTEPISAESGEQVER.2
820.9037 943.4355 31.2 10.1 14.1 Positive APOL1_HUMAN.VTEPISAESGEQVER.2
820.9037 814.3929 31.2 10.1 14.1 Positive APOL1_HUMAN.VTEPISAESGEQVER.2
820.9037 1311.6415 31.2 10.1 14.1 Positive APOL1_HUMAN.VTEPISAESGEQVER.2
413.2345 678.3933 17.4 13.9 17.9 Positive APOM_HUMAN.FLLYNR.2
413.2345 565.3093 17.4 13.9 17.9 Positive APOM_HUMAN.FLLYNR.2
413.2345 452.2252 17.4 13.9 17.9 Positive APOM_HUMAN.FLLYNR.2
418.2386 688.4016 17.5 13.9 17.9 Positive APOM_HUMAN.FLLYNR.2
418.2386 575.3175 17.5 13.9 17.9 Positive APOM_HUMAN.FLLYNR.2
418.2386 462.2335 17.5 13.9 17.9 Positive APOM_HUMAN.FLLYNR.2
527.7529 300.1554 21.3 8.5 12.5 Positive B3AT_HUMAN.IDAYMAQSR.2
527.7529 592.2872 21.3 8.5 12.5 Positive B3AT_HUMAN.IDAYMAQSR.2
527.7529 755.3505 21.3 8.5 12.5 Positive B3AT_HUMAN.IDAYMAQSR.2
527.7529 826.3876 21.3 8.5 12.5 Positive B3AT_HUMAN.IDAYMAQSR.2
532.7570 300.1560 21.4 8.5 12.5 Positive B3AT_HUMAN.IDAYMAQSR.2
532.7570 602.2960 21.4 8.5 12.5 Positive B3AT_HUMAN.IDAYMAQSR.2
532.7570 765.3590 21.4 8.5 12.5 Positive B3AT_HUMAN.IDAYMAQSR.2
532.7570 836.3960 21.4 8.5 12.5 Positive B3AT_HUMAN.IDAYMAQSR.2
538.7706 632.3548 21.6 13.8 17.8 Positive C1QB_HUMAN.GNLC[CAM]VNLMR.2
538.7706 533.2864 21.6 13.8 17.8 Positive C1QB_HUMAN.GNLC[CAM]VNLMR.2
538.7706 792.3855 21.6 13.8 17.8 Positive C1QB_HUMAN.GNLC[CAM]VNLMR.2
538.7706 905.4696 21.6 13.8 17.8 Positive C1QB_HUMAN.GNLC[CAM]VNLMR.2
543.7701 543.2853 21.8 13.8 17.8 Positive C1QB_HUMAN.GNLC[CAM]VNLMR.2
543.7701 915.4684 21.8 13.8 17.8 Positive C1QB_HUMAN.GNLC[CAM]VNLMR.2
543.7701 802.3844 21.8 13.8 17.8 Positive C1QB_HUMAN.GNLC[CAM]VNLMR.2
543.7701 642.3537 21.8 13.8 17.8 Positive C1QB_HUMAN.GNLC[CAM]VNLMR.2
542.7929 623.3511 21.8 15.1 19.1 Positive C1QC_HUMAN.FQSVFTVTR.2
542.7929 363.1663 21.8 15.1 19.1 Positive C1QC_HUMAN.FQSVFTVTR.2
542.7929 722.4196 21.8 15.1 19.1 Positive C1QC_HUMAN.FQSVFTVTR.2
542.7929 809.4516 21.8 15.1 19.1 Positive C1QC_HUMAN.FQSVFTVTR.2
547.7971 633.3594 21.9 15.1 19.1 Positive C1QC_HUMAN.FQSVFTVTR.2
547.7971 363.1663 21.9 15.1 19.1 Positive C1QC_HUMAN.FQSVFTVTR.2
547.7971 819.4598 21.9 15.1 19.1 Positive C1QC_HUMAN.FQSVFTVTR.2
547.7971 732.4278 21.9 15.1 19.1 Positive C1QC_HUMAN.FQSVFTVTR.2
639.8054 812.3971 25.1 10.1 14.1 Positive C1R_HUMAN.YTTTMGVNTYK.2
639.8054 913.4448 25.1 10.1 14.1 Positive C1R_HUMAN.YTTTMGVNTYK.2
639.8054 681.3566 25.1 10.1 14.1 Positive C1R_HUMAN.YTTTMGVNTYK.2
639.8054 1014.4925 25.1 10.1 14.1 Positive C1R_HUMAN.YTTTMGVNTYK.2
643.8125 689.3708 25.2 10.1 14.1 Positive C1R_HUMAN.YTTTMGVNTYK.2
643.8125 1022.5067 25.2 10.1 14.1 Positive C1R_HUMAN.YTTTMGVNTYK.2
643.8125 820.4113 25.2 10.1 14.1 Positive C1R_HUMAN.YTTTMGVNTYK.2
643.8125 921.4590 25.2 10.1 14.1 Positive C1R_HUMAN.YTTTMGVNTYK.2
639.3279 571.3926 25.1 16.1 20.1 Positive C1S_HUMAN.TNFDNDIALVR.2
639.3279 800.4625 25.1 16.1 20.1 Positive C1S_HUMAN.TNFDNDIALVR.2
639.3279 915.4894 25.1 16.1 20.1 Positive C1S_HUMAN.TNFDNDIALVR.2
639.3279 1062.5578 25.1 16.1 20.1 Positive C1S_HUMAN.TNFDNDIALVR.2
644.3320 581.4009 25.2 15.9 19.9 Positive C1S_HUMAN.TNFDNDIALVR.2
644.3320 810.4707 25.2 15.9 19.9 Positive C1S_HUMAN.TNFDNDIALVR.2
644.3320 1072.5661 25.2 15.9 19.9 Positive C1S_HUMAN.TNFDNDIALVR.2
644.3320 925.4977 25.2 15.9 19.9 Positive C1S_HUMAN.TNFDNDIALVR.2
625.3430 743.4774 24.6 17.4 21.4 Positive C4BPA_HUMAN.EDVYVVGTVLR.2
625.3430 644.4090 24.6 17.4 21.4 Positive C4BPA_HUMAN.EDVYVVGTVLR.2
625.3430 545.3406 24.6 17.4 21.4 Positive C4BPA_HUMAN.EDVYVVGTVLR.2
625.3430 344.1452 24.6 17.4 21.4 Positive C4BPA_HUMAN.EDVYVVGTVLR.2
630.3471 753.4857 24.7 17.4 21.4 Positive C4BPA_HUMAN.EDVYVVGTVLR.2
630.3471 654.4173 24.7 17.4 21.4 Positive C4BPA_HUMAN.EDVYVVGTVLR.2
630.3471 555.3488 24.7 17.4 21.4 Positive C4BPA_HUMAN.EDVYVVGTVLR.2
630.3471 344.1452 24.7 17.4 21.4 Positive C4BPA_HUMAN.EDVYVVGTVLR.2
740.3650 547.3200 28.5 18.7 22.7 Positive CBG_HUMAN.GTWTQPFDLASTR.2
740.3650 906.4690 28.5 18.7 22.7 Positive CBG_HUMAN.GTWTQPFDLASTR.2
740.3650 363.1990 28.5 18.7 22.7 Positive CBG_HUMAN.GTWTQPFDLASTR.2
740.3650 434.2360 28.5 18.7 22.7 Positive CBG_HUMAN.GTWTQPFDLASTR.2
745.3690 557.3290 28.7 18.6 22.6 Positive CBG_HUMAN.GTWTQPFDLASTR.2
745.3690 373.2070 28.7 18.6 22.6 Positive CBG_HUMAN.GTWTQPFDLASTR.2
745.3690 916.4770 28.7 18.6 22.6 Positive CBG_HUMAN.GTWTQPFDLASTR.2
745.3690 444.2450 28.7 18.6 22.6 Positive CBG_HUMAN.GTWTQPFDLASTR.2
458.2560 616.3413 18.9 14.8 18.8 Positive CD5L_HUMAN.IWLDNVR.2
458.2560 802.4206 18.9 14.8 18.8 Positive CD5L_HUMAN.IWLDNVR.2
458.2560 388.2303 18.9 14.8 18.8 Positive CD5L_HUMAN.IWLDNVR.2
458.2560 503.2572 18.9 14.8 18.8 Positive CD5L_HUMAN.IWLDNVR.2
463.2601 626.3496 19.1 14.8 18.8 Positive CD5L_HUMAN.IWLDNVR.2
463.2601 812.4289 19.1 14.8 18.8 Positive CD5L_HUMAN.IWLDNVR.2
463.2601 398.2386 19.1 14.8 18.8 Positive CD5L_HUMAN.IWLDNVR.2
463.2601 513.2655 19.1 14.8 18.8 Positive CD5L_HUMAN.IWLDNVR.2
735.4234 420.2275 28.3 24.7 28.7 Positive CERU_HUMAN.DIASGLIGPLIIC[CAM]K.2
735.4234 743.4484 28.3 24.7 28.7 Positive CERU_HUMAN.DIASGLIGPLIIC[CAM]K.2
735.4234 913.5539 28.3 24.7 28.7 Positive CERU_HUMAN.DIASGLIGPLIIC[CAM]K.2
735.4234 800.4699 28.3 24.7 28.7 Positive CERU_HUMAN.DIASGLIGPLIIC[CAM]K.2
739.4210 808.4649 28.5 24.7 28.7 Positive CERU_HUMAN.DIASGLIGPLIIC[CAM]K.2
739.4210 921.5490 28.5 24.7 28.7 Positive CERU_HUMAN.DIASGLIGPLIIC[CAM]K.2
739.4210 428.2226 28.5 24.7 28.7 Positive CERU_HUMAN.DIASGLIGPLIIC[CAM]K.2
739.4210 751.4434 28.5 24.7 28.7 Positive CERU_HUMAN.DIASGLIGPLIIC[CAM]K.2
638.3346 843.4247 25.0 15.1 19.1 Positive CFAB_HUMAN.YGLVTYATYPK.2
638.3346 742.3770 25.0 15.1 19.1 Positive CFAB_HUMAN.YGLVTYATYPK.2
638.3346 334.1761 25.0 15.1 19.1 Positive CFAB_HUMAN.YGLVTYATYPK.2
638.3346 942.4931 25.0 15.1 19.1 Positive CFAB_HUMAN.YGLVTYATYPK.2
642.3417 334.1761 25.2 15.1 19.1 Positive CFAB_HUMAN.YGLVTYATYPK.2
642.3417 851.4389 25.2 15.1 19.1 Positive CFAB_HUMAN.YGLVTYATYPK.2
642.3417 950.5073 25.2 15.1 19.1 Positive CFAB_HUMAN.YGLVTYATYPK.2
642.3417 750.3912 25.2 15.1 19.1 Positive CFAB_HUMAN.YGLVTYATYPK.2
355.2013 486.2671 18.9 12.2 16.2 Positive CFAH_HUMAN.IDVHLVPDR.3
355.2013 599.3511 18.9 12.2 16.2 Positive CFAH_HUMAN.IDVHLVPDR.3
355.2013 387.1987 18.9 12.2 16.2 Positive CFAH_HUMAN.IDVHLVPDR.3
355.2013 465.2456 18.9 12.2 16.2 Positive CFAH_HUMAN.IDVHLVPDR.3
358.5374 496.2753 19.1 12.2 16.2 Positive CFAH_HUMAN.IDVHLVPDR.3
358.5374 609.3594 19.1 12.2 16.2 Positive CFAH_HUMAN.IDVHLVPDR.3
358.5374 397.2069 19.1 12.2 16.2 Positive CFAH_HUMAN.IDVHLVPDR.3
358.5374 465.2456 19.1 12.2 16.2 Positive CFAH_HUMAN.IDVHLVPDR.3
503.7820 893.4727 20.4 13.6 17.6 Positive CFAI_HUMAN.IVIEYVDR.2
503.7820 681.3202 20.4 13.6 17.6 Positive CFAI_HUMAN.IVIEYVDR.2
503.7820 794.4043 20.4 13.6 17.6 Positive CFAI_HUMAN.IVIEYVDR.2
503.7820 552.2776 20.4 13.6 17.6 Positive CFAI_HUMAN.IVIEYVDR.2
508.7862 903.4810 20.6 13.6 17.6 Positive CFAI_HUMAN.IVIEYVDR.2
508.7862 562.2859 20.6 13.6 17.6 Positive CFAI_HUMAN.IVIEYVDR.2
508.7862 691.3285 20.6 13.6 17.6 Positive CFAI_HUMAN.IVIEYVDR.2
508.7862 804.4126 20.6 13.6 17.6 Positive CFAI_HUMAN.IVIEYVDR.2
697.3515 678.3570 27.0 23.1 27.1 Positive CLUS_HUMAN.ASSIIDELFQDR.2
697.3515 922.4265 27.0 23.1 27.1 Positive CLUS_HUMAN.ASSIIDELFQDR.2
697.3515 1035.5106 27.0 23.1 27.1 Positive CLUS_HUMAN.ASSIIDELFQDR.2
697.3515 565.2729 27.0 23.1 27.1 Positive CLUS_HUMAN.ASSIIDELFQDR.2
702.3557 575.2812 27.2 23.0 27.0 Positive CLUS_HUMAN.ASSIIDELFQDR.2
702.3557 688.3652 27.2 23.0 27.0 Positive CLUS_HUMAN.ASSIIDELFQDR.2
702.3557 932.4348 27.2 23.0 27.0 Positive CLUS_HUMAN.ASSIIDELFQDR.2
702.3557 1045.5188 27.2 23.0 27.0 Positive CLUS_HUMAN.ASSIIDELFQDR.2
625.8426 783.4036 24.6 19.6 23.6 Positive CO2_HUMAN.AVISPGFDVFAK.2
625.8426 880.4563 24.6 19.6 23.6 Positive CO2_HUMAN.AVISPGFDVFAK.2
625.8426 967.4884 24.6 19.6 23.6 Positive CO2_HUMAN.AVISPGFDVFAK.2
625.8426 371.2289 24.6 19.6 23.6 Positive CO2_HUMAN.AVISPGFDVFAK.2
629.8497 888.4705 24.7 19.6 23.6 Positive CO2_HUMAN.AVISPGFDVFAK.2
629.8497 371.2289 24.7 19.6 23.6 Positive CO2_HUMAN.AVISPGFDVFAK.2
629.8497 791.4178 24.7 19.6 23.6 Positive CO2_HUMAN.AVISPGFDVFAK.2
629.8497 975.5026 24.7 19.6 23.6 Positive CO2_HUMAN.AVISPGFDVFAK.2
606.3302 775.4308 23.9 14.5 18.5 Positive CO3_HUMAN.IHWESASLLR.2
606.3302 646.3883 23.9 14.5 18.5 Positive CO3_HUMAN.IHWESASLLR.2
606.3302 961.5102 23.9 14.5 18.5 Positive CO3_HUMAN.IHWESASLLR.2
606.3302 437.2296 23.9 14.5 18.5 Positive CO3_HUMAN.IHWESASLLR.2
611.3343 437.2296 24.1 14.5 18.5 Positive CO3_HUMAN.IHWESASLLR.2
611.3343 656.3965 24.1 14.5 18.5 Positive CO3_HUMAN.IHWESASLLR.2
611.3343 971.5184 24.1 14.5 18.5 Positive CO3_HUMAN.IHWESASLLR.2
611.3343 785.4391 24.1 14.5 18.5 Positive CO3_HUMAN.IHWESASLLR.2
728.3392 956.4796 28.1 9.8 13.8 Positive CO5_HUMAN.TDAPDLPEENQAR.2
728.3392 843.3955 28.1 9.8 13.8 Positive CO5_HUMAN.TDAPDLPEENQAR.2
728.3392 1168.5593 28.1 9.8 13.8 Positive CO5_HUMAN.TDAPDLPEENQAR.2
733.3433 966.4879 28.2 9.8 13.8 Positive CO5_HUMAN.TDAPDLPEENQAR.2
733.3433 853.4038 28.2 9.8 13.8 Positive CO5_HUMAN.TDAPDLPEENQAR.2
733.3433 1178.5676 28.2 9.8 13.8 Positive CO5_HUMAN.TDAPDLPEENQAR.2
623.8210 747.3706 24.5 13.2 17.2 Positive CO6_HUMAN.IGESIELTC[CAM]PK.2
623.8210 947.4866 24.5 13.2 17.2 Positive CO6_HUMAN.IGESIELTC[CAM]PK.2
623.8210 618.3280 24.5 13.2 17.2 Positive CO6_HUMAN.IGESIELTC[CAM]PK.2
623.8210 404.1962 24.5 13.2 17.2 Positive CO6_HUMAN.IGESIELTC[CAM]PK.2
627.8185 412.1913 24.7 13.1 17.1 Positive CO6_HUMAN.IGESIELTC[CAM]PK.2
627.8185 955.4817 24.7 13.1 17.1 Positive CO6_HUMAN.IGESIELTC[CAM]PK.2
627.8185 755.3656 24.7 13.1 17.1 Positive CO6_HUMAN.IGESIELTC[CAM]PK.2
627.8185 626.3230 24.7 13.1 17.1 Positive CO6_HUMAN.IGESIELTC[CAM]PK.2
550.2871 577.2828 22.0 14.9 18.9 Positive CO7_HUMAN.VLFYVDSEK.2
550.2871 887.4145 22.0 14.9 18.9 Positive CO7_HUMAN.VLFYVDSEK.2
550.2871 740.3461 22.0 14.9 18.9 Positive CO7_HUMAN.VLFYVDSEK.2
550.2871 363.1874 22.0 14.9 18.9 Positive CO7_HUMAN.VLFYVDSEK.2
554.2942 585.2970 22.2 14.9 18.9 Positive CO7_HUMAN.VLFYVDSEK.2
554.2942 371.2016 22.2 14.9 18.9 Positive CO7_HUMAN.VLFYVDSEK.2
554.2942 895.4287 22.2 14.9 18.9 Positive CO7_HUMAN.VLFYVDSEK.2
554.2942 748.3603 22.2 14.9 18.9 Positive CO7_HUMAN.VLFYVDSEK.2
526.7904 915.5146 21.2 8.0 12.0 Positive CO8A_HUMAN.HTSLGPLEAK.2
526.7904 814.4669 21.2 8.0 12.0 Positive CO8A_HUMAN.HTSLGPLEAK.2
526.7904 614.3508 21.2 8.0 12.0 Positive CO8A_HUMAN.HTSLGPLEAK.2
526.7904 835.4308 21.2 8.0 12.0 Positive CO8A_HUMAN.HTSLGPLEAK.2
530.7975 822.4811 21.4 8.0 12.0 Positive CO8A_HUMAN.HTSLGPLEAK.2
530.7975 923.5288 21.4 8.0 12.0 Positive CO8A_HUMAN.HTSLGPLEAK.2
530.7975 835.4308 21.4 8.0 12.0 Positive CO8A_HUMAN.HTSLGPLEAK.2
530.7975 622.3650 21.4 8.0 12.0 Positive CO8A_HUMAN.HTSLGPLEAK.2
621.8765 1042.6295 24.5 19.4 23.4 Positive CO9_HUMAN.LSPIYNLVPVK.2
621.8765 343.2340 24.5 19.4 23.4 Positive CO9_HUMAN.LSPIYNLVPVK.2
621.8765 669.4294 24.5 19.4 23.4 Positive CO9_HUMAN.LSPIYNLVPVK.2
621.8765 832.4927 24.5 19.4 23.4 Positive CO9_HUMAN.LSPIYNLVPVK.2
625.8836 840.5069 24.6 19.4 23.4 Positive CO9_HUMAN.LSPIYNLVPVK.2
625.8836 677.4436 24.6 19.4 23.4 Positive CO9_HUMAN.LSPIYNLVPVK.2
625.8836 351.2482 24.6 19.4 23.4 Positive CO9_HUMAN.LSPIYNLVPVK.2
625.8836 1050.6437 24.6 19.4 23.4 Positive CO9_HUMAN.LSPIYNLVPVK.2
801.4359 732.4039 30.6 19.0 23.0 Positive CPN2_HUMAN.LSNNALSGLPQGVFGK.2
801.4359 989.5415 30.6 19.0 23.0 Positive CPN2_HUMAN.LSNNALSGLPQGVFGK.2
801.4359 1102.6255 30.6 19.0 23.0 Positive CPN2_HUMAN.LSNNALSGLPQGVFGK.2
801.4359 351.2027 30.6 19.0 23.0 Positive CPN2_HUMAN.LSNNALSGLPQGVFGK.2
805.4430 740.4181 30.7 18.9 22.9 Positive CPN2_HUMAN.LSNNALSGLPQGVFGK.2
805.4430 997.5557 30.7 18.9 22.9 Positive CPN2_HUMAN.LSNNALSGLPQGVFGK.2
805.4430 1110.6397 30.7 18.9 22.9 Positive CPN2_HUMAN.LSNNALSGLPQGVFGK.2
805.4430 359.2169 30.7 18.9 22.9 Positive CPN2_HUMAN.LSNNALSGLPQGVFGK.2
464.2822 763.4723 19.1 12.0 18.0 Positive DECOY1
464.2822 562.3562 19.1 12.0 18.0 Positive DECOY1
464.2822 444.2722 19.1 12.0 18.0 Positive DECOY1
493.2766 657.3563 20.1 11.0 15.0 Positive DECOY2
493.2766 381.1667 20.1 11.0 15.0 Positive DECOY2
493.2766 728.3934 20.1 11.0 15.0 Positive DECOY2
496.2766 731.3934 20.2 15.5 19.5 Positive DECOY3
496.2766 660.3563 20.2 15.5 19.5 Positive DECOY3
496.2766 332.1969 20.2 15.5 19.5 Positive DECOY3
570.8144 589.3257 22.7 13.2 17.2 Positive DECOY4
570.8144 855.4996 22.7 13.2 17.2 Positive DECOY4
570.8144 704.4097 22.7 13.2 17.2 Positive DECOY4
575.8088 765.4141 22.9 14.5 18.5 Positive DECOY5
575.8088 618.3457 22.9 14.5 18.5 Positive DECOY5
575.8088 992.5411 22.9 14.5 18.5 Positive DECOY5
617.8666 660.4090 24.3 14.0 35.0 Positive DECOY6
617.8666 723.4461 24.3 14.0 35.0 Positive DECOY6
617.8666 882.5152 24.3 14.0 35.0 Positive DECOY6
658.8508 846.4567 25.7 14.9 18.9 Positive DECOY7
658.8508 658.3770 25.7 14.9 18.9 Positive DECOY7
658.8508 745.4090 25.7 14.9 18.9 Positive DECOY7
708.3621 875.4472 27.4 14.0 35.0 Positive DECOY8
708.3621 974.4949 27.4 14.0 35.0 Positive DECOY8
708.3621 646.2998 27.4 14.0 35.0 Positive DECOY8
716.3308 891.4108 27.7 18.0 24.0 Positive DECOY9
716.3308 801.3424 27.7 18.0 24.0 Positive DECOY9
716.3308 1243.5590 27.7 18.0 24.0 Positive DECOY9
663.9158 373.2809 25.9 22.5 26.5 Positive F13A_HUMAN.STVLTIPEIIIK.2
663.9158 825.5444 25.9 22.5 26.5 Positive F13A_HUMAN.STVLTIPEIIIK.2
663.9158 712.4604 25.9 22.5 26.5 Positive F13A_HUMAN.STVLTIPEIIIK.2
663.9158 926.5921 25.9 22.5 26.5 Positive F13A_HUMAN.STVLTIPEIIIK.2
667.9133 833.5395 26.0 22.5 26.5 Positive F13A_HUMAN.STVLTIPEIIIK.2
667.9133 934.5871 26.0 22.5 26.5 Positive F13A_HUMAN.STVLTIPEIIIK.2
667.9133 381.2760 26.0 22.5 26.5 Positive F13A_HUMAN.STVLTIPEIIIK.2
667.9133 720.4554 26.0 22.5 26.5 Positive F13A_HUMAN.STVLTIPEIIIK.2
589.7775 322.1397 23.4 14.9 18.9 Positive FBLN1_HUMAN.TGYYFDGISR.2
589.7775 432.2565 23.4 14.9 18.9 Positive FBLN1_HUMAN.TGYYFDGISR.2
589.7775 857.4152 23.4 14.9 18.9 Positive FBLN1_HUMAN.TGYYFDGISR.2
589.7775 694.3519 23.4 14.9 18.9 Positive FBLN1_HUMAN.TGYYFDGISR.2
594.7816 442.2648 23.5 14.9 18.9 Positive FBLN1_HUMAN.TGYYFDGISR.2
594.7816 867.4235 23.5 14.9 18.9 Positive FBLN1_HUMAN.TGYYFDGISR.2
594.7816 704.3601 23.5 14.9 18.9 Positive FBLN1_HUMAN.TGYYFDGISR.2
594.7816 322.1397 23.5 14.9 18.9 Positive FBLN1_HUMAN.TGYYFDGISR.2
512.7460 576.2889 20.7 14.4 18.4 Positive FCN3_HUMAN.YGIDWASGR.2
512.7460 861.4213 20.7 14.4 18.4 Positive FCN3_HUMAN.YGIDWASGR.2
512.7460 691.3158 20.7 14.4 18.4 Positive FCN3_HUMAN.YGIDWASGR.2
512.7460 390.2096 20.7 14.4 18.4 Positive FCN3_HUMAN.YGIDWASGR.2
517.7501 871.4296 20.9 14.4 18.4 Positive FCN3_HUMAN.YGIDWASGR.2
517.7501 400.2178 20.9 14.4 18.4 Positive FCN3_HUMAN.YGIDWASGR.2
517.7501 586.2971 20.9 14.4 18.4 Positive FCN3_HUMAN.YGIDWASGR.2
517.7501 701.3241 20.9 14.4 18.4 Positive FCN3_HUMAN.YGIDWASGR.2
407.2289 579.3501 17.2 10.9 14.9 Positive FETUA_HUMAN.FSVVYAK.2
407.2289 666.3821 17.2 10.9 14.9 Positive FETUA_HUMAN.FSVVYAK.2
407.2289 381.2132 17.2 10.9 14.9 Positive FETUA_HUMAN.FSVVYAK.2
407.2289 480.2817 17.2 10.9 14.9 Positive FETUA_HUMAN.FSVVYAK.2
411.2360 587.3643 17.3 10.9 14.9 Positive FETUA_HUMAN.FSVVYAK.2
411.2360 674.3963 17.3 10.9 14.9 Positive FETUA_HUMAN.FSVVYAK.2
411.2360 389.2274 17.3 10.9 14.9 Positive FETUA_HUMAN.FSVVYAK.2
411.2360 488.2959 17.3 10.9 14.9 Positive FETUA_HUMAN.FSVVYAK.2
570.7802 723.4036 22.7 9.1 13.1 Positive FIBA_HUMAN.GSESGIFTNTK.2
570.7802 610.3195 22.7 9.1 13.1 Positive FIBA_HUMAN.GSESGIFTNTK.2
570.7802 867.4571 22.7 9.1 13.1 Positive FIBA_HUMAN.GSESGIFTNTK.2
570.7802 780.4250 22.7 9.1 13.1 Positive FIBA_HUMAN.GSESGIFTNTK.2
574.7873 618.3337 22.9 9.1 13.1 Positive FIBA_HUMAN.GSESGIFTNTK.2
574.7873 731.4178 22.9 9.1 13.1 Positive FIBA_HUMAN.GSESGIFTNTK.2
574.7873 788.4392 22.9 9.1 13.1 Positive FIBA_HUMAN.GSESGIFTNTK.2
574.7873 875.4713 22.9 9.1 13.1 Positive FIBA_HUMAN.GSESGIFTNTK.2
654.8126 706.3366 25.6 8.4 12.4 Positive FIBB_HUMAN.QGFGNVATNTDGK.2
654.8126 805.4050 25.6 8.4 12.4 Positive FIBB_HUMAN.QGFGNVATNTDGK.2
654.8126 333.1557 25.6 8.4 12.4 Positive FIBB_HUMAN.QGFGNVATNTDGK.2
654.8126 635.2995 25.6 8.4 12.4 Positive FIBB_HUMAN.QGFGNVATNTDGK.2
658.8197 813.4192 25.7 8.4 12.4 Positive FIBB_HUMAN.QGFGNVATNTDGK.2
658.8197 333.1557 25.7 8.4 12.4 Positive FIBB_HUMAN.QGFGNVATNTDGK.2
658.8197 643.3137 25.7 8.4 12.4 Positive FIBB_HUMAN.QGFGNVATNTDGK.2
658.8197 714.3508 25.7 8.4 12.4 Positive FIBB_HUMAN.QGFGNVATNTDGK.2
597.7475 645.3566 23.6 11.3 15.3 Positive FIBG_HUMAN.DNC[CAM]C[CAM]ILDER.2
597.7475 532.2726 23.6 11.3 15.3 Positive FIBG_HUMAN.DNC[CAM]C[CAM]ILDER.2
597.7475 419.1885 23.6 11.3 15.3 Positive FIBG_HUMAN.DNC[CAM]C[CAM]ILDER.2
597.7475 805.3873 23.6 11.3 15.3 Positive FIBG_HUMAN.DNC[CAM]C[CAM]ILDER.2
602.7517 655.3649 23.8 11.3 15.3 Positive FIBG_HUMAN.DNC[CAM]C[CAM]ILDER.2
602.7517 815.3955 23.8 11.3 15.3 Positive FIBG_HUMAN.DNC[CAM]C[CAM]ILDER.2
602.7517 542.2808 23.8 11.3 15.3 Positive FIBG_HUMAN.DNC[CAM]C[CAM]ILDER.2
602.7517 429.1968 23.8 11.3 15.3 Positive FIBG_HUMAN.DNC[CAM]C[CAM]ILDER.2
772.3856 978.4891 29.6 14.8 18.8 Positive FINC_HUMAN.SYTITGLQPGTDYK.2
772.3856 680.3250 29.6 14.8 18.8 Positive FINC_HUMAN.SYTITGLQPGTDYK.2
772.3856 1079.5368 29.6 14.8 18.8 Positive FINC_HUMAN.SYTITGLQPGTDYK.2
772.3856 352.1503 29.6 14.8 18.8 Positive FINC_HUMAN.SYTITGLQPGTDYK.2
776.3927 986.5033 29.7 14.8 18.8 Positive FINC_HUMAN.SYTITGLQPGTDYK.2
776.3927 688.3392 29.7 14.8 18.8 Positive FINC_HUMAN.SYTITGLQPGTDYK.2
776.3927 1087.5510 29.7 14.8 18.8 Positive FINC_HUMAN.SYTITGLQPGTDYK.2
776.3927 352.1503 29.7 14.8 18.8 Positive FINC_HUMAN.SYTITGLQPGTDYK.2
660.3513 893.4727 25.8 15.2 19.2 Positive GELS_HUMAN.AGALNSNDAFVLK.2
660.3513 359.2653 25.8 15.2 19.2 Positive GELS_HUMAN.AGALNSNDAFVLK.2
660.3513 806.4407 25.8 15.2 19.2 Positive GELS_HUMAN.AGALNSNDAFVLK.2
660.3513 1007.5156 25.8 15.2 19.2 Positive GELS_HUMAN.AGALNSNDAFVLK.2
664.3584 367.2795 25.9 15.2 19.2 Positive GELS_HUMAN.AGALNSNDAFVLK.2
664.3584 814.4549 25.9 15.2 19.2 Positive GELS_HUMAN.AGALNSNDAFVLK.2
664.3584 901.4869 25.9 15.2 19.2 Positive GELS_HUMAN.AGALNSNDAFVLK.2
664.3584 1015.5298 25.9 15.2 19.2 Positive GELS_HUMAN.AGALNSNDAFVLK.2
657.8656 516.2963 25.7 21.1 25.1 Positive GPX3_HUMAN.FLVGPDGIPIMR.2
657.8656 898.4815 25.7 21.1 25.1 Positive GPX3_HUMAN.FLVGPDGIPIMR.2
657.8656 955.5030 25.7 21.1 25.1 Positive GPX3_HUMAN.FLVGPDGIPIMR.2
657.8656 686.4018 25.7 21.1 25.1 Positive GPX3_HUMAN.FLVGPDGIPIMR.2
662.8697 526.3045 25.9 21.1 25.1 Positive GPX3_HUMAN.FLVGPDGIPIMR.2
662.8697 908.4898 25.9 21.1 25.1 Positive GPX3_HUMAN.FLVGPDGIPIMR.2
662.8697 696.4101 25.9 21.1 25.1 Positive GPX3_HUMAN.FLVGPDGIPIMR.2
662.8697 965.5112 25.9 21.1 25.1 Positive GPX3_HUMAN.FLVGPDGIPIMR.2
765.3708 365.1932 29.3 9.3 13.3 Positive HBA_HUMAN.VGAHAGEYGAEALER.2
765.3708 436.2303 29.3 9.3 13.3 Positive HBA_HUMAN.VGAHAGEYGAEALER.2
765.3708 1094.5113 29.3 9.3 13.3 Positive HBA_HUMAN.VGAHAGEYGAEALER.2
765.3708 1165.5484 29.3 9.3 13.3 Positive HBA_HUMAN.VGAHAGEYGAEALER.2
770.3749 1175.5567 29.5 9.2 13.2 Positive HBA_HUMAN.VGAHAGEYGAEALER.2
770.3749 1104.5195 29.5 9.2 13.2 Positive HBA_HUMAN.VGAHAGEYGAEALER.2
770.3749 365.1932 29.5 9.2 13.2 Positive HBA_HUMAN.VGAHAGEYGAEALER.2
770.3749 436.2303 29.5 9.2 13.2 Positive HBA_HUMAN.VGAHAGEYGAEALER.2
663.8999 717.4076 25.9 23.3 27.3 Positive HBD_HUMAN.LLGNVLVC[CAM]VLAR.2
663.8999 1100.6245 25.9 23.3 27.3 Positive HBD_HUMAN.LLGNVLVC[CAM]VLAR.2
663.8999 618.3392 25.9 23.3 27.3 Positive HBD_HUMAN.LLGNVLVC[CAM]VLAR.2
663.8999 830.4917 25.9 23.3 27.3 Positive HBD_HUMAN.LLGNVLVC[CAM]VLAR.2
668.8994 727.4065 26.1 23.3 27.3 Positive HBD_HUMAN.LLGNVLVC[CAM]VLAR.2
668.8994 840.4906 26.1 23.3 27.3 Positive HBD_HUMAN.LLGNVLVC[CAM]VLAR.2
668.8994 1110.6234 26.1 23.3 27.3 Positive HBD_HUMAN.LLGNVLVC[CAM]VLAR.2
668.8994 628.3381 26.1 23.3 27.3 Positive HBD_HUMAN.LLGNVLVC[CAM]VLAR.2
501.2397 422.1704 20.4 2.5 6.5 Positive HBE_HUMAN.LSELHC[CAM]DK.2
501.2397 559.2293 20.4 2.5 6.5 Positive HBE_HUMAN.LSELHC[CAM]DK.2
501.2397 672.3134 20.4 2.5 6.5 Positive HBE_HUMAN.LSELHC[CAM]DK.2
501.2397 888.3880 20.4 2.5 6.5 Positive HBE_HUMAN.LSELHC[CAM]DK.2
505.3140 567.3780 20.5 2.6 6.6 Positive HBE_HUMAN.LSELHC[CAM]DK.2
505.3140 896.5360 20.5 2.6 6.6 Positive HBE_HUMAN.LSELHC[CAM]DK.2
505.3140 430.3190 20.5 2.6 6.6 Positive HBE_HUMAN.LSELHC[CAM]DK.2
505.3140 680.4620 20.5 2.6 6.6 Positive HBE_HUMAN.LSELHC[CAM]DK.2
610.8066 775.4097 24.1 17.2 21.2 Positive HEMO_HUMAN.NFPSPVDAAFR.2
610.8066 579.2885 24.1 17.2 21.2 Positive HEMO_HUMAN.NFPSPVDAAFR.2
610.8066 862.4417 24.1 17.2 21.2 Positive HEMO_HUMAN.NFPSPVDAAFR.2
610.8066 959.4945 24.1 17.2 21.2 Positive HEMO_HUMAN.NFPSPVDAAFR.2
615.8107 785.4180 24.3 17.2 21.2 Positive HEMO_HUMAN.NFPSPVDAAFR.2
615.8107 589.2968 24.3 17.2 21.2 Positive HEMO_HUMAN.NFPSPVDAAFR.2
615.8107 969.5028 24.3 17.2 21.2 Positive HEMO_HUMAN.NFPSPVDAAFR.2
615.8107 872.4500 24.3 17.2 21.2 Positive HEMO_HUMAN.NFPSPVDAAFR.2
514.7904 814.4417 20.8 11.0 15.0 Positive HEP2_HUMAN.TLEAQLTPR.2
514.7904 373.2194 20.8 11.0 15.0 Positive HEP2_HUMAN.TLEAQLTPR.2
514.7904 614.3620 20.8 11.0 15.0 Positive HEP2_HUMAN.TLEAQLTPR.2
514.7904 685.3991 20.8 11.0 15.0 Positive HEP2_HUMAN.TLEAQLTPR.2
519.7945 824.4500 21.0 11.0 15.0 Positive HEP2_HUMAN.TLEAQLTPR.2
519.7945 624.3703 21.0 11.0 15.0 Positive HEP2_HUMAN.TLEAQLTPR.2
519.7945 695.4074 21.0 11.0 15.0 Positive HEP2_HUMAN.TLEAQLTPR.2
519.7945 383.2277 21.0 11.0 15.0 Positive HEP2_HUMAN.TLEAQLTPR.2
602.3220 374.2398 23.8 14.9 18.9 Positive HPT_HUMAN.VTSIQDWVQK.2
602.3220 675.3461 23.8 14.9 18.9 Positive HPT_HUMAN.VTSIQDWVQK.2
602.3220 803.4046 23.8 14.9 18.9 Positive HPT_HUMAN.VTSIQDWVQK.2
602.3220 1003.5207 23.8 14.9 18.9 Positive HPT_HUMAN.VTSIQDWVQK.2
606.3291 382.2540 23.9 14.9 18.9 Positive HPT_HUMAN.VTSIQDWVQK.2
606.3291 811.4188 23.9 14.9 18.9 Positive HPT_HUMAN.VTSIQDWVQK.2
606.3291 683.3603 23.9 14.9 18.9 Positive HPT_HUMAN.VTSIQDWVQK.2
606.3291 1011.5349 23.9 14.9 18.9 Positive HPT_HUMAN.VTSIQDWVQK.2
772.3624 795.3632 29.6 15.3 19.3 Positive HPTR_HUMAN.VGYVSGWGQSDNFK.2
772.3624 320.1605 29.6 15.3 19.3 Positive HPTR_HUMAN.VGYVSGWGQSDNFK.2
772.3624 1038.4639 29.6 15.3 19.3 Positive HPTR_HUMAN.VGYVSGWGQSDNFK.2
772.3624 1125.4960 29.6 15.3 19.3 Positive HPTR_HUMAN.VGYVSGWGQSDNFK.2
776.3695 803.3774 29.7 15.3 19.3 Positive HPTR_HUMAN.VGYVSGWGQSDNFK.2
776.3695 320.1605 29.7 15.3 19.3 Positive HPTR_HUMAN.VGYVSGWGQSDNFK.2
776.3695 1046.4781 29.7 15.3 19.3 Positive HPTR_HUMAN.VGYVSGWGQSDNFK.2
776.3695 1133.5102 29.7 15.3 19.3 Positive HPTR_HUMAN.VGYVSGWGQSDNFK.2
745.8492 722.3832 28.7 19.1 23.1 Positive HRG_HUMAN.GGEGTGYFVDFSVR.2
745.8492 869.4516 28.7 19.1 23.1 Positive HRG_HUMAN.GGEGTGYFVDFSVR.2
745.8492 1089.5364 28.7 19.1 23.1 Positive HRG_HUMAN.GGEGTGYFVDFSVR.2
745.8492 623.3148 28.7 19.1 23.1 Positive HRG_HUMAN.GGEGTGYFVDFSVR.2
750.8486 633.3136 28.8 19.1 23.1 Positive HRG_HUMAN.GGEGTGYFVDFSVR.2
750.8486 732.3821 28.8 19.1 23.1 Positive HRG_HUMAN.GGEGTGYFVDFSVR.2
750.8486 879.4505 28.8 19.1 23.1 Positive HRG_HUMAN.GGEGTGYFVDFSVR.2
750.8486 1099.5353 28.8 19.1 23.1 Positive HRG_HUMAN.GGEGTGYFVDFSVR.2
609.6635 908.4948 30.1 18.8 22.8 Positive IC1_HUMAN.GVTSVSQIFHSPDLAIR.3
609.6635 771.4359 30.1 18.8 22.8 Positive IC1_HUMAN.GVTSVSQIFHSPDLAIR.3
609.6635 1055.5633 30.1 18.8 22.8 Positive IC1_HUMAN.GVTSVSQIFHSPDLAIR.3
612.9996 1065.5715 30.3 18.8 22.8 Positive IC1_HUMAN.GVTSVSQIFHSPDLAIR.3
612.9996 781.4442 30.3 18.8 22.8 Positive IC1_HUMAN.GVTSVSQIFHSPDLAIR.3
612.9996 918.5031 30.3 18.8 22.8 Positive IC1_HUMAN.GVTSVSQIFHSPDLAIR.3
770.8675 576.2988 29.5 17.6 21.6 Positive IGHA1_HUMAN.DASGVTFTWTPSSGK.2
770.8675 331.1248 29.5 17.6 21.6 Positive IGHA1_HUMAN.DASGVTFTWTPSSGK.2
770.8675 331.1248 29.5 17.6 21.6 Positive IGHA1_HUMAN.DASGVTFTWTPSSGK.2
770.8675 475.2511 29.5 17.6 21.6 Positive IGHA1_HUMAN.DASGVTFTWTPSSGK.2
774.8651 313.1143 29.7 17.6 21.6 Positive IGHA1_HUMAN.DASGVTFTWTPSSGK.2
774.8651 331.1248 29.7 17.6 21.6 Positive IGHA1_HUMAN.DASGVTFTWTPSSGK.2
774.8651 483.2461 29.7 17.6 21.6 Positive IGHA1_HUMAN.DASGVTFTWTPSSGK.2
774.8651 584.2938 29.7 17.6 21.6 Positive IGHA1_HUMAN.DASGVTFTWTPSSGK.2
756.8519 576.2988 29.0 15.6 19.6 Positive IGHA2_HUMAN.DASGATFTWTPSSGK.2
756.8519 863.4258 29.0 15.6 19.6 Positive IGHA2_HUMAN.DASGATFTWTPSSGK.2
756.8519 1111.5419 29.0 15.6 19.6 Positive IGHA2_HUMAN.DASGATFTWTPSSGK.2
756.8519 475.2511 29.0 15.6 19.6 Positive IGHA2_HUMAN.DASGATFTWTPSSGK.2
760.8590 584.3140 29.2 15.6 19.6 Positive IGHA2_HUMAN.DASGATFTWTPSSGK.2
760.8590 871.4410 29.2 15.6 19.6 Positive IGHA2_HUMAN.DASGATFTWTPSSGK.2
760.8590 1119.5570 29.2 15.6 19.6 Positive IGHA2_HUMAN.DASGATFTWTPSSGK.2
760.8590 483.2660 29.2 15.6 19.6 Positive IGHA2_HUMAN.DASGATFTWTPSSGK.2
593.8270 418.2296 23.5 15.4 19.4 Positive IGHG1_HUMAN.GPSVFPLAPSSK.2
593.8270 846.4720 23.5 15.4 19.4 Positive IGHG1_HUMAN.GPSVFPLAPSSK.2
593.8270 699.4036 23.5 15.4 19.4 Positive IGHG1_HUMAN.GPSVFPLAPSSK.2
597.8341 426.2438 23.6 15.4 19.4 Positive IGHG1_HUMAN.GPSVFPLAPSSK.2
597.8341 707.4178 23.6 15.4 19.4 Positive IGHG1_HUMAN.GPSVFPLAPSSK.2
597.8341 854.4862 23.6 15.4 19.4 Positive IGHG1_HUMAN.GPSVFPLAPSSK.2
412.7475 557.3293 17.3 9.8 13.8 Positive IGHG2_HUMAN.GLPAPIEK.2
412.7475 654.3821 17.3 9.8 13.8 Positive IGHG2_HUMAN.GLPAPIEK.2
412.7475 389.2395 17.3 9.8 13.8 Positive IGHG2_HUMAN.GLPAPIEK.2
412.7475 486.2922 17.3 9.8 13.8 Positive IGHG2_HUMAN.GLPAPIEK.2
416.7550 565.3440 17.5 9.8 13.8 Positive IGHG2_HUMAN.GLPAPIEK.2
416.7550 662.3970 17.5 9.8 13.8 Positive IGHG2_HUMAN.GLPAPIEK.2
416.7550 397.2540 17.5 9.8 13.8 Positive IGHG2_HUMAN.GLPAPIEK.2
416.7550 494.3070 17.5 9.8 13.8 Positive IGHG2_HUMAN.GLPAPIEK.2
708.8490 853.4526 27.4 12.2 16.2 Positive IGHG3_HUMAN.WYVDGVEVHNAK.2
708.8490 968.4796 27.4 12.2 16.2 Positive IGHG3_HUMAN.WYVDGVEVHNAK.2
708.8490 1067.5480 27.4 12.2 16.2 Positive IGHG3_HUMAN.WYVDGVEVHNAK.2
708.8490 1230.6113 27.4 12.2 16.2 Positive IGHG3_HUMAN.WYVDGVEVHNAK.2
712.8561 861.4668 27.6 12.2 16.2 Positive IGHG3_HUMAN.WYVDGVEVHNAK.2
712.8561 976.4938 27.6 12.2 16.2 Positive IGHG3_HUMAN.WYVDGVEVHNAK.2
712.8561 1075.5622 27.6 12.2 16.2 Positive IGHG3_HUMAN.WYVDGVEVHNAK.2
712.8561 1238.6255 27.6 12.2 16.2 Positive IGHG3_HUMAN.WYVDGVEVHNAK.2
951.4676 1406.6587 35.7 21.9 25.9 Positive IGHG4_HUMAN.TTPPVLDSDGSFFLYSR.2
951.4676 976.4887 35.7 21.9 25.9 Positive IGHG4_HUMAN.TTPPVLDSDGSFFLYSR.2
951.4676 1178.5477 35.7 21.9 25.9 Positive IGHG4_HUMAN.TTPPVLDSDGSFFLYSR.2
951.4676 1293.5746 35.7 21.9 25.9 Positive IGHG4_HUMAN.TTPPVLDSDGSFFLYSR.2
956.4718 1303.5829 35.8 21.9 25.9 Positive IGHG4_HUMAN.TTPPVLDSDGSFFLYSR.2
956.4718 1416.6669 35.8 21.9 25.9 Positive IGHG4_HUMAN.TTPPVLDSDGSFFLYSR.2
956.4718 986.4970 35.8 21.9 25.9 Positive IGHG4_HUMAN.TTPPVLDSDGSFFLYSR.2
956.4718 1188.5559 35.8 21.9 25.9 Positive IGHG4_HUMAN.TTPPVLDSDGSFFLYSR.2
809.4076 546.2882 30.8 8.9 12.9 Positive IGHM_HUMAN.QVGSGVTTDQVQAEAK.2
809.4076 989.4898 30.8 8.9 12.9 Positive IGHM_HUMAN.QVGSGVTTDQVQAEAK.2
809.4076 1090.5375 30.8 8.9 12.9 Positive IGHM_HUMAN.QVGSGVTTDQVQAEAK.2
809.4076 1390.6809 30.8 8.9 12.9 Positive IGHM_HUMAN.QVGSGVTTDQVQAEAK.2
813.4147 554.3024 31.0 8.9 12.9 Positive IGHM_HUMAN.QVGSGVTTDQVQAEAK.2
813.4147 997.5040 31.0 8.9 12.9 Positive IGHM_HUMAN.QVGSGVTTDQVQAEAK.2
813.4147 1098.5517 31.0 8.9 12.9 Positive IGHM_HUMAN.QVGSGVTTDQVQAEAK.2
813.4147 1398.6951 31.0 8.9 12.9 Positive IGHM_HUMAN.QVGSGVTTDQVQAEAK.2
695.3101 631.3410 27.0 8.8 12.8 Positive IGJ_HUMAN.SSEDPNEDIVER.2
695.3101 971.4793 27.0 8.8 12.8 Positive IGJ_HUMAN.SSEDPNEDIVER.2
695.3101 1086.5062 27.0 8.8 12.8 Positive IGJ_HUMAN.SSEDPNEDIVER.2
695.3101 486.2433 27.0 8.8 12.8 Positive IGJ_HUMAN.SSEDPNEDIVER.2
700.3142 641.3492 27.1 8.8 12.8 Positive IGJ_HUMAN.SSEDPNEDIVER.2
700.3142 491.2474 27.1 8.8 12.8 Positive IGJ_HUMAN.SSEDPNEDIVER.2
700.3142 981.4875 27.1 8.8 12.8 Positive IGJ_HUMAN.SSEDPNEDIVER.2
700.3142 1096.5145 27.1 8.8 12.8 Positive IGJ_HUMAN.SSEDPNEDIVER.2
644.8220 604.3310 25.2 8.7 12.7 Positive iRT-pep.AGGSSEPVTGLADK.2
644.8220 1016.5300 25.2 8.7 12.7 Positive iRT-pep.AGGSSEPVTGLADK.2
644.8220 800.4520 25.2 8.7 12.7 Positive iRT-pep.AGGSSEPVTGLADK.2
726.8350 584.2700 28.0 17.3 21.3 Positive iRT-pep.DAVTPADFSEWSK.2
726.8350 1066.4800 28.0 17.3 21.3 Positive iRT-pep.DAVTPADFSEWSK.2
726.8350 533.7460 28.0 17.3 21.3 Positive iRT-pep.DAVTPADFSEWSK.2
776.9290 1051.5600 29.7 23.1 27.1 Positive iRT-pep.FLLQFGAQGSPLFK.2
776.9290 504.3190 29.7 23.1 27.1 Positive iRT-pep.FLLQFGAQGSPLFK.2
776.9290 904.4890 29.7 23.1 27.1 Positive iRT-pep.FLLQFGAQGSPLFK.2
699.3380 855.4360 27.1 16.4 20.4 Positive iRT-pep.GDLDAASYYAPVR.2
699.3380 605.3410 27.1 16.4 20.4 Positive iRT-pep.GDLDAASYYAPVR.2
699.3380 926.4740 27.1 16.4 20.4 Positive iRT-pep.GDLDAASYYAPVR.2
636.8690 626.3990 25.0 21.6 25.6 Positive iRT-pep.GTFIIDPAAIVR.2
636.8690 741.4260 25.0 21.6 25.6 Positive iRT-pep.GTFIIDPAAIVR.2
636.8690 854.5100 25.0 21.6 25.6 Positive iRT-pep.GTFIIDPAAIVR.2
487.2570 503.2940 19.9 3.9 7.9 Positive iRT-pep.LGGNETQVR.2
487.2570 860.4230 19.9 3.9 7.9 Positive iRT-pep.LGGNETQVR.2
487.2570 803.4010 19.9 3.9 7.9 Positive iRT-pep.LGGNETQVR.2
622.8530 598.3680 24.5 19.6 23.6 Positive iRT-pep.TGFIIDPGGVIR.2
622.8530 713.3950 24.5 19.6 23.6 Positive iRT-pep.TGFIIDPGGVIR.2
622.8530 826.4790 24.5 19.6 23.6 Positive iRT-pep.TGFIIDPGGVIR.2
669.8380 1041.5000 26.1 13.0 17.0 Positive iRT-pep.TPVISGGPYYER.2
669.8380 841.3840 26.1 13.0 17.0 Positive iRT-pep.TPVISGGPYYER.2
669.8380 928.4160 26.1 13.0 17.0 Positive iRT-pep.TPVISGGPYYER.2
683.8530 1069.5300 26.6 13.9 17.9 Positive iRT-pep.TPVITGAPYYER.2
683.8530 956.4480 26.6 13.9 17.9 Positive iRT-pep.TPVITGAPYYER.2
683.8530 855.4000 26.6 13.9 17.9 Positive iRT-pep.TPVITGAPYYER.2
683.8270 819.3890 26.6 10.8 14.8 Positive iRT-pep.VEATFGVDESANK.2
683.8270 663.2950 26.6 10.8 14.8 Positive iRT-pep.VEATFGVDESANK.2
683.8270 966.4530 26.6 10.8 14.8 Positive iRT-pep.VEATFGVDESANK.2
547.2970 704.3580 21.9 11.9 15.9 Positive iRT-pep.YILAGVESNK.2
547.2970 817.4420 21.9 11.9 15.9 Positive iRT-pep.YILAGVESNK.2
547.2970 633.3210 21.9 11.9 15.9 Positive iRT-pep.YILAGVESNK.2
579.3173 444.2929 23.0 9.7 13.7 Positive ITIH1_HUMAN.AAISGENAGLVR.2
579.3173 629.3729 23.0 9.7 13.7 Positive ITIH1_HUMAN.AAISGENAGLVR.2
579.3173 815.4370 23.0 9.7 13.7 Positive ITIH1_HUMAN.AAISGENAGLVR.2
579.3173 902.4690 23.0 9.7 13.7 Positive ITIH1_HUMAN.AAISGENAGLVR.2
584.3214 454.3012 23.2 9.7 13.7 Positive ITIH1_HUMAN.AAISGENAGLVR.2
584.3214 639.3812 23.2 9.7 13.7 Positive ITIH1_HUMAN.AAISGENAGLVR.2
584.3214 825.4453 23.2 9.7 13.7 Positive ITIH1_HUMAN.AAISGENAGLVR.2
584.3214 912.4773 23.2 9.7 13.7 Positive ITIH1_HUMAN.AAISGENAGLVR.2
791.9310 942.5367 30.2 14.7 18.7 Positive ITIH2_HUMAN.IQPSGGTNINEALLR.2
791.9310 1341.7121 30.2 14.7 18.7 Positive ITIH2_HUMAN.IQPSGGTNINEALLR.2
791.9310 715.4097 30.2 14.7 18.7 Positive ITIH2_HUMAN.IQPSGGTNINEALLR.2
791.9310 1244.6593 30.2 14.7 18.7 Positive ITIH2_HUMAN.IQPSGGTNINEALLR.2
796.9351 952.5450 30.4 14.7 18.7 Positive ITIH2_HUMAN.IQPSGGTNINEALLR.2
796.9351 725.4180 30.4 14.7 18.7 Positive ITIH2_HUMAN.IQPSGGTNINEALLR.2
796.9351 1351.7204 30.4 14.7 18.7 Positive ITIH2_HUMAN.IQPSGGTNINEALLR.2
796.9351 1254.6676 30.4 14.7 18.7 Positive ITIH2_HUMAN.IQPSGGTNINEALLR.2
524.3261 615.4076 21.1 21.2 25.2 Positive ITIH4_HUMAN.LGVYELLLK.2
524.3261 934.5608 21.1 21.2 25.2 Positive ITIH4_HUMAN.LGVYELLLK.2
524.3261 877.5393 21.1 21.2 25.2 Positive ITIH4_HUMAN.LGVYELLLK.2
524.3261 778.4709 21.1 21.2 25.2 Positive ITIH4_HUMAN.LGVYELLLK.2
528.3332 942.5750 21.3 21.2 25.2 Positive ITIH4_HUMAN.LGVYELLLK.2
528.3332 885.5535 21.3 21.2 25.2 Positive ITIH4_HUMAN.LGVYELLLK.2
528.3332 786.4851 21.3 21.2 25.2 Positive ITIH4_HUMAN.LGVYELLLK.2
528.3332 623.4218 21.3 21.2 25.2 Positive ITIH4_HUMAN.LGVYELLLK.2
730.3624 1112.5331 28.1 11.6 15.6 Positive KLKB1_HUMAN.IAYGTQGSSGYSLR.2
730.3624 954.4639 28.1 11.6 15.6 Positive KLKB1_HUMAN.IAYGTQGSSGYSLR.2
730.3624 826.4054 28.1 11.6 15.6 Positive KLKB1_HUMAN.IAYGTQGSSGYSLR.2
730.3624 769.3839 28.1 11.6 15.6 Positive KLKB1_HUMAN.IAYGTQGSSGYSLR.2
735.3666 779.3922 28.3 11.6 15.6 Positive KLKB1_HUMAN.IAYGTQGSSGYSLR.2
735.3666 836.4136 28.3 11.6 15.6 Positive KLKB1_HUMAN.IAYGTQGSSGYSLR.2
735.3666 964.4722 28.3 11.6 15.6 Positive KLKB1_HUMAN.IAYGTQGSSGYSLR.2
735.3666 1122.5413 28.3 11.6 15.6 Positive KLKB1_HUMAN.IAYGTQGSSGYSLR.2
515.7715 607.3198 20.9 19.4 23.4 Positive KNG1_HUMAN.YFIDFVAR.2
515.7715 492.2929 20.9 19.4 23.4 Positive KNG1_HUMAN.YFIDFVAR.2
515.7715 720.4039 20.9 19.4 23.4 Positive KNG1_HUMAN.YFIDFVAR.2
515.7715 867.4723 20.9 19.4 23.4 Positive KNG1_HUMAN.YFIDFVAR.2
520.7756 617.3281 21.0 19.4 23.4 Positive KNG1_HUMAN.YFIDFVAR.2
520.7756 877.4806 21.0 19.4 23.4 Positive KNG1_HUMAN.YFIDFVAR.2
520.7756 730.4122 21.0 19.4 23.4 Positive KNG1_HUMAN.YFIDFVAR.2
520.7756 502.3012 21.0 19.4 23.4 Positive KNG1_HUMAN.YFIDFVAR.2
488.7642 347.1714 19.9 8.6 12.6 Positive MBL2_HUMAN.FQASVATPR.2
488.7642 444.2565 19.9 8.6 12.6 Positive MBL2_HUMAN.FQASVATPR.2
488.7642 630.3570 19.9 8.6 12.6 Positive MBL2_HUMAN.FQASVATPR.2
488.7642 701.3941 19.9 8.6 12.6 Positive MBL2_HUMAN.FQASVATPR.2
493.7683 640.3652 20.1 8.6 12.6 Positive MBL2_HUMAN.FQASVATPR.2
493.7683 347.1714 20.1 8.6 12.6 Positive MBL2_HUMAN.FQASVATPR.2
493.7683 454.2648 20.1 8.6 12.6 Positive MBL2_HUMAN.FQASVATPR.2
493.7683 711.4023 20.1 8.6 12.6 Positive MBL2_HUMAN.FQASVATPR.2
607.8350 372.2241 24.0 13.1 17.1 Positive PEDF_HUMAN.ELLDTVTAPQK.2
607.8350 544.3089 24.0 13.1 17.1 Positive PEDF_HUMAN.ELLDTVTAPQK.2
607.8350 744.4250 24.0 13.1 17.1 Positive PEDF_HUMAN.ELLDTVTAPQK.2
607.8350 859.4520 24.0 13.1 17.1 Positive PEDF_HUMAN.ELLDTVTAPQK.2
611.8421 867.4662 24.1 13.1 17.1 Positive PEDF_HUMAN.ELLDTVTAPQK.2
611.8421 752.4392 24.1 13.1 17.1 Positive PEDF_HUMAN.ELLDTVTAPQK.2
611.8421 552.3231 24.1 13.1 17.1 Positive PEDF_HUMAN.ELLDTVTAPQK.2
611.8421 380.2383 24.1 13.1 17.1 Positive PEDF_HUMAN.ELLDTVTAPQK.2
517.9633 312.1779 26.1 14.8 18.8 Positive PGRP2_HUMAN.AGLLRPDYALLGHR.3
517.9633 369.1993 26.1 14.8 18.8 Positive PGRP2_HUMAN.AGLLRPDYALLGHR.3
517.9633 482.2834 26.1 14.8 18.8 Positive PGRP2_HUMAN.AGLLRPDYALLGHR.3
517.9633 595.3675 26.1 14.8 18.8 Positive PGRP2_HUMAN.AGLLRPDYALLGHR.3
521.6050 605.3760 26.3 14.8 18.8 Positive PGRP2_HUMAN.AGLLRPDYALLGHR.3
521.6050 322.1870 26.3 14.8 18.8 Positive PGRP2_HUMAN.AGLLRPDYALLGHR.3
521.6050 379.2080 26.3 14.8 18.8 Positive PGRP2_HUMAN.AGLLRPDYALLGHR.3
521.6050 492.2920 26.3 14.8 18.8 Positive PGRP2_HUMAN.AGLLRPDYALLGHR.3
667.3629 591.3501 26.0 19.2 23.2 Positive PLF4_HUMAN.IC[CAM]LDLQAPLYK.2
667.3629 947.5197 26.0 19.2 23.2 Positive PLF4_HUMAN.IC[CAM]LDLQAPLYK.2
667.3629 1060.6037 26.0 19.2 23.2 Positive PLF4_HUMAN.IC[CAM]LDLQAPLYK.2
667.3629 520.3130 26.0 19.2 23.2 Positive PLF4_HUMAN.IC[CAM]LDLQAPLYK.2
671.3604 599.3451 26.1 19.1 23.1 Positive PLF4_HUMAN.IC[CAM]LDLQAPLYK.2
671.3604 955.5147 26.1 19.1 23.1 Positive PLF4_HUMAN.IC[CAM]LDLQAPLYK.2
671.3604 1068.5988 26.1 19.1 23.1 Positive PLF4_HUMAN.IC[CAM]LDLQAPLYK.2
671.3604 528.3080 26.1 19.1 23.1 Positive PLF4_HUMAN.IC[CAM]LDLQAPLYK.2
649.8280 961.4738 25.4 9.0 13.0 Positive PLMN_HUMAN.HSIFTPETNPR.2
649.8280 713.3577 25.4 9.0 13.0 Positive PLMN_HUMAN.HSIFTPETNPR.2
649.8280 1161.5899 25.4 9.0 13.0 Positive PLMN_HUMAN.HSIFTPETNPR.2
649.8280 1074.5578 25.4 9.0 13.0 Positive PLMN_HUMAN.HSIFTPETNPR.2
654.8322 723.3659 25.6 9.0 13.0 Positive PLMN_HUMAN.HSIFTPETNPR.2
654.8322 1171.5981 25.6 9.0 13.0 Positive PLMN_HUMAN.HSIFTPETNPR.2
654.8322 1084.5661 25.6 9.0 13.0 Positive PLMN_HUMAN.HSIFTPETNPR.2
654.8322 971.4820 25.6 9.0 13.0 Positive PLMN_HUMAN.HSIFTPETNPR.2
514.3186 431.2401 20.8 14.8 18.8 Positive PON1_HUMAN.LLIGTVFHK.2
514.3186 801.4618 20.8 14.8 18.8 Positive PON1_HUMAN.LLIGTVFHK.2
514.3186 688.3777 20.8 14.8 18.8 Positive PON1_HUMAN.LLIGTVFHK.2
514.3186 631.3562 20.8 14.8 18.8 Positive PON1_HUMAN.LLIGTVFHK.2
518.3257 439.2543 20.9 14.8 18.8 Positive PON1_HUMAN.LLIGTVFHK.2
518.3257 639.3704 20.9 14.8 18.8 Positive PON1_HUMAN.LLIGTVFHK.2
518.3257 696.3919 20.9 14.8 18.8 Positive PON1_HUMAN.LLIGTVFHK.2
518.3257 809.4759 20.9 14.8 18.8 Positive PON1_HUMAN.LLIGTVFHK.2
581.2735 927.4393 23.1 15.6 19.6 Positive RET4_HUMAN.FSGTWYAMAK.2
581.2735 583.2908 23.1 15.6 19.6 Positive RET4_HUMAN.FSGTWYAMAK.2
581.2735 420.2275 23.1 15.6 19.6 Positive RET4_HUMAN.FSGTWYAMAK.2
581.2735 1014.4713 23.1 15.6 19.6 Positive RET4_HUMAN.FSGTWYAMAK.2
585.2806 591.3050 23.2 15.5 19.5 Positive RET4_HUMAN.FSGTWYAMAK.2
585.2806 935.4535 23.2 15.5 19.5 Positive RET4_HUMAN.FSGTWYAMAK.2
585.2806 1022.4855 23.2 15.5 19.5 Positive RET4_HUMAN.FSGTWYAMAK.2
585.2806 428.2417 23.2 15.5 19.5 Positive RET4_HUMAN.FSGTWYAMAK.2
566.7744 819.3778 22.6 10.9 14.9 Positive SAA4_HUMAN.EALQGVGDMGR.2
566.7744 535.2293 22.6 10.9 14.9 Positive SAA4_HUMAN.EALQGVGDMGR.2
566.7744 363.1809 22.6 10.9 14.9 Positive SAA4_HUMAN.EALQGVGDMGR.2
566.7744 691.3192 22.6 10.9 14.9 Positive SAA4_HUMAN.EALQGVGDMGR.2
571.7785 701.3275 22.8 10.9 14.9 Positive SAA4_HUMAN.EALQGVGDMGR.2
571.7785 373.1892 22.8 10.9 14.9 Positive SAA4_HUMAN.EALQGVGDMGR.2
571.7785 829.3860 22.8 10.9 14.9 Positive SAA4_HUMAN.EALQGVGDMGR.2
571.7785 545.2376 22.8 10.9 14.9 Positive SAA4_HUMAN.EALQGVGDMGR.2
549.7931 985.4949 22.0 11.0 15.0 Positive SEPP1_HUMAN.LPTDSELAPR.2
549.7931 787.3945 22.0 11.0 15.0 Positive SEPP1_HUMAN.LPTDSELAPR.2
549.7931 888.4421 22.0 11.0 15.0 Positive SEPP1_HUMAN.LPTDSELAPR.2
549.7931 672.3675 22.0 11.0 15.0 Positive SEPP1_HUMAN.LPTDSELAPR.2
554.7973 682.3758 22.2 11.0 15.0 Positive SEPP1_HUMAN.LPTDSELAPR.2
554.7973 797.4027 22.2 11.0 15.0 Positive SEPP1_HUMAN.LPTDSELAPR.2
554.7973 995.5032 22.2 11.0 15.0 Positive SEPP1_HUMAN.LPTDSELAPR.2
554.7973 898.4504 22.2 11.0 15.0 Positive SEPP1_HUMAN.LPTDSELAPR.2
721.4299 804.4363 27.8 23.8 27.8 Positive SHBG_HUMAN.IALGGLLFPASNLR.2
721.4299 657.3678 27.8 23.8 27.8 Positive SHBG_HUMAN.IALGGLLFPASNLR.2
721.4299 1144.6473 27.8 23.8 27.8 Positive SHBG_HUMAN.IALGGLLFPASNLR.2
721.4299 917.5203 27.8 23.8 27.8 Positive SHBG_HUMAN.IALGGLLFPASNLR.2
726.4341 927.5286 28.0 23.8 27.8 Positive SHBG_HUMAN.IALGGLLFPASNLR.2
726.4341 1154.6556 28.0 23.8 27.8 Positive SHBG_HUMAN.IALGGLLFPASNLR.2
726.4341 814.4445 28.0 23.8 27.8 Positive SHBG_HUMAN.IALGGLLFPASNLR.2
726.4341 667.3761 28.0 23.8 27.8 Positive SHBG_HUMAN.IALGGLLFPASNLR.2
676.3770 846.4931 26.3 15.5 19.5 Positive STOM_HUMAN.YLQTLTTIAAEK.2
676.3770 733.4090 26.3 15.5 19.5 Positive STOM_HUMAN.YLQTLTTIAAEK.2
676.3770 418.2296 26.3 15.5 19.5 Positive STOM_HUMAN.YLQTLTTIAAEK.2
676.3770 947.5408 26.3 15.5 19.5 Positive STOM_HUMAN.YLQTLTTIAAEK.2
680.3840 854.5080 26.4 15.4 19.4 Positive STOM_HUMAN.YLQTLTTIAAEK.2
680.3840 955.5560 26.4 15.4 19.4 Positive STOM_HUMAN.YLQTLTTIAAEK.2
680.3840 426.2440 26.4 15.4 19.4 Positive STOM_HUMAN.YLQTLTTIAAEK.2
680.3840 741.4240 26.4 15.4 19.4 Positive STOM_HUMAN.YLQTLTTIAAEK.2
657.3874 672.4291 25.7 20.6 24.6 Positive TETN_HUMAN.LDTLAQEVALLK.2
657.3874 871.5247 25.7 20.6 24.6 Positive TETN_HUMAN.LDTLAQEVALLK.2
657.3874 800.4876 25.7 20.6 24.6 Positive TETN_HUMAN.LDTLAQEVALLK.2
657.3874 330.1660 25.7 20.6 24.6 Positive TETN_HUMAN.LDTLAQEVALLK.2
661.3945 330.1660 25.8 20.6 24.6 Positive TETN_HUMAN.LDTLAQEVALLK.2
661.3945 680.4433 25.8 20.6 24.6 Positive TETN_HUMAN.LDTLAQEVALLK.2
661.3945 879.5389 25.8 20.6 24.6 Positive TETN_HUMAN.LDTLAQEVALLK.2
661.3945 808.5018 25.8 20.6 24.6 Positive TETN_HUMAN.LDTLAQEVALLK.2
543.3395 900.5917 21.8 21.8 25.8 Positive THBG_HUMAN.NALALFVLPK.2
543.3395 603.3865 21.8 21.8 25.8 Positive THBG_HUMAN.NALALFVLPK.2
543.3395 787.5076 21.8 21.8 25.8 Positive THBG_HUMAN.NALALFVLPK.2
543.3395 716.4705 21.8 21.8 25.8 Positive THBG_HUMAN.NALALFVLPK.2
547.3466 795.5218 21.9 21.7 25.7 Positive THBG_HUMAN.NALALFVLPK.2
547.3466 724.4847 21.9 21.7 25.7 Positive THBG_HUMAN.NALALFVLPK.2
547.3466 908.6059 21.9 21.7 25.7 Positive THBG_HUMAN.NALALFVLPK.2
547.3466 611.4007 21.9 21.7 25.7 Positive THBG_HUMAN.NALALFVLPK.2
781.3677 909.4577 29.9 16.3 20.3 Positive THRB_HUMAN.TATSEYQTFFNPR.2
781.3677 680.3515 29.9 16.3 20.3 Positive THRB_HUMAN.TATSEYQTFFNPR.2
781.3677 1072.5211 29.9 16.3 20.3 Positive THRB_HUMAN.TATSEYQTFFNPR.2
786.3718 919.4660 30.1 16.3 20.3 Positive THRB_HUMAN.TATSEYQTFFNPR.2
786.3718 690.3597 30.1 16.3 20.3 Positive THRB_HUMAN.TATSEYQTFFNPR.2
786.3718 1082.5293 30.1 16.3 20.3 Positive THRB_HUMAN.TATSEYQTFFNPR.2
418.2207 506.2755 17.5 11.0 15.0 Positive TotalIGHG.DTLMISR.2
418.2207 619.3596 17.5 11.0 15.0 Positive TotalIGHG.DTLMISR.2
418.2207 330.1660 17.5 11.0 15.0 Positive TotalIGHG.DTLMISR.2
418.2207 375.2350 17.5 11.0 15.0 Positive TotalIGHG.DTLMISR.2
423.2249 516.2838 17.7 11.0 15.0 Positive TotalIGHG.DTLMISR.2
423.2249 629.3679 17.7 11.0 15.0 Positive TotalIGHG.DTLMISR.2
423.2249 330.1660 17.7 11.0 15.0 Positive TotalIGHG.DTLMISR.2
423.2249 385.2433 17.7 11.0 15.0 Positive TotalIGHG.DTLMISR.2
642.2882 771.3784 25.2 14.6 18.6 Positive TRFE_HUMAN.EGYYGYTGAFR.2
642.2882 934.4417 25.2 14.6 18.6 Positive TRFE_HUMAN.EGYYGYTGAFR.2
642.2882 551.2936 25.2 14.6 18.6 Positive TRFE_HUMAN.EGYYGYTGAFR.2
642.2882 714.3570 25.2 14.6 18.6 Positive TRFE_HUMAN.EGYYGYTGAFR.2
647.2923 781.3867 25.3 14.6 18.6 Positive TRFE_HUMAN.EGYYGYTGAFR.2
647.2923 944.4500 25.3 14.6 18.6 Positive TRFE_HUMAN.EGYYGYTGAFR.2
647.2923 561.3019 25.3 14.6 18.6 Positive TRFE_HUMAN.EGYYGYTGAFR.2
647.2923 724.3652 25.3 14.6 18.6 Positive TRFE_HUMAN.EGYYGYTGAFR.2
683.8831 941.5316 26.6 15.5 19.5 Positive TTHY_HUMAN.GSPAINVAVHVFR.2
683.8831 728.4202 26.6 15.5 19.5 Positive TTHY_HUMAN.GSPAINVAVHVFR.2
683.8831 1054.6156 26.6 15.5 19.5 Positive TTHY_HUMAN.GSPAINVAVHVFR.2
683.8831 313.1506 26.6 15.5 19.5 Positive TTHY_HUMAN.GSPAINVAVHVFR.2
688.8873 951.5398 26.7 15.5 19.5 Positive TTHY_HUMAN.GSPAINVAVHVFR.2
688.8873 738.4285 26.7 15.5 19.5 Positive TTHY_HUMAN.GSPAINVAVHVFR.2
688.8873 313.1506 26.7 15.5 19.5 Positive TTHY_HUMAN.GSPAINVAVHVFR.2
688.8873 1064.6239 26.7 15.5 19.5 Positive TTHY_HUMAN.GSPAINVAVHVFR.2
627.8619 691.3733 24.7 15.2 19.2 Positive VTDB_HUMAN.HLSLLTTLSNR.2
627.8619 804.4574 24.7 15.2 19.2 Positive VTDB_HUMAN.HLSLLTTLSNR.2
627.8619 1117.6575 24.7 15.2 19.2 Positive VTDB_HUMAN.HLSLLTTLSNR.2
627.8619 1004.5735 24.7 15.2 19.2 Positive VTDB_HUMAN.HLSLLTTLSNR.2
632.8660 1014.5818 24.8 15.2 19.2 Positive VTDB_HUMAN.HLSLLTTLSNR.2
632.8660 1127.6658 24.8 15.2 19.2 Positive VTDB_HUMAN.HLSLLTTLSNR.2
632.8660 814.4657 24.8 15.2 19.2 Positive VTDB_HUMAN.HLSLLTTLSNR.2
632.8660 701.3816 24.8 15.2 19.2 Positive VTDB_HUMAN.HLSLLTTLSNR.2
711.8304 762.3417 27.5 16.2 20.2 Positive VTNC_HUMAN.FEDGVLDPDYPR.2
711.8304 875.4258 27.5 16.2 20.2 Positive VTNC_HUMAN.FEDGVLDPDYPR.2
711.8304 435.2350 27.5 16.2 20.2 Positive VTNC_HUMAN.FEDGVLDPDYPR.2
711.8304 647.3148 27.5 16.2 20.2 Positive VTNC_HUMAN.FEDGVLDPDYPR.2
716.8346 772.3500 27.7 16.2 20.2 Positive VTNC_HUMAN.FEDGVLDPDYPR.2
716.8346 885.4340 27.7 16.2 20.2 Positive VTNC_HUMAN.FEDGVLDPDYPR.2
716.8346 445.2433 27.7 16.2 20.2 Positive VTNC_HUMAN.FEDGVLDPDYPR.2
716.8346 657.3230 27.7 16.2 20.2 Positive VTNC_HUMAN.FEDGVLDPDYPR.2
726.3454 717.3712 28.0 13.0 17.0 Positive ZA2G_HUMAN.AYLEEEC[CAM]PATLR.2
726.3454 975.4564 28.0 13.0 17.0 Positive ZA2G_HUMAN.AYLEEEC[CAM]PATLR.2
726.3454 1104.4990 28.0 13.0 17.0 Positive ZA2G_HUMAN.AYLEEEC[CAM]PATLR.2
726.3454 557.3406 28.0 13.0 17.0 Positive ZA2G_HUMAN.AYLEEEC[CAM]PATLR.2
731.3448 727.3701 28.2 12.9 16.9 Positive ZA2G_HUMAN.AYLEEEC[CAM]PATLR.2
731.3448 985.4553 28.2 12.9 16.9 Positive ZA2G_HUMAN.AYLEEEC[CAM]PATLR.2
731.3448 1114.4979 28.2 12.9 16.9 Positive ZA2G_HUMAN.AYLEEEC[CAM]PATLR.2
731.3448 567.3395 28.2 12.9 16.9 Positive ZA2G_HUMAN.AYLEEEC[CAM]PATLR.2
SUPPLEMENTAL	TABLE	2:
Compound	Group Compound	Name ISTD? Precursor	Ion MS1	Res Product	Ion MS2	Res Primary Ret	Time	(min) Delta	Ret	Time Collision	Energy
A1AG1_HUMAN SDVVYTDWK.heavy TRUE 560.773671 Unit 819.41268 Unit TRUE 10.58 0.8 18.3
A1AG1_HUMAN SDVVYTDWK.heavy TRUE 560.773671 Unit 720.344266 Unit TRUE 10.58 0.8 18.3
A1AG1_HUMAN SDVVYTDWK.heavy TRUE 560.773671 Unit 302.134661 Unit TRUE 10.58 0.8 18.3
A1AG1_HUMAN SDVVYTDWK.light FALSE 556.766571 Unit 811.398481 Unit TRUE 10.58 0.8 18.3
A1AG1_HUMAN SDVVYTDWK.light FALSE 556.766571 Unit 712.330067 Unit TRUE 10.58 0.8 18.3
A1AG1_HUMAN SDVVYTDWK.light FALSE 556.766571 Unit 302.134661 Unit TRUE 10.58 0.8 18.3
A1AG2_HUMAN EHVAHLLFLR.heavy TRUE 622.860524 Unit 978.612266 Unit TRUE 13.16 0.8 20.2
A1AG2_HUMAN EHVAHLLFLR.heavy TRUE 622.860524 Unit 879.543852 Unit TRUE 13.16 0.8 20.2
A1AG2_HUMAN EHVAHLLFLR.heavy TRUE 622.860524 Unit 808.506739 Unit TRUE 13.16 0.8 20.2
A1AG2_HUMAN EHVAHLLFLR.light FALSE 617.856389 Unit 968.603997 Unit TRUE 13.16 0.8 20.2
A1AG2_HUMAN EHVAHLLFLR.light FALSE 617.856389 Unit 869.535583 Unit TRUE 13.16 0.8 20.2
A1AG2_HUMAN EHVAHLLFLR.light FALSE 617.856389 Unit 798.49847 Unit TRUE 13.16 0.8 20.2
A1AT_HUMAN SVLGQLGITK.heavy TRUE 512.318048 Unit 837.528378 Unit TRUE 13.95 0.8 16.8
A1AT_HUMAN SVLGQLGITK.heavy TRUE 512.318048 Unit 724.444314 Unit TRUE 13.95 0.8 16.8
A1AT_HUMAN SVLGQLGITK.heavy TRUE 512.318048 Unit 419.267827 Unit TRUE 13.95 0.8 16.8
A1AT_HUMAN SVLGQLGITK.light FALSE 508.310949 Unit 829.514179 Unit TRUE 13.95 0.8 16.8
A1AT_HUMAN SVLGQLGITK.light FALSE 508.310949 Unit 716.430115 Unit TRUE 13.95 0.8 16.8
A1AT_HUMAN SVLGQLGITK.light FALSE 508.310949 Unit 415.260728 Unit TRUE 13.95 0.8 16.8
A1BG_HUMAN SGLSTGWTQLSK.heavy TRUE 636.837334 Unit 1015.529835 Unit TRUE 12.29 0.8 20.6
A1BG_HUMAN SGLSTGWTQLSK.heavy TRUE 636.837334 Unit 928.497806 Unit TRUE 12.29 0.8 20.6
A1BG_HUMAN SGLSTGWTQLSK.heavy TRUE 636.837334 Unit 827.450128 Unit TRUE 12.29 0.8 20.6
A1BG_HUMAN SGLSTGWTQLSK.light FALSE 632.830234 Unit 1007.515636 Unit TRUE 12.29 0.8 20.6
A1BG_HUMAN SGLSTGWTQLSK.light FALSE 632.830234 Unit 920.483607 Unit TRUE 12.29 0.8 20.6
A1BG_HUMAN SGLSTGWTQLSK.light FALSE 632.830234 Unit 819.435929 Unit TRUE 12.29 0.8 20.6
A2AP_HUMAN LFGPDLK.heavy TRUE 399.235996 Unit 684.380651 Unit TRUE 11.66 0.8 13.3
A2AP_HUMAN LFGPDLK.heavy TRUE 399.235996 Unit 537.312237 Unit TRUE 11.66 0.8 13.3
A2AP_HUMAN LFGPDLK.heavy TRUE 399.235996 Unit 268.2111 Unit TRUE 11.66 0.8 13.3
A2AP_HUMAN LFGPDLK.heavy TRUE 399.235996 Unit 155.127 Unit TRUE 11.66 0.8 13.3
A2AP_HUMAN LFGPDLK.light FALSE 395.228896 Unit 676.366452 Unit TRUE 11.66 0.8 13.3
A2AP_HUMAN LFGPDLK.light FALSE 395.228896 Unit 529.298038 Unit TRUE 11.66 0.8 13.3
A2AP_HUMAN LFGPDLK.light FALSE 395.228896 Unit 260.1969 Unit TRUE 11.66 0.8 13.3
A2AP_HUMAN LFGPDLK.light FALSE 395.228896 Unit 147.1128 Unit TRUE 11.66 0.8 13.3
A2GL_HUMAN VAAGAFQGLR.heavy TRUE 500.284118 Unit 829.455431 Unit TRUE 10.07 0.8 16.4
A2GL_HUMAN VAAGAFQGLR.heavy TRUE 500.284118 Unit 758.418318 Unit TRUE 10.07 0.8 16.4
A2GL_HUMAN VAAGAFQGLR.heavy TRUE 500.284118 Unit 630.35974 Unit TRUE 10.07 0.8 16.4
A2GL_HUMAN VAAGAFQGLR.light FALSE 495.279983 Unit 819.447162 Unit TRUE 10.07 0.8 16.4
A2GL_HUMAN VAAGAFQGLR.light FALSE 495.279983 Unit 748.410049 Unit TRUE 10.07 0.8 16.4
A2GL_HUMAN VAAGAFQGLR.light FALSE 495.279983 Unit 620.351471 Unit TRUE 10.07 0.8 16.4
A2MG_HUMAN HYDGSYSTFGER.heavy TRUE 476.873318 Unit 560.209952 Unit TRUE 6.61 0.8 15.8
A2MG_HUMAN HYDGSYSTFGER.heavy TRUE 476.873318 Unit 518.259692 Unit TRUE 6.61 0.8 15.8
A2MG_HUMAN HYDGSYSTFGER.heavy TRUE 476.873318 Unit 371.191278 Unit TRUE 6.61 0.8 15.8
A2MG_HUMAN HYDGSYSTFGER.light FALSE 473.537229 Unit 560.209952 Unit TRUE 6.61 0.8 12.2
A2MG_HUMAN HYDGSYSTFGER.light FALSE 473.537229 Unit 508.251423 Unit TRUE 6.61 0.8 12.2
A2MG_HUMAN HYDGSYSTFGER.light FALSE 473.537229 Unit 361.183009 Unit TRUE 6.61 0.8 12.2
AACT_HUMAN EIGELYLPK.heavy TRUE 535.304607 Unit 827.47528 Unit TRUE 13.93 0.8 17.5
AACT_HUMAN EIGELYLPK.heavy TRUE 535.304607 Unit 641.411223 Unit TRUE 13.93 0.8 17.5
AACT_HUMAN EIGELYLPK.heavy TRUE 535.304607 Unit 365.263831 Unit TRUE 13.93 0.8 17.5
AACT_HUMAN EIGELYLPK.light FALSE 531.297507 Unit 819.461081 Unit TRUE 13.93 0.8 17.5
AACT_HUMAN EIGELYLPK.light FALSE 531.297507 Unit 633.397024 Unit TRUE 13.93 0.8 17.5
AACT_HUMAN EIGELYLPK.light FALSE 531.297507 Unit 357.249632 Unit TRUE 13.93 0.8 17.5
ABCF1_HUMAN IGFFNQQYAEQLR.heavy TRUE 812.411306 Unit 917.471475 Unit TRUE 16.06 0.8 26
ABCF1_HUMAN IGFFNQQYAEQLR.heavy TRUE 812.411306 Unit 789.412898 Unit TRUE 16.06 0.8 26
ABCF1_HUMAN IGFFNQQYAEQLR.heavy TRUE 812.411306 Unit 626.349569 Unit TRUE 16.06 0.8 26
ABCF1_HUMAN IGFFNQQYAEQLR.light FALSE 807.407172 Unit 907.463206 Unit TRUE 16.06 0.8 26
ABCF1_HUMAN IGFFNQQYAEQLR.light FALSE 807.407172 Unit 779.404629 Unit TRUE 16.06 0.8 26
ABCF1_HUMAN IGFFNQQYAEQLR.light FALSE 807.407172 Unit 616.3413 Unit TRUE 16.06 0.8 26
AFAM_HUMAN AESPEVC[+57.0]FNEESPK.heavy TRUE 815.860877 Unit 1018.438971 Unit TRUE 9.11 0.8 26.2
AFAM_HUMAN AESPEVC[+57.0]FNEESPK.heavy TRUE 815.860877 Unit 715.821023 Unit TRUE 9.11 0.8 26.2
AFAM_HUMAN AESPEVC[+57.0]FNEESPK.heavy TRUE 815.860877 Unit 672.305009 Unit TRUE 9.11 0.8 26.2
AFAM_HUMAN AESPEVC[+57.0]FNEESPK.light FALSE 811.853777 Unit 1010.424772 Unit TRUE 9.11 0.8 26.2
AFAM_HUMAN AESPEVC[+57.0]FNEESPK.light FALSE 811.853777 Unit 711.813924 Unit TRUE 9.11 0.8 26.2
AFAM_HUMAN AESPEVC[+57.0]FNEESPK.light FALSE 811.853777 Unit 668.29791 Unit TRUE 9.11 0.8 26.2
ALBU_HUMAN YLYEIAR.heavy TRUE 469.254494 Unit 774.438384 Unit TRUE 10.57 0.8 15.4
ALBU_HUMAN YLYEIAR.heavy TRUE 469.254494 Unit 498.290992 Unit TRUE 10.57 0.8 15.4
ALBU_HUMAN YLYEIAR.heavy TRUE 469.254494 Unit 369.248399 Unit TRUE 10.57 0.8 15.4
ALBU_HUMAN YLYEIAR.light FALSE 464.25036 Unit 764.430115 Unit TRUE 10.57 0.8 15.4
ALBU_HUMAN YLYEIAR.light FALSE 464.25036 Unit 488.282723 Unit TRUE 10.57 0.8 15.4
ALBU_HUMAN YLYEIAR.light FALSE 464.25036 Unit 359.24013 Unit TRUE 10.57 0.8 15.4
AMBP_HUMAN TVAAC[+57.0]NLPIVR.heavy TRUE 612.343849 Unit 1023.56433 Unit TRUE 12.09 0.8 19.8
AMBP_HUMAN TVAAC[+57.0]NLPIVR.heavy TRUE 612.343849 Unit 952.527216 Unit TRUE 12.09 0.8 19.8
AMBP_HUMAN TVAAC[+57.0]NLPIVR.heavy TRUE 612.343849 Unit 881.490103 Unit TRUE 12.09 0.8 19.8
AMBP_HUMAN TVAAC[+57.0]NLPIVR.light FALSE 607.339715 Unit 1013.556061 Unit TRUE 12.09 0.8 19.8
AMBP_HUMAN TVAAC[+57.0]NLPIVR.light FALSE 607.339715 Unit 942.518947 Unit TRUE 12.09 0.8 19.8
AMBP_HUMAN TVAAC[+57.0]NLPIVR.light FALSE 607.339715 Unit 871.481834 Unit TRUE 12.09 0.8 19.8
ANGT_HUMAN ALQDQLVLVAAK.heavy TRUE 638.889369 Unit 1092.650284 Unit TRUE 14.74 0.8 25
ANGT_HUMAN ALQDQLVLVAAK.heavy TRUE 638.889369 Unit 964.591707 Unit TRUE 14.74 0.8 25
ANGT_HUMAN ALQDQLVLVAAK.heavy TRUE 638.889369 Unit 608.422122 Unit TRUE 14.74 0.8 25
ANGT_HUMAN ALQDQLVLVAAK.light FALSE 634.88227 Unit 1084.636085 Unit TRUE 14.74 0.8 25
ANGT_HUMAN ALQDQLVLVAAK.light FALSE 634.88227 Unit 956.577508 Unit TRUE 14.74 0.8 25
ANGT_HUMAN ALQDQLVLVAAK.light FALSE 634.88227 Unit 600.407923 Unit TRUE 14.74 0.8 25
ANT3_HUMAN EVPLNTIIFMGR.heavy TRUE 700.385714 Unit 961.516317 Unit TRUE 19.87 0.8 22.6
ANT3_HUMAN EVPLNTIIFMGR.heavy TRUE 700.385714 Unit 633.341647 Unit TRUE 19.87 0.8 22.6
ANT3_HUMAN EVPLNTIIFMGR.heavy TRUE 700.385714 Unit 586.33021 Unit TRUE 19.87 0.8 22.6
ANT3_HUMAN EVPLNTIIFMGR.light FALSE 695.38158 Unit 951.508048 Unit TRUE 19.87 0.8 22.6
ANT3_HUMAN EVPLNTIIFMGR.light FALSE 695.38158 Unit 623.333378 Unit TRUE 19.87 0.8 22.6
ANT3_HUMAN EVPLNTIIFMGR.light FALSE 695.38158 Unit 581.326076 Unit TRUE 19.87 0.8 22.6
APOA_HUMAN GTYSTTVTGR.heavy TRUE 526.765955 Unit 731.392162 Unit TRUE 4.35 0.8 17.2
APOA_HUMAN GTYSTTVTGR.heavy TRUE 526.765955 Unit 644.360134 Unit TRUE 4.35 0.8 17.2
APOA_HUMAN GTYSTTVTGR.heavy TRUE 526.765955 Unit 543.312455 Unit TRUE 4.35 0.8 17.2
APOA_HUMAN GTYSTTVTGR.light FALSE 521.76182 Unit 721.383893 Unit TRUE 4.35 0.8 17.2
APOA_HUMAN GTYSTTVTGR.light FALSE 521.76182 Unit 634.351865 Unit TRUE 4.35 0.8 17.2
APOA_HUMAN GTYSTTVTGR.light FALSE 521.76182 Unit 533.304186 Unit TRUE 4.35 0.8 17.2
APOA1_HUMAN VSFLSALEEYTK.heavy TRUE 697.868299 Unit 1061.560466 Unit TRUE 19.93 0.8 22.5
APOA1_HUMAN VSFLSALEEYTK.heavy TRUE 697.868299 Unit 948.476402 Unit TRUE 19.93 0.8 22.5
APOA1_HUMAN VSFLSALEEYTK.heavy TRUE 697.868299 Unit 861.444374 Unit TRUE 19.93 0.8 22.5
APOA1_HUMAN VSFLSALEEYTK.light FALSE 693.8612 Unit 1053.546267 Unit TRUE 19.93 0.8 22.5
APOA1_HUMAN VSFLSALEEYTK.light FALSE 693.8612 Unit 940.462203 Unit TRUE 19.93 0.8 22.5
APOA1_HUMAN VSFLSALEEYTK.light FALSE 693.8612 Unit 853.430175 Unit TRUE 19.93 0.8 22.5
APOA2_HUMAN EQLTPLIK.heavy TRUE 475.294042 Unit 692.479637 Unit TRUE 11.89 0.8 15.6
APOA2_HUMAN EQLTPLIK.heavy TRUE 475.294042 Unit 579.395573 Unit TRUE 11.89 0.8 15.6
APOA2_HUMAN EQLTPLIK.heavy TRUE 475.294042 Unit 478.347895 Unit TRUE 11.89 0.8 15.6
APOA2_HUMAN EQLTPLIK.light FALSE 471.286942 Unit 684.465438 Unit TRUE 11.89 0.8 15.6
APOA2_HUMAN EQLTPLIK.light FALSE 471.286942 Unit 571.381374 Unit TRUE 11.89 0.8 15.6
APOA2_HUMAN EQLTPLIK.light FALSE 471.286942 Unit 470.333696 Unit TRUE 11.89 0.8 15.6
APOA4_HUMAN LAPLAEDVR.heavy TRUE 497.283783 Unit 809.439113 Unit TRUE 9.92 0.8 16.3
APOA4_HUMAN LAPLAEDVR.heavy TRUE 497.283783 Unit 712.386349 Unit TRUE 9.92 0.8 16.3
APOA4_HUMAN LAPLAEDVR.heavy TRUE 497.283783 Unit 599.302285 Unit TRUE 9.92 0.8 16.3
APOA4_HUMAN LAPLAEDVR.light FALSE 492.279649 Unit 799.430844 Unit TRUE 9.92 0.8 16.3
APOA4_HUMAN LAPLAEDVR.light FALSE 492.279649 Unit 702.37808 Unit TRUE 9.92 0.8 16.3
APOA4_HUMAN LAPLAEDVR.light FALSE 492.279649 Unit 589.294016 Unit TRUE 9.92 0.8 16.3
APOB_HUMAN FSVPAGIVIPSFQALTAR.heavy TRUE 942.534495 Unit 1212.697453 Unit TRUE 19.99 0.8 30.1
APOB_HUMAN FSVPAGIVIPSFQALTAR.heavy TRUE 942.534495 Unit 1113.629039 Unit TRUE 19.99 0.8 30.1
APOB_HUMAN FSVPAGIVIPSFQALTAR.heavy TRUE 942.534495 Unit 1000.544975 Unit TRUE 19.99 0.8 30.1
APOB_HUMAN FSVPAGIVIPSFQALTAR.light FALSE 937.530361 Unit 1202.689184 Unit TRUE 19.99 0.8 30.1
APOB_HUMAN FSVPAGIVIPSFQALTAR.light FALSE 937.530361 Unit 1103.62077 Unit TRUE 19.99 0.8 30.1
APOB_HUMAN FSVPAGIVIPSFQALTAR.light FALSE 937.530361 Unit 990.536706 Unit TRUE 19.99 0.8 30.1
APOC1_HUMAN EFGNTLEDK.heavy TRUE 530.755478 Unit 784.392673 Unit TRUE 7.06 0.8 17.3
APOC1_HUMAN EFGNTLEDK.heavy TRUE 530.755478 Unit 613.328281 Unit TRUE 7.06 0.8 17.3
APOC1_HUMAN EFGNTLEDK.heavy TRUE 530.755478 Unit 512.280603 Unit TRUE 7.06 0.8 17.3
APOC1_HUMAN EFGNTLEDK.light FALSE 526.748378 Unit 776.378474 Unit TRUE 7.06 0.8 17.3
APOC1_HUMAN EFGNTLEDK.light FALSE 526.748378 Unit 605.314082 Unit TRUE 7.06 0.8 17.3
APOC1_HUMAN EFGNTLEDK.light FALSE 526.748378 Unit 504.266404 Unit TRUE 7.06 0.8 17.3
APOC2_HUMAN TAAQNLYEK.heavy TRUE 523.273838 Unit 873.455607 Unit TRUE 4.97 0.8 17.1
APOC2_HUMAN TAAQNLYEK.heavy TRUE 523.273838 Unit 802.418493 Unit TRUE 4.97 0.8 17.1
APOC2_HUMAN TAAQNLYEK.heavy TRUE 523.273838 Unit 674.359916 Unit TRUE 4.97 0.8 17.1
APOC2_HUMAN TAAQNLYEK.light FALSE 519.266738 Unit 865.441408 Unit TRUE 4.97 0.8 17.1
APOC2_HUMAN TAAQNLYEK.light FALSE 519.266738 Unit 794.404294 Unit TRUE 4.97 0.8 17.1
APOC2_HUMAN TAAQNLYEK.light FALSE 519.266738 Unit 666.345717 Unit TRUE 4.97 0.8 17.1
APOC3_HUMAN GWVTDGFSSLK.heavy TRUE 602.808045 Unit 961.508037 Unit TRUE 15.27 0.8 19.6
APOC3_HUMAN GWVTDGFSSLK.heavy TRUE 602.808045 Unit 862.439623 Unit TRUE 15.27 0.8 19.6
APOC3_HUMAN GWVTDGFSSLK.heavy TRUE 602.808045 Unit 646.365001 Unit TRUE 15.27 0.8 19.6
APOC3_HUMAN GWVTDGFSSLK.light FALSE 598.800945 Unit 953.493838 Unit TRUE 15.27 0.8 19.6
APOC3_HUMAN GWVTDGFSSLK.light FALSE 598.800945 Unit 854.425424 Unit TRUE 15.27 0.8 19.6
APOC3_HUMAN GWVTDGFSSLK.light FALSE 598.800945 Unit 638.350802 Unit TRUE 15.27 0.8 19.6
APOD_HUMAN NILTSNNIDVK.heavy TRUE 619.845159 Unit 1011.55605 Unit TRUE 11.04 0.8 20.1
APOD_HUMAN NILTSNNIDVK.heavy TRUE 619.845159 Unit 898.471986 Unit TRUE 11.04 0.8 20.1
APOD_HUMAN NILTSNNIDVK.heavy TRUE 619.845159 Unit 797.424307 Unit TRUE 11.04 0.8 20.1
APOD_HUMAN NILTSNNIDVK.light FALSE 615.838059 Unit 1003.541851 Unit TRUE 11.04 0.8 20.1
APOD_HUMAN NILTSNNIDVK.light FALSE 615.838059 Unit 890.457787 Unit TRUE 11.04 0.8 20.1
APOD_HUMAN NILTSNNIDVK.light FALSE 615.838059 Unit 789.410108 Unit TRUE 11.04 0.8 20.1
APOE_HUMAN AATVGSLAGQPLQER.heavy TRUE 754.408763 Unit 908.482374 Unit TRUE 10.22 0.8 24.2
APOE_HUMAN AATVGSLAGQPLQER.heavy TRUE 754.408763 Unit 837.445261 Unit TRUE 10.22 0.8 24.2
APOE_HUMAN AATVGSLAGQPLQER.heavy TRUE 754.408763 Unit 652.365219 Unit TRUE 10.22 0.8 24.2
APOE_HUMAN AATVGSLAGQPLQER.light FALSE 749.404629 Unit 898.474105 Unit TRUE 10.22 0.8 24.2
APOE_HUMAN AATVGSLAGQPLQER.light FALSE 749.404629 Unit 827.436992 Unit TRUE 10.22 0.8 24.2
APOE_HUMAN AATVGSLAGQPLQER.light FALSE 749.404629 Unit 642.35695 Unit TRUE 10.22 0.8 24.2
APOH_HUMAN VC[+57.0]PFAGILENGAVR.heavy TRUE 756.896977 Unit 1253.687616 Unit TRUE 17.24 0.8 24.3
APOH_HUMAN VC[+57.0]PFAGILENGAVR.heavy TRUE 756.896977 Unit 707.3628 Unit TRUE 17.24 0.8 24.3
APOH_HUMAN VC[+57.0]PFAGILENGAVR.heavy TRUE 756.896977 Unit 627.347446 Unit TRUE 17.24 0.8 24.3
APOH_HUMAN VC[+57.0]PFAGILENGAVR.light FALSE 751.892843 Unit 1243.679347 Unit TRUE 17.24 0.8 24.3
APOH_HUMAN VC[+57.0]PFAGILENGAVR.light FALSE 751.892843 Unit 702.3586 Unit TRUE 17.24 0.8 24.3
APOH_HUMAN VC[+57.0]PFAGILENGAVR.light FALSE 751.892843 Unit 622.343312 Unit TRUE 17.24 0.8 24.3
APOL1_HUMAN VTEPISAESGEQVER.heavy TRUE 820.903708 Unit 1311.641454 Unit TRUE 7.44 0.8 26.3
APOL1_HUMAN VTEPISAESGEQVER.heavy TRUE 820.903708 Unit 1101.504626 Unit TRUE 7.44 0.8 26.3
APOL1_HUMAN VTEPISAESGEQVER.heavy TRUE 820.903708 Unit 943.435484 Unit TRUE 7.44 0.8 26.3
APOL1_HUMAN VTEPISAESGEQVER.light FALSE 815.899573 Unit 1301.633185 Unit TRUE 7.44 0.8 26.3
APOL1_HUMAN VTEPISAESGEQVER.light FALSE 815.899573 Unit 1091.496357 Unit TRUE 7.44 0.8 26.3
APOL1_HUMAN VTEPISAESGEQVER.light FALSE 815.899573 Unit 933.427215 Unit TRUE 7.44 0.8 26.3
APOM_HUMAN FLLYNR.heavy TRUE 418.238647 Unit 688.401605 Unit TRUE 12.16 0.8 13.8
APOM_HUMAN FLLYNR.heavy TRUE 418.238647 Unit 575.317541 Unit TRUE 12.16 0.8 13.8
APOM_HUMAN FLLYNR.heavy TRUE 418.238647 Unit 462.233477 Unit TRUE 12.16 0.8 13.8
APOM_HUMAN FLLYNR.light FALSE 413.234513 Unit 678.393336 Unit TRUE 12.16 0.8 13.8
APOM_HUMAN FLLYNR.light FALSE 413.234513 Unit 565.309272 Unit TRUE 12.16 0.8 13.8
APOM_HUMAN FLLYNR.light FALSE 413.234513 Unit 452.225208 Unit TRUE 12.16 0.8 13.8
B3AT_HUMAN IDAYMAQSR.heavy TRUE 532.757075 Unit 836.395868 Unit TRUE 6.37 0.8 17.4
B3AT_HUMAN IDAYMAQSR.heavy TRUE 532.757075 Unit 602.295425 Unit TRUE 6.37 0.8 17.4
B3AT_HUMAN IDAYMAQSR.heavy TRUE 532.757075 Unit 300.155397 Unit TRUE 6.37 0.8 17.4
B3AT_HUMAN IDAYMAQSR.light FALSE 527.752941 Unit 826.387599 Unit TRUE 6.37 0.8 17.4
B3AT_HUMAN IDAYMAQSR.light FALSE 527.752941 Unit 592.287156 Unit TRUE 6.37 0.8 17.4
B3AT_HUMAN IDAYMAQSR.light FALSE 527.752941 Unit 300.155397 Unit TRUE 6.37 0.8 17.4
C1QB_HUMAN GNLC[+57.0]VNLMR.heavy TRUE 543.774745 Unit 915.477823 Unit TRUE 12.05 0.8 17.7
C1QB_HUMAN GNLC[+57.0]VNLMR.heavy TRUE 543.774745 Unit 802.393759 Unit TRUE 12.05 0.8 17.7
C1QB_HUMAN GNLC[+57.0]VNLMR.heavy TRUE 543.774745 Unit 642.363111 Unit TRUE 12.05 0.8 17.7
C1QB_HUMAN GNLC[+57.0]VNLMR.heavy TRUE 543.774745 Unit 543.294697 Unit TRUE 12.05 0.8 17.7
C1QB_HUMAN GNLC[+57.0]VNLMR.light FALSE 538.770611 Unit 905.469554 Unit TRUE 12.05 0.8 17.7
C1QB_HUMAN GNLC[+57.0]VNLMR.light FALSE 538.770611 Unit 792.38549 Unit TRUE 12.05 0.8 17.7
C1QB_HUMAN GNLC[+57.0]VNLMR.light FALSE 538.770611 Unit 632.354842 Unit TRUE 12.05 0.8 17.7
C1QB_HUMAN GNLC[+57.0]VNLMR.light FALSE 538.770611 Unit 533.286428 Unit TRUE 12.05 0.8 17.7
C1QC_HUMAN FQSVFTVTR.heavy TRUE 547.797058 Unit 732.42782 Unit TRUE 13.15 0.8 17.8
C1QC_HUMAN FQSVFTVTR.heavy TRUE 547.797058 Unit 633.359406 Unit TRUE 13.15 0.8 17.8
C1QC_HUMAN FQSVFTVTR.heavy TRUE 547.797058 Unit 363.166296 Unit TRUE 13.15 0.8 17.8
C1QC_HUMAN FQSVFTVTR.light FALSE 542.792923 Unit 722.419551 Unit TRUE 13.15 0.8 17.8
C1QC_HUMAN FQSVFTVTR.light FALSE 542.792923 Unit 623.351137 Unit TRUE 13.15 0.8 17.8
C1QC_HUMAN FQSVFTVTR.light FALSE 542.792923 Unit 363.166296 Unit TRUE 13.15 0.8 17.8
C1R_HUMAN YTTTMGVNTYK.heavy TRUE 643.81247 Unit 1022.506657 Unit TRUE 7.78 0.8 20.8
C1R_HUMAN YTTTMGVNTYK.heavy TRUE 643.81247 Unit 921.458978 Unit TRUE 7.78 0.8 20.8
C1R_HUMAN YTTTMGVNTYK.heavy TRUE 643.81247 Unit 689.370815 Unit TRUE 7.78 0.8 20.8
C1R_HUMAN YTTTMGVNTYK.light FALSE 639.80537 Unit 1014.492458 Unit TRUE 7.78 0.8 20.8
C1R_HUMAN YTTTMGVNTYK.light FALSE 639.80537 Unit 913.444779 Unit TRUE 7.78 0.8 20.8
C1R_HUMAN YTTTMGVNTYK.light FALSE 639.80537 Unit 681.356616 Unit TRUE 7.78 0.8 20.8
C1S_HUMAN TNFDNDIALVR.heavy TRUE 644.331993 Unit 1072.566104 Unit TRUE 13.26 0.8 20.8
C1S_HUMAN TNFDNDIALVR.heavy TRUE 644.331993 Unit 925.49769 Unit TRUE 13.26 0.8 20.8
C1S_HUMAN TNFDNDIALVR.heavy TRUE 644.331993 Unit 581.400877 Unit TRUE 13.26 0.8 20.8
C1S_HUMAN TNFDNDIALVR.light FALSE 639.327859 Unit 1062.557835 Unit TRUE 13.26 0.8 20.8
C1S_HUMAN TNFDNDIALVR.light FALSE 639.327859 Unit 915.489421 Unit TRUE 13.26 0.8 20.8
C1S_HUMAN TNFDNDIALVR.light FALSE 639.327859 Unit 571.392608 Unit TRUE 13.26 0.8 20.8
C4BPA_HUMAN EDVYVVGTVLR.heavy TRUE 630.347112 Unit 753.485669 Unit TRUE 14.74 0.8 20.4
C4BPA_HUMAN EDVYVVGTVLR.heavy TRUE 630.347112 Unit 654.417255 Unit TRUE 14.74 0.8 20.4
C4BPA_HUMAN EDVYVVGTVLR.heavy TRUE 630.347112 Unit 555.348841 Unit TRUE 14.74 0.8 20.4
C4BPA_HUMAN EDVYVVGTVLR.light FALSE 625.342977 Unit 743.4774 Unit TRUE 14.74 0.8 20.4
C4BPA_HUMAN EDVYVVGTVLR.light FALSE 625.342977 Unit 644.408986 Unit TRUE 14.74 0.8 20.4
C4BPA_HUMAN EDVYVVGTVLR.light FALSE 625.342977 Unit 545.340572 Unit TRUE 14.74 0.8 20.4
CBG_HUMAN GTWTQPFDLASTR.heavy TRUE 745.369107 Unit 1145.5825 Unit TRUE 15.81 0.8 24
CBG_HUMAN GTWTQPFDLASTR.heavy TRUE 745.369107 Unit 916.476226 Unit TRUE 15.81 0.8 24
CBG_HUMAN GTWTQPFDLASTR.heavy TRUE 745.369107 Unit 666.3345 Unit TRUE 15.81 0.8 24
CBG_HUMAN GTWTQPFDLASTR.light FALSE 740.364972 Unit 1135.5742 Unit TRUE 15.81 0.8 24
CBG_HUMAN GTWTQPFDLASTR.light FALSE 740.364972 Unit 906.467957 Unit TRUE 15.81 0.8 24
CBG_HUMAN GTWTQPFDLASTR.light FALSE 740.364972 Unit 661.3304 Unit TRUE 15.81 0.8 24
CD5L_HUMAN IWLDNVR.heavy TRUE 463.260111 Unit 812.428882 Unit TRUE 12.69 0.8 15.2
CD5L_HUMAN IWLDNVR.heavy TRUE 463.260111 Unit 626.349569 Unit TRUE 12.69 0.8 15.2
CD5L_HUMAN IWLDNVR.heavy TRUE 463.260111 Unit 513.265505 Unit TRUE 12.69 0.8 15.2
CD5L_HUMAN IWLDNVR.light FALSE 458.255977 Unit 802.420613 Unit TRUE 12.69 0.8 15.2
CD5L_HUMAN IWLDNVR.light FALSE 458.255977 Unit 616.3413 Unit TRUE 12.69 0.8 15.2
CD5L_HUMAN IWLDNVR.light FALSE 458.255977 Unit 503.257236 Unit TRUE 12.69 0.8 15.2
CERU_HUMAN DIASGLIGPLIIC[+57.0]K.heavy TRUE 739.430544 Unit 921.568135 Unit TRUE 19.95 0.8 23.8
CERU_HUMAN DIASGLIGPLIIC[+57.0]K.heavy TRUE 739.430544 Unit 808.484071 Unit TRUE 19.95 0.8 23.8
CERU_HUMAN DIASGLIGPLIIC[+57.0]K.heavy TRUE 739.430544 Unit 751.462607 Unit TRUE 19.95 0.8 23.8
CERU_HUMAN DIASGLIGPLIIC[+57.0]K.light FALSE 735.423444 Unit 913.553936 Unit TRUE 19.95 0.8 23.8
CERU_HUMAN DIASGLIGPLIIC[+57.0]K.light FALSE 735.423444 Unit 800.469872 Unit TRUE 19.95 0.8 23.8
CERU_HUMAN DIASGLIGPLIIC[+57.0]K.light FALSE 735.423444 Unit 743.448408 Unit TRUE 19.95 0.8 23.8
CFAB_HUMAN YGLVTYATYPK.heavy TRUE 642.34172 Unit 950.507309 Unit TRUE 12.65 0.8 20.8
CFAB_HUMAN YGLVTYATYPK.heavy TRUE 642.34172 Unit 851.438895 Unit TRUE 12.65 0.8 20.8
CFAB_HUMAN YGLVTYATYPK.heavy TRUE 642.34172 Unit 334.176132 Unit TRUE 12.65 0.8 20.8
CFAB_HUMAN YGLVTYATYPK.light FALSE 638.334621 Unit 942.49311 Unit TRUE 12.65 0.8 20.8
CFAB_HUMAN YGLVTYATYPK.light FALSE 638.334621 Unit 843.424696 Unit TRUE 12.65 0.8 20.8
CFAB_HUMAN YGLVTYATYPK.light FALSE 638.334621 Unit 334.176132 Unit TRUE 12.65 0.8 20.8
CFAH_HUMAN IDVHLVPDR.heavy TRUE 358.53743 Unit 609.359406 Unit TRUE 10.39 0.8 12.2
CFAH_HUMAN IDVHLVPDR.heavy TRUE 358.53743 Unit 496.275342 Unit TRUE 10.39 0.8 12.2
CFAH_HUMAN IDVHLVPDR.heavy TRUE 358.53743 Unit 465.245609 Unit TRUE 10.39 0.8 12.2
CFAH_HUMAN IDVHLVPDR.light FALSE 355.201341 Unit 599.351137 Unit TRUE 10.39 0.8 12.2
CFAH_HUMAN IDVHLVPDR.light FALSE 355.201341 Unit 486.267073 Unit TRUE 10.39 0.8 12.2
CFAH_HUMAN IDVHLVPDR.light FALSE 355.201341 Unit 465.245609 Unit TRUE 10.39 0.8 12.2
CFAI_HUMAN IVIEYVDR.heavy TRUE 508.786159 Unit 804.412563 Unit TRUE 11.19 0.8 16.6
CFAI_HUMAN IVIEYVDR.heavy TRUE 508.786159 Unit 691.328499 Unit TRUE 11.19 0.8 16.6
CFAI_HUMAN IVIEYVDR.heavy TRUE 508.786159 Unit 562.285906 Unit TRUE 11.19 0.8 16.6
CFAI_HUMAN IVIEYVDR.light FALSE 503.782024 Unit 794.404294 Unit TRUE 11.19 0.8 16.6
CFAI_HUMAN IVIEYVDR.light FALSE 503.782024 Unit 681.32023 Unit TRUE 11.19 0.8 16.6
CFAI_HUMAN IVIEYVDR.light FALSE 503.782024 Unit 552.277637 Unit TRUE 11.19 0.8 16.6
CLUS_HUMAN ASSIIDELFQDR.heavy TRUE 702.355665 Unit 1045.51882 Unit TRUE 19.87 0.8 22.6
CLUS_HUMAN ASSIIDELFQDR.heavy TRUE 702.355665 Unit 932.434756 Unit TRUE 19.87 0.8 22.6
CLUS_HUMAN ASSIIDELFQDR.heavy TRUE 702.355665 Unit 575.281155 Unit TRUE 19.87 0.8 22.6
CLUS_HUMAN ASSIIDELFQDR.light FALSE 697.351531 Unit 1035.510551 Unit TRUE 19.87 0.8 22.6
CLUS_HUMAN ASSIIDELFQDR.light FALSE 697.351531 Unit 922.426487 Unit TRUE 19.87 0.8 22.6
CLUS_HUMAN ASSIIDELFQDR.light FALSE 697.351531 Unit 565.272886 Unit TRUE 19.87 0.8 22.6
CO2_HUMAN AVISPGFDVFAK.heavy TRUE 629.849713 Unit 975.502558 Unit TRUE 17.39 0.8 20.4
CO2_HUMAN AVISPGFDVFAK.heavy TRUE 629.849713 Unit 888.470529 Unit TRUE 17.39 0.8 20.4
CO2_HUMAN AVISPGFDVFAK.heavy TRUE 629.849713 Unit 444.738903 Unit TRUE 17.39 0.8 20.4
CO2_HUMAN AVISPGFDVFAK.light FALSE 625.842613 Unit 967.488358 Unit TRUE 17.39 0.8 20.4
CO2_HUMAN AVISPGFDVFAK.light FALSE 625.842613 Unit 880.45633 Unit TRUE 17.39 0.8 20.4
CO2_HUMAN AVISPGFDVFAK.light FALSE 625.842613 Unit 440.731803 Unit TRUE 17.39 0.8 20.4
CO3_HUMAN IHWESASLLR.heavy TRUE 611.334339 Unit 971.518426 Unit TRUE 12.78 0.8 19.8
CO3_HUMAN IHWESASLLR.heavy TRUE 611.334339 Unit 785.439113 Unit TRUE 12.78 0.8 19.8
CO3_HUMAN IHWESASLLR.heavy TRUE 611.334339 Unit 656.396519 Unit TRUE 12.78 0.8 19.8
CO3_HUMAN IHWESASLLR.light FALSE 606.330204 Unit 961.510157 Unit TRUE 12.78 0.8 19.8
CO3_HUMAN IHWESASLLR.light FALSE 606.330204 Unit 775.430844 Unit TRUE 12.78 0.8 19.8
CO3_HUMAN IHWESASLLR.light FALSE 606.330204 Unit 646.38825 Unit TRUE 12.78 0.8 19.8
CO5_HUMAN TDAPDLPEENQAR.heavy TRUE 733.343286 Unit 1178.567561 Unit TRUE 7.1 0.8 23.6
CO5_HUMAN TDAPDLPEENQAR.heavy TRUE 733.343286 Unit 853.40379 Unit TRUE 7.1 0.8 23.6
CO5_HUMAN TDAPDLPEENQAR.heavy TRUE 733.343286 Unit 589.787418 Unit TRUE 7.1 0.8 23.6
CO5_HUMAN TDAPDLPEENQAR.light FALSE 728.339152 Unit 1168.559292 Unit TRUE 7.1 0.8 23.6
CO5_HUMAN TDAPDLPEENQAR.light FALSE 728.339152 Unit 843.395521 Unit TRUE 7.1 0.8 23.6
CO5_HUMAN TDAPDLPEENQAR.light FALSE 728.339152 Unit 584.783284 Unit TRUE 7.1 0.8 23.6
CO6_HUMAN IGESIELTC[+57.0]PK.heavy TRUE 627.82812 Unit 955.500843 Unit TRUE 10.69 0.8 20.3
CO6_HUMAN IGESIELTC[+57.0]PK.heavy TRUE 627.82812 Unit 755.384751 Unit TRUE 10.69 0.8 20.3
CO6_HUMAN IGESIELTC[+57.0]PK.heavy TRUE 627.82812 Unit 626.342158 Unit TRUE 10.69 0.8 20.3
CO6_HUMAN IGESIELTC[+57.0]PK.light FALSE 623.821021 Unit 947.486644 Unit TRUE 10.69 0.8 20.3
CO6_HUMAN IGESIELTC[+57.0]PK.light FALSE 623.821021 Unit 747.370552 Unit TRUE 10.69 0.8 20.3
CO6_HUMAN IGESIELTC[+57.0]PK.light FALSE 623.821021 Unit 618.327959 Unit TRUE 10.69 0.8 20.3
CO7_HUMAN VLFYVDSEK.heavy TRUE 554.294239 Unit 895.428724 Unit TRUE 12.84 0.8 18.1
CO7_HUMAN VLFYVDSEK.heavy TRUE 554.294239 Unit 748.36031 Unit TRUE 12.84 0.8 18.1
CO7_HUMAN VLFYVDSEK.heavy TRUE 554.294239 Unit 585.296981 Unit TRUE 12.84 0.8 18.1
CO7_HUMAN VLFYVDSEK.light FALSE 550.287139 Unit 887.414525 Unit TRUE 12.84 0.8 18.1
CO7_HUMAN VLFYVDSEK.light FALSE 550.287139 Unit 740.346111 Unit TRUE 12.84 0.8 18.1
CO7_HUMAN VLFYVDSEK.light FALSE 550.287139 Unit 577.282782 Unit TRUE 12.84 0.8 18.1
CO8A_HUMAN HTSLGPLEAK.heavy TRUE 530.79748 Unit 923.528772 Unit TRUE 7.36 0.8 17.3
CO8A_HUMAN HTSLGPLEAK.heavy TRUE 530.79748 Unit 835.430844 Unit TRUE 7.36 0.8 17.3
CO8A_HUMAN HTSLGPLEAK.heavy TRUE 530.79748 Unit 822.481094 Unit TRUE 7.36 0.8 17.3
CO8A_HUMAN HTSLGPLEAK.light FALSE 526.790381 Unit 915.514573 Unit TRUE 7.36 0.8 17.3
CO8A_HUMAN HTSLGPLEAK.light FALSE 526.790381 Unit 835.430844 Unit TRUE 7.36 0.8 17.3
CO8A_HUMAN HTSLGPLEAK.light FALSE 526.790381 Unit 814.466895 Unit TRUE 7.36 0.8 17.3
CO9_HUMAN LSPIYNLVPVK.heavy TRUE 625.883555 Unit 1050.643742 Unit TRUE 17.56 0.8 20.3
CO9_HUMAN LSPIYNLVPVK.heavy TRUE 625.883555 Unit 840.506915 Unit TRUE 17.56 0.8 20.3
CO9_HUMAN LSPIYNLVPVK.heavy TRUE 625.883555 Unit 351.248181 Unit TRUE 17.56 0.8 20.3
CO9_HUMAN LSPIYNLVPVK.light FALSE 621.876456 Unit 1042.629543 Unit TRUE 17.56 0.8 20.3
CO9_HUMAN LSPIYNLVPVK.light FALSE 621.876456 Unit 832.492716 Unit TRUE 17.56 0.8 20.3
CO9_HUMAN LSPIYNLVPVK.light FALSE 621.876456 Unit 343.233982 Unit TRUE 17.56 0.8 20.3
CPN2_HUMAN LSNNALSGLPQGVFGK.heavy TRUE 805.443028 Unit 997.555656 Unit TRUE 16.22 0.8 25.8
CPN2_HUMAN LSNNALSGLPQGVFGK.heavy TRUE 805.443028 Unit 740.4181 Unit TRUE 16.22 0.8 25.8
CPN2_HUMAN LSNNALSGLPQGVFGK.heavy TRUE 805.443028 Unit 359.21688 Unit TRUE 16.22 0.8 25.8
CPN2_HUMAN LSNNALSGLPQGVFGK.light FALSE 801.435929 Unit 989.541457 Unit TRUE 16.22 0.8 25.8
CPN2_HUMAN LSNNALSGLPQGVFGK.light FALSE 801.435929 Unit 732.403901 Unit TRUE 16.22 0.8 25.8
CPN2_HUMAN LSNNALSGLPQGVFGK.light FALSE 801.435929 Unit 351.202681 Unit TRUE 16.22 0.8 25.8
F13A_HUMAN STVLTIPEIIIK.heavy TRUE 667.922878 Unit 1047.690358 Unit TRUE 19.93 0.8 21.6
F13A_HUMAN STVLTIPEIIIK.heavy TRUE 667.922878 Unit 934.606294 Unit TRUE 19.93 0.8 21.6
F13A_HUMAN STVLTIPEIIIK.heavy TRUE 667.922878 Unit 720.474552 Unit TRUE 19.93 0.8 21.6
F13A_HUMAN STVLTIPEIIIK.light FALSE 663.915778 Unit 1039.676159 Unit TRUE 19.93 0.8 21.6
F13A_HUMAN STVLTIPEIIIK.light FALSE 663.915778 Unit 926.592095 Unit TRUE 19.93 0.8 21.6
F13A_HUMAN STVLTIPEIIIK.light FALSE 663.915778 Unit 712.460353 Unit TRUE 19.93 0.8 21.6
FBLN1_HUMAN TGYYFDGISR.heavy TRUE 594.781605 Unit 867.423463 Unit TRUE 11.94 0.8 19.3
FBLN1_HUMAN TGYYFDGISR.heavy TRUE 594.781605 Unit 704.360134 Unit TRUE 11.94 0.8 19.3
FBLN1_HUMAN TGYYFDGISR.heavy TRUE 594.781605 Unit 322.139747 Unit TRUE 11.94 0.8 19.3
FBLN1_HUMAN TGYYFDGISR.light FALSE 589.77747 Unit 857.415194 Unit TRUE 11.94 0.8 19.3
FBLN1_HUMAN TGYYFDGISR.light FALSE 589.77747 Unit 694.351865 Unit TRUE 11.94 0.8 19.3
FBLN1_HUMAN TGYYFDGISR.light FALSE 589.77747 Unit 322.139747 Unit TRUE 11.94 0.8 19.3
FCN3_HUMAN YGIDWASGR.heavy TRUE 517.750108 Unit 701.324083 Unit TRUE 11.62 0.8 16.9
FCN3_HUMAN YGIDWASGR.heavy TRUE 517.750108 Unit 586.29714 Unit TRUE 11.62 0.8 16.9
FCN3_HUMAN YGIDWASGR.heavy TRUE 517.750108 Unit 400.217827 Unit TRUE 11.62 0.8 16.9
FCN3_HUMAN YGIDWASGR.light FALSE 512.745973 Unit 691.315814 Unit TRUE 11.62 0.8 16.9
FCN3_HUMAN YGIDWASGR.light FALSE 512.745973 Unit 576.288871 Unit TRUE 11.62 0.8 16.9
FCN3_HUMAN YGIDWASGR.light FALSE 512.745973 Unit 390.209558 Unit TRUE 11.62 0.8 16.9
FETUA_HUMAN FSVVYAK.heavy TRUE 411.235996 Unit 674.396301 Unit TRUE 9.47 0.8 13.6
FETUA_HUMAN FSVVYAK.heavy TRUE 411.235996 Unit 587.364273 Unit TRUE 9.47 0.8 13.6
FETUA_HUMAN FSVVYAK.heavy TRUE 411.235996 Unit 488.295859 Unit TRUE 9.47 0.8 13.6
FETUA_HUMAN FSVVYAK.light FALSE 407.228896 Unit 666.382102 Unit TRUE 9.47 0.8 13.6
FETUA_HUMAN FSVVYAK.light FALSE 407.228896 Unit 579.350074 Unit TRUE 9.47 0.8 13.6
FETUA_HUMAN FSVVYAK.light FALSE 407.228896 Unit 480.28166 Unit TRUE 9.47 0.8 13.6
FIBA_HUMAN GSESGIFTNTK.heavy TRUE 574.787309 Unit 875.471257 Unit TRUE 7.78 0.8 18.7
FIBA_HUMAN GSESGIFTNTK.heavy TRUE 574.787309 Unit 788.439229 Unit TRUE 7.78 0.8 18.7
FIBA_HUMAN GSESGIFTNTK.heavy TRUE 574.787309 Unit 618.333701 Unit TRUE 7.78 0.8 18.7
FIBA_HUMAN GSESGIFTNTK.light FALSE 570.78021 Unit 867.457058 Unit TRUE 7.78 0.8 18.7
FIBA_HUMAN GSESGIFTNTK.light FALSE 570.78021 Unit 780.42503 Unit TRUE 7.78 0.8 18.7
FIBA_HUMAN GSESGIFTNTK.light FALSE 570.78021 Unit 610.319502 Unit TRUE 7.78 0.8 18.7
FIBB_HUMAN QGFGNVATNTDGK.heavy TRUE 658.819672 Unit 714.350808 Unit TRUE 12.1 0.8 30
FIBB_HUMAN QGFGNVATNTDGK.heavy TRUE 658.819672 Unit 643.313694 Unit TRUE 12.1 0.8 30
FIBB_HUMAN QGFGNVATNTDGK.heavy TRUE 658.819672 Unit 333.155731 Unit TRUE 12.1 0.8 30
FIBB_HUMAN QGFGNVATNTDGK.light FALSE 654.812573 Unit 706.336609 Unit TRUE 12.1 0.8 21.3
FIBB_HUMAN QGFGNVATNTDGK.light FALSE 654.812573 Unit 635.299495 Unit TRUE 12.1 0.8 21.3
FIBB_HUMAN QGFGNVATNTDGK.light FALSE 654.812573 Unit 333.155731 Unit TRUE 12.1 0.8 21.3
FIBG_HUMAN DNC[+57.0]C[+57.0]ILDER.heavy TRUE 602.751664 Unit 655.364885 Unit TRUE 8.2 0.8 19.5
FIBG_HUMAN DNC[+57.0]C[+57.0]ILDER.heavy TRUE 602.751664 Unit 542.280821 Unit TRUE 8.2 0.8 19.5
FIBG_HUMAN DNC[+57.0]C[+57.0]ILDER.heavy TRUE 602.751664 Unit 429.196757 Unit TRUE 8.2 0.8 19.5
FIBG_HUMAN DNC[+57.0]C[+57.0]ILDER.light FALSE 597.74753 Unit 645.356616 Unit TRUE 8.2 0.8 19.5
FIBG_HUMAN DNC[+57.0]C[+57.0]ILDER.light FALSE 597.74753 Unit 532.272552 Unit TRUE 8.2 0.8 19.5
FIBG_HUMAN DNC[+57.0]C[+57.0]ILDER.light FALSE 597.74753 Unit 419.188488 Unit TRUE 8.2 0.8 19.5
FINC_HUMAN SYTITGLQPGTDYK.heavy TRUE 776.39267 Unit 1087.550964 Unit TRUE 11.87 0.8 24.9
FINC_HUMAN SYTITGLQPGTDYK.heavy TRUE 776.39267 Unit 986.503286 Unit TRUE 11.87 0.8 24.9
FINC_HUMAN SYTITGLQPGTDYK.heavy TRUE 776.39267 Unit 688.339181 Unit TRUE 11.87 0.8 24.9
FINC_HUMAN SYTITGLQPGTDYK.light FALSE 772.38557 Unit 1079.536765 Unit TRUE 11.87 0.8 24.9
FINC_HUMAN SYTITGLQPGTDYK.light FALSE 772.38557 Unit 978.489087 Unit TRUE 11.87 0.8 24.9
FINC_HUMAN SYTITGLQPGTDYK.light FALSE 772.38557 Unit 680.324982 Unit TRUE 11.87 0.8 24.9
GELS_HUMAN AGALNSNDAFVLK.heavy TRUE 664.358433 Unit 1015.529835 Unit TRUE 13.08 0.8 21.5
GELS_HUMAN AGALNSNDAFVLK.heavy TRUE 664.358433 Unit 901.486907 Unit TRUE 13.08 0.8 21.5
GELS_HUMAN AGALNSNDAFVLK.heavy TRUE 664.358433 Unit 814.454879 Unit TRUE 13.08 0.8 21.5
GELS_HUMAN AGALNSNDAFVLK.light FALSE 660.351334 Unit 1007.515636 Unit TRUE 13.08 0.8 21.5
GELS_HUMAN AGALNSNDAFVLK.light FALSE 660.351334 Unit 893.472708 Unit TRUE 13.08 0.8 21.5
GELS_HUMAN AGALNSNDAFVLK.light FALSE 660.351334 Unit 806.44068 Unit TRUE 13.08 0.8 21.5
GPX3_HUMAN FLVGPDGIPIMR.heavy TRUE 662.8697 Unit 965.511232 Unit TRUE 18.76 0.8 21.4
GPX3_HUMAN FLVGPDGIPIMR.heavy TRUE 662.8697 Unit 908.489768 Unit TRUE 18.76 0.8 21.4
GPX3_HUMAN FLVGPDGIPIMR.heavy TRUE 662.8697 Unit 526.304533 Unit TRUE 18.76 0.8 21.4
GPX3_HUMAN FLVGPDGIPIMR.light FALSE 657.865565 Unit 955.502963 Unit TRUE 18.76 0.8 21.4
GPX3_HUMAN FLVGPDGIPIMR.light FALSE 657.865565 Unit 898.481499 Unit TRUE 18.76 0.8 21.4
GPX3_HUMAN FLVGPDGIPIMR.light FALSE 657.865565 Unit 516.296264 Unit TRUE 18.76 0.8 21.4
HBA_HUMAN VGAHAGEYGAEALER.heavy TRUE 770.37492 Unit 1175.556662 Unit TRUE 7.12 0.8 24.7
HBA_HUMAN VGAHAGEYGAEALER.heavy TRUE 770.37492 Unit 1104.519548 Unit TRUE 7.12 0.8 24.7
HBA_HUMAN VGAHAGEYGAEALER.heavy TRUE 770.37492 Unit 365.193179 Unit TRUE 7.12 0.8 24.7
HBA_HUMAN VGAHAGEYGAEALER.light FALSE 765.370786 Unit 1165.548393 Unit TRUE 7.12 0.8 24.7
HBA_HUMAN VGAHAGEYGAEALER.light FALSE 765.370786 Unit 1094.511279 Unit TRUE 7.12 0.8 24.7
HBA_HUMAN VGAHAGEYGAEALER.light FALSE 765.370786 Unit 365.193179 Unit TRUE 7.12 0.8 24.7
HBD_HUMAN LLGNVLVC[+57.0]VLAR.heavy TRUE 668.904074 Unit 1110.632744 Unit TRUE 19.96 0.8 28
HBD_HUMAN LLGNVLVC[+57.0]VLAR.heavy TRUE 668.904074 Unit 840.499939 Unit TRUE 19.96 0.8 28
HBD_HUMAN LLGNVLVC[+57.0]VLAR.heavy TRUE 668.904074 Unit 628.347461 Unit TRUE 19.96 0.8 28
HBD_HUMAN LLGNVLVC[+57.0]VLAR.light FALSE 663.89994 Unit 1100.624475 Unit TRUE 19.96 0.8 28
HBD_HUMAN LLGNVLVC[+57.0]VLAR.light FALSE 663.89994 Unit 830.49167 Unit TRUE 19.96 0.8 28
HBD_HUMAN LLGNVLVC[+57.0]VLAR.light FALSE 663.89994 Unit 618.339192 Unit TRUE 19.96 0.8 28
HBE_HUMAN LSELHC[+57.0]DK.heavy TRUE 505.246766 Unit 896.402192 Unit TRUE 3.21 0.8 16.5
HBE_HUMAN LSELHC[+57.0]DK.heavy TRUE 505.246766 Unit 680.32757 Unit TRUE 3.21 0.8 16.5
HBE_HUMAN LSELHC[+57.0]DK.heavy TRUE 505.246766 Unit 567.243506 Unit TRUE 3.21 0.8 16.5
HBE_HUMAN LSELHC[+57.0]DK.light FALSE 501.239666 Unit 888.387993 Unit TRUE 3.21 0.8 16.5
HBE_HUMAN LSELHC[+57.0]DK.light FALSE 501.239666 Unit 672.313371 Unit TRUE 3.21 0.8 16.5
HBE_HUMAN LSELHC[+57.0]DK.light FALSE 501.239666 Unit 559.229307 Unit TRUE 3.21 0.8 16.5
HEMO_HUMAN NFPSPVDAAFR.heavy TRUE 615.810696 Unit 969.502775 Unit TRUE 14.71 0.8 19.9
HEMO_HUMAN NFPSPVDAAFR.heavy TRUE 615.810696 Unit 785.417983 Unit TRUE 14.71 0.8 19.9
HEMO_HUMAN NFPSPVDAAFR.heavy TRUE 615.810696 Unit 589.296805 Unit TRUE 14.71 0.8 19.9
HEMO_HUMAN NFPSPVDAAFR.light FALSE 610.806562 Unit 959.494506 Unit TRUE 14.71 0.8 19.9
HEMO_HUMAN NFPSPVDAAFR.light FALSE 610.806562 Unit 775.409714 Unit TRUE 14.71 0.8 19.9
HEMO_HUMAN NFPSPVDAAFR.light FALSE 610.806562 Unit 579.288536 Unit TRUE 14.71 0.8 19.9
HEP2_HUMAN TLEAQLTPR.heavy TRUE 519.794515 Unit 824.450012 Unit TRUE 9.01 0.8 17
HEP2_HUMAN TLEAQLTPR.heavy TRUE 519.794515 Unit 695.407418 Unit TRUE 9.01 0.8 17
HEP2_HUMAN TLEAQLTPR.heavy TRUE 519.794515 Unit 624.370305 Unit TRUE 9.01 0.8 17
HEP2_HUMAN TLEAQLTPR.light FALSE 514.790381 Unit 814.441743 Unit TRUE 9.01 0.8 17
HEP2_HUMAN TLEAQLTPR.light FALSE 514.790381 Unit 685.399149 Unit TRUE 9.01 0.8 17
HEP2_HUMAN TLEAQLTPR.light FALSE 514.790381 Unit 614.362036 Unit TRUE 9.01 0.8 17
HPT_HUMAN VTSIQDWVQK.heavy TRUE 606.329144 Unit 1011.53492 Unit TRUE 12.21 0.8 19.7
HPT_HUMAN VTSIQDWVQK.heavy TRUE 606.329144 Unit 811.418828 Unit TRUE 12.21 0.8 19.7
HPT_HUMAN VTSIQDWVQK.heavy TRUE 606.329144 Unit 683.36025 Unit TRUE 12.21 0.8 19.7
HPT_HUMAN VTSIQDWVQK.light FALSE 602.322045 Unit 1003.520721 Unit TRUE 12.21 0.8 19.7
HPT_HUMAN VTSIQDWVQK.light FALSE 602.322045 Unit 803.404629 Unit TRUE 12.21 0.8 19.7
HPT_HUMAN VTSIQDWVQK.light FALSE 602.322045 Unit 675.346051 Unit TRUE 12.21 0.8 19.7
HPTR_HUMAN VGYVSGWGQSDNFK.heavy TRUE 776.369529 Unit 1133.510162 Unit TRUE 12.34 0.8 28
HPTR_HUMAN VGYVSGWGQSDNFK.heavy TRUE 776.369529 Unit 1046.478134 Unit TRUE 12.34 0.8 28
HPTR_HUMAN VGYVSGWGQSDNFK.heavy TRUE 776.369529 Unit 320.160482 Unit TRUE 12.34 0.8 28
HPTR_HUMAN VGYVSGWGQSDNFK.light FALSE 772.36243 Unit 1125.495963 Unit TRUE 12.34 0.8 28
HPTR_HUMAN VGYVSGWGQSDNFK.light FALSE 772.36243 Unit 1038.463935 Unit TRUE 12.34 0.8 28
HPTR_HUMAN VGYVSGWGQSDNFK.light FALSE 772.36243 Unit 320.160482 Unit TRUE 12.34 0.8 28
HRG_HUMAN GGEGTGYFVDFSVR.heavy TRUE 750.85329 Unit 1099.54464 Unit TRUE 16.07 0.8 24.1
HRG_HUMAN GGEGTGYFVDFSVR.heavy TRUE 750.85329 Unit 879.459848 Unit TRUE 16.07 0.8 24.1
HRG_HUMAN GGEGTGYFVDFSVR.heavy TRUE 750.85329 Unit 633.32302 Unit TRUE 16.07 0.8 24.1
HRG_HUMAN GGEGTGYFVDFSVR.light FALSE 745.849155 Unit 1089.536371 Unit TRUE 16.07 0.8 24.1
HRG_HUMAN GGEGTGYFVDFSVR.light FALSE 745.849155 Unit 869.451579 Unit TRUE 16.07 0.8 24.1
HRG_HUMAN GGEGTGYFVDFSVR.light FALSE 745.849155 Unit 623.314751 Unit TRUE 16.07 0.8 24.1
IC1_HUMAN GVTSVSQIFHSPDLAIR.heavy TRUE 612.999581 Unit 790.426956 Unit TRUE 16.84 0.8 19.8
IC1_HUMAN GVTSVSQIFHSPDLAIR.heavy TRUE 612.999581 Unit 781.444198 Unit TRUE 16.84 0.8 19.8
IC1_HUMAN GVTSVSQIFHSPDLAIR.heavy TRUE 612.999581 Unit 697.376735 Unit TRUE 16.84 0.8 19.8
IC1_HUMAN GVTSVSQIFHSPDLAIR.light FALSE 609.663492 Unit 785.422822 Unit TRUE 16.84 0.8 19.8
IC1_HUMAN GVTSVSQIFHSPDLAIR.light FALSE 609.663492 Unit 771.435929 Unit TRUE 16.84 0.8 19.8
IC1_HUMAN GVTSVSQIFHSPDLAIR.light FALSE 609.663492 Unit 692.3726 Unit TRUE 16.84 0.8 19.8
IGHA1_HUMAN DASGVTFTWTPSSGK.heavy TRUE 774.874644 Unit 871.439957 Unit TRUE 13.78 0.8 24.9
IGHA1_HUMAN DASGVTFTWTPSSGK.heavy TRUE 774.874644 Unit 584.312966 Unit TRUE 13.78 0.8 24.9
IGHA1_HUMAN DASGVTFTWTPSSGK.heavy TRUE 774.874644 Unit 483.265287 Unit TRUE 13.78 0.8 24.9
IGHA1_HUMAN DASGVTFTWTPSSGK.light FALSE 770.867545 Unit 863.425758 Unit TRUE 13.78 0.8 24.9
IGHA1_HUMAN DASGVTFTWTPSSGK.light FALSE 770.867545 Unit 576.298767 Unit TRUE 13.78 0.8 24.9
IGHA1_HUMAN DASGVTFTWTPSSGK.light FALSE 770.867545 Unit 475.251088 Unit TRUE 13.78 0.8 24.9
IGHA2_HUMAN DASGATFTWTPSSGK.heavy TRUE 760.858994 Unit 1119.55605 Unit TRUE 11.96 0.8 24.5
IGHA2_HUMAN DASGATFTWTPSSGK.heavy TRUE 760.858994 Unit 584.312966 Unit TRUE 11.96 0.8 24.5
IGHA2_HUMAN DASGATFTWTPSSGK.heavy TRUE 760.858994 Unit 483.265287 Unit TRUE 11.96 0.8 24.5
IGHA2_HUMAN DASGATFTWTPSSGK.light FALSE 756.851895 Unit 1111.541851 Unit TRUE 11.96 0.8 24.5
IGHA2_HUMAN DASGATFTWTPSSGK.light FALSE 756.851895 Unit 576.298767 Unit TRUE 11.96 0.8 24.5
IGHA2_HUMAN DASGATFTWTPSSGK.light FALSE 756.851895 Unit 475.251088 Unit TRUE 11.96 0.8 24.5
IGHG1_HUMAN GPSVFPLAPSSK.heavy TRUE 597.834063 Unit 854.486179 Unit TRUE 13.84 0.8 19.4
IGHG1_HUMAN GPSVFPLAPSSK.heavy TRUE 597.834063 Unit 707.417765 Unit TRUE 13.84 0.8 19.4
IGHG1_HUMAN GPSVFPLAPSSK.heavy TRUE 597.834063 Unit 426.243823 Unit TRUE 13.84 0.8 19.4
IGHG1_HUMAN GPSVFPLAPSSK.light FALSE 593.826963 Unit 846.47198 Unit TRUE 13.84 0.8 19.4
IGHG1_HUMAN GPSVFPLAPSSK.light FALSE 593.826963 Unit 699.403566 Unit TRUE 13.84 0.8 19.4
IGHG1_HUMAN GPSVFPLAPSSK.light FALSE 593.826963 Unit 418.229624 Unit TRUE 13.84 0.8 19.4
IGHG2_HUMAN GLPAPIEK.heavy TRUE 416.754553 Unit 662.396301 Unit TRUE 8.69 0.8 13.8
IGHG2_HUMAN GLPAPIEK.heavy TRUE 416.754553 Unit 565.343538 Unit TRUE 8.69 0.8 13.8
IGHG2_HUMAN GLPAPIEK.heavy TRUE 416.754553 Unit 494.306424 Unit TRUE 8.69 0.8 13.8
IGHG2_HUMAN GLPAPIEK.light FALSE 412.747453 Unit 654.382102 Unit TRUE 8.69 0.8 13.8
IGHG2_HUMAN GLPAPIEK.light FALSE 412.747453 Unit 557.329339 Unit TRUE 8.69 0.8 13.8
IGHG2_HUMAN GLPAPIEK.light FALSE 412.747453 Unit 486.292225 Unit TRUE 8.69 0.8 13.8
IGHG3_HUMAN WYVDGVEVHNAK.heavy TRUE 475.57313 Unit 976.493784 Unit TRUE 10.24 0.8 18
IGHG3_HUMAN WYVDGVEVHNAK.heavy TRUE 475.57313 Unit 861.466841 Unit TRUE 10.24 0.8 18
IGHG3_HUMAN WYVDGVEVHNAK.heavy TRUE 475.57313 Unit 804.445377 Unit TRUE 10.24 0.8 18
IGHG3_HUMAN WYVDGVEVHNAK.light FALSE 472.901731 Unit 968.479585 Unit TRUE 10.24 0.8 18
IGHG3_HUMAN WYVDGVEVHNAK.light FALSE 472.901731 Unit 853.452642 Unit TRUE 10.24 0.8 18
IGHG3_HUMAN WYVDGVEVHNAK.light FALSE 472.901731 Unit 796.431178 Unit TRUE 10.24 0.8 18
IGHG4_HUMAN TTPPVLDSDGSFFLYSR.heavy TRUE 956.471758 Unit 1416.66694 Unit TRUE 18.68 0.8 30.5
IGHG4_HUMAN TTPPVLDSDGSFFLYSR.heavy TRUE 956.471758 Unit 1303.582876 Unit TRUE 18.68 0.8 30.5
IGHG4_HUMAN TTPPVLDSDGSFFLYSR.heavy TRUE 956.471758 Unit 1188.555933 Unit TRUE 18.68 0.8 30.5
IGHG4_HUMAN TTPPVLDSDGSFFLYSR.light FALSE 951.467623 Unit 1406.658671 Unit TRUE 18.68 0.8 30.5
IGHG4_HUMAN TTPPVLDSDGSFFLYSR.light FALSE 951.467623 Unit 1293.574607 Unit TRUE 18.68 0.8 30.5
IGHG4_HUMAN TTPPVLDSDGSFFLYSR.light FALSE 951.467623 Unit 1178.547664 Unit TRUE 18.68 0.8 30.5
IGHM_HUMAN QVGSGVTTDQVQAEAK.heavy TRUE 813.414665 Unit 1398.695062 Unit TRUE 6.18 0.8 26.1
IGHM_HUMAN QVGSGVTTDQVQAEAK.heavy TRUE 813.414665 Unit 1098.551693 Unit TRUE 6.18 0.8 26.1
IGHM_HUMAN QVGSGVTTDQVQAEAK.heavy TRUE 813.414665 Unit 997.504014 Unit TRUE 6.18 0.8 26.1
IGHM_HUMAN QVGSGVTTDQVQAEAK.light FALSE 809.407565 Unit 1390.680863 Unit TRUE 6.18 0.8 26.1
IGHM_HUMAN QVGSGVTTDQVQAEAK.light FALSE 809.407565 Unit 1090.537494 Unit TRUE 6.18 0.8 26.1
IGHM_HUMAN QVGSGVTTDQVQAEAK.light FALSE 809.407565 Unit 989.489815 Unit TRUE 6.18 0.8 26.1
IGJ_HUMAN SSEDPNEDIVER.heavy TRUE 700.314194 Unit 981.487519 Unit TRUE 6.15 0.8 22.6
IGJ_HUMAN SSEDPNEDIVER.heavy TRUE 700.314194 Unit 641.349235 Unit TRUE 6.15 0.8 22.6
IGJ_HUMAN SSEDPNEDIVER.heavy TRUE 700.314194 Unit 491.247398 Unit TRUE 6.15 0.8 22.6
IGJ_HUMAN SSEDPNEDIVER.light FALSE 695.31006 Unit 971.47925 Unit TRUE 6.15 0.8 22.6
IGJ_HUMAN SSEDPNEDIVER.light FALSE 695.31006 Unit 631.340966 Unit TRUE 6.15 0.8 22.6
IGJ_HUMAN SSEDPNEDIVER.light FALSE 695.31006 Unit 486.243263 Unit TRUE 6.15 0.8 22.6
ITIH1_HUMAN AAISGENAGLVR.heavy TRUE 584.321428 Unit 912.477289 Unit TRUE 7.91 0.8 19
ITIH1_HUMAN AAISGENAGLVR.heavy TRUE 584.321428 Unit 825.445261 Unit TRUE 7.91 0.8 19
ITIH1_HUMAN AAISGENAGLVR.heavy TRUE 584.321428 Unit 639.381204 Unit TRUE 7.91 0.8 19
ITIH1_HUMAN AAISGENAGLVR.light FALSE 579.317294 Unit 902.46902 Unit TRUE 7.91 0.8 19
ITIH1_HUMAN AAISGENAGLVR.light FALSE 579.317294 Unit 815.436992 Unit TRUE 7.91 0.8 19
ITIH1_HUMAN AAISGENAGLVR.light FALSE 579.317294 Unit 629.372935 Unit TRUE 7.91 0.8 19
ITIH2_HUMAN IQPSGGTNINEALLR.heavy TRUE 796.935145 Unit 1351.720373 Unit TRUE 12.33 0.8 25.5
ITIH2_HUMAN IQPSGGTNINEALLR.heavy TRUE 796.935145 Unit 725.417983 Unit TRUE 12.33 0.8 25.5
ITIH2_HUMAN IQPSGGTNINEALLR.heavy TRUE 796.935145 Unit 676.363824 Unit TRUE 12.33 0.8 25.5
ITIH2_HUMAN IQPSGGTNINEALLR.light FALSE 791.931011 Unit 1341.712104 Unit TRUE 12.33 0.8 25.5
ITIH2_HUMAN IQPSGGTNINEALLR.light FALSE 791.931011 Unit 715.409714 Unit TRUE 12.33 0.8 25.5
ITIH2_HUMAN IQPSGGTNINEALLR.light FALSE 791.931011 Unit 671.35969 Unit TRUE 12.33 0.8 25.5
ITIH4_HUMAN LGVYELLLK.heavy TRUE 528.333167 Unit 942.574994 Unit TRUE 19.1 0.8 17.3
ITIH4_HUMAN LGVYELLLK.heavy TRUE 528.333167 Unit 786.485117 Unit TRUE 19.1 0.8 17.3
ITIH4_HUMAN LGVYELLLK.heavy TRUE 528.333167 Unit 623.421788 Unit TRUE 19.1 0.8 17.3
ITIH4_HUMAN LGVYELLLK.light FALSE 524.326068 Unit 934.560795 Unit TRUE 19.1 0.8 17.3
ITIH4_HUMAN LGVYELLLK.light FALSE 524.326068 Unit 778.470918 Unit TRUE 19.1 0.8 17.3
ITIH4_HUMAN LGVYELLLK.light FALSE 524.326068 Unit 615.407589 Unit TRUE 19.1 0.8 17.3
KLKB1_HUMAN IAYGTQGSSGYSLR.heavy TRUE 735.366564 Unit 1122.541346 Unit TRUE 8.84 0.8 23.6
KLKB1_HUMAN IAYGTQGSSGYSLR.heavy TRUE 735.366564 Unit 964.472204 Unit TRUE 8.84 0.8 23.6
KLKB1_HUMAN IAYGTQGSSGYSLR.heavy TRUE 735.366564 Unit 836.413626 Unit TRUE 8.84 0.8 23.6
KLKB1_HUMAN IAYGTQGSSGYSLR.light FALSE 730.36243 Unit 1112.533077 Unit TRUE 8.84 0.8 23.6
KLKB1_HUMAN IAYGTQGSSGYSLR.light FALSE 730.36243 Unit 954.463935 Unit TRUE 8.84 0.8 23.6
KLKB1_HUMAN IAYGTQGSSGYSLR.light FALSE 730.36243 Unit 826.405357 Unit TRUE 8.84 0.8 23.6
KNG1_HUMAN YFIDFVAR.heavy TRUE 520.775594 Unit 730.41217 Unit TRUE 16.9 0.8 17
KNG1_HUMAN YFIDFVAR.heavy TRUE 520.775594 Unit 617.328106 Unit TRUE 16.9 0.8 17
KNG1_HUMAN YFIDFVAR.heavy TRUE 520.775594 Unit 502.301162 Unit TRUE 16.9 0.8 17
KNG1_HUMAN YFIDFVAR.light FALSE 515.77146 Unit 720.403901 Unit TRUE 16.9 0.8 17
KNG1_HUMAN YFIDFVAR.light FALSE 515.77146 Unit 607.319837 Unit TRUE 16.9 0.8 17
KNG1_HUMAN YFIDFVAR.light FALSE 515.77146 Unit 492.292893 Unit TRUE 16.9 0.8 17
MBL2_HUMAN FQASVATPR.heavy TRUE 493.7683 Unit 711.402333 Unit TRUE 6.99 0.8 16.2
MBL2_HUMAN FQASVATPR.heavy TRUE 493.7683 Unit 640.365219 Unit TRUE 6.99 0.8 16.2
MBL2_HUMAN FQASVATPR.heavy TRUE 493.7683 Unit 454.264777 Unit TRUE 6.99 0.8 16.2
MBL2_HUMAN FQASVATPR.light FALSE 488.764166 Unit 701.394064 Unit TRUE 6.99 0.8 16.2
MBL2_HUMAN FQASVATPR.light FALSE 488.764166 Unit 630.35695 Unit TRUE 6.99 0.8 16.2
MBL2_HUMAN FQASVATPR.light FALSE 488.764166 Unit 444.256508 Unit TRUE 6.99 0.8 16.2
PEDF_HUMAN ELLDTVTAPQK.heavy TRUE 611.842085 Unit 867.466172 Unit TRUE 10.47 0.8 19.8
PEDF_HUMAN ELLDTVTAPQK.heavy TRUE 611.842085 Unit 552.323136 Unit TRUE 10.47 0.8 19.8
PEDF_HUMAN ELLDTVTAPQK.heavy TRUE 611.842085 Unit 380.238344 Unit TRUE 10.47 0.8 19.8
PEDF_HUMAN ELLDTVTAPQK.light FALSE 607.834985 Unit 859.451973 Unit TRUE 10.47 0.8 19.8
PEDF_HUMAN ELLDTVTAPQK.light FALSE 607.834985 Unit 544.308937 Unit TRUE 10.47 0.8 19.8
PEDF_HUMAN ELLDTVTAPQK.light FALSE 607.834985 Unit 372.224145 Unit TRUE 10.47 0.8 19.8
PGRP2_HUMAN AGLLRPDYALLGHR.heavy TRUE 521.299414 Unit 745.926926 Unit TRUE 13.19 0.8 17.1
PGRP2_HUMAN AGLLRPDYALLGHR.heavy TRUE 521.299414 Unit 605.375724 Unit TRUE 13.19 0.8 17.1
PGRP2_HUMAN AGLLRPDYALLGHR.heavy TRUE 521.299414 Unit 492.29166 Unit TRUE 13.19 0.8 17.1
PGRP2_HUMAN AGLLRPDYALLGHR.light FALSE 517.963324 Unit 740.922792 Unit TRUE 13.19 0.8 16.9
PGRP2_HUMAN AGLLRPDYALLGHR.light FALSE 517.963324 Unit 595.367455 Unit TRUE 13.19 0.8 16.9
PGRP2_HUMAN AGLLRPDYALLGHR.light FALSE 517.963324 Unit 482.283391 Unit TRUE 13.19 0.8 16.9
PLF4_HUMAN IC[+57.0]LDLQAPLYK.heavy TRUE 671.369955 Unit 1068.617922 Unit TRUE 16.57 0.8 21.7
PLF4_HUMAN IC[+57.0]LDLQAPLYK.heavy TRUE 671.369955 Unit 955.533858 Unit TRUE 16.57 0.8 21.7
PLF4_HUMAN IC[+57.0]LDLQAPLYK.heavy TRUE 671.369955 Unit 528.327159 Unit TRUE 16.57 0.8 21.7
PLF4_HUMAN IC[+57.0]LDLQAPLYK.light FALSE 667.362856 Unit 1060.603723 Unit TRUE 16.57 0.8 21.7
PLF4_HUMAN IC[+57.0]LDLQAPLYK.light FALSE 667.362856 Unit 947.519659 Unit TRUE 16.57 0.8 21.7
PLF4_HUMAN IC[+57.0]LDLQAPLYK.light FALSE 667.362856 Unit 520.31296 Unit TRUE 16.57 0.8 21.7
PLMN_HUMAN HSIFTPETNPR.heavy TRUE 654.83216 Unit 1171.598133 Unit TRUE 7.97 0.8 21.1
PLMN_HUMAN HSIFTPETNPR.heavy TRUE 654.83216 Unit 1084.566104 Unit TRUE 7.97 0.8 21.1
PLMN_HUMAN HSIFTPETNPR.heavy TRUE 654.83216 Unit 971.48204 Unit TRUE 7.97 0.8 21.1
PLMN_HUMAN HSIFTPETNPR.light FALSE 649.828026 Unit 1161.589864 Unit TRUE 7.97 0.8 21.1
PLMN_HUMAN HSIFTPETNPR.light FALSE 649.828026 Unit 1074.557835 Unit TRUE 7.97 0.8 21.1
PLMN_HUMAN HSIFTPETNPR.light FALSE 649.828026 Unit 961.473771 Unit TRUE 7.97 0.8 21.1
PON1_HUMAN LLIGTVFHK.heavy TRUE 518.325676 Unit 922.560013 Unit TRUE 15.45 0.8 16.9
PON1_HUMAN LLIGTVFHK.heavy TRUE 518.325676 Unit 639.370421 Unit TRUE 15.45 0.8 16.9
PON1_HUMAN LLIGTVFHK.heavy TRUE 518.325676 Unit 439.254329 Unit TRUE 15.45 0.8 16.9
PON1_HUMAN LLIGTVFHK.light FALSE 514.318577 Unit 914.545814 Unit TRUE 15.45 0.8 16.9
PON1_HUMAN LLIGTVFHK.light FALSE 514.318577 Unit 631.356222 Unit TRUE 15.45 0.8 16.9
PON1_HUMAN LLIGTVFHK.light FALSE 514.318577 Unit 431.24013 Unit TRUE 15.45 0.8 16.9
RET4_HUMAN FSGTWYAMAK.heavy TRUE 585.280609 Unit 1022.485527 Unit TRUE 13.22 0.8 19
RET4_HUMAN FSGTWYAMAK.heavy TRUE 585.280609 Unit 935.453499 Unit TRUE 13.22 0.8 19
RET4_HUMAN FSGTWYAMAK.heavy TRUE 585.280609 Unit 591.305044 Unit TRUE 13.22 0.8 19
RET4_HUMAN FSGTWYAMAK.light FALSE 581.273509 Unit 1014.471328 Unit TRUE 13.22 0.8 19
RET4_HUMAN FSGTWYAMAK.light FALSE 581.273509 Unit 927.4393 Unit TRUE 13.22 0.8 19
RET4_HUMAN FSGTWYAMAK.light FALSE 581.273509 Unit 583.290845 Unit TRUE 13.22 0.8 19
SAA4_HUMAN EALQGVGDMGR.heavy TRUE 571.778539 Unit 829.386031 Unit TRUE 8.37 0.8 18.6
SAA4_HUMAN EALQGVGDMGR.heavy TRUE 571.778539 Unit 701.327454 Unit TRUE 8.37 0.8 18.6
SAA4_HUMAN EALQGVGDMGR.heavy TRUE 571.778539 Unit 545.237576 Unit TRUE 8.37 0.8 18.6
SAA4_HUMAN EALQGVGDMGR.light FALSE 566.774405 Unit 819.377762 Unit TRUE 8.37 0.8 18.6
SAA4_HUMAN EALQGVGDMGR.light FALSE 566.774405 Unit 691.319185 Unit TRUE 8.37 0.8 18.6
SAA4_HUMAN EALQGVGDMGR.light FALSE 566.774405 Unit 535.229307 Unit TRUE 8.37 0.8 18.6
SEPP1_HUMAN LPTDSELAPR.heavy TRUE 554.797255 Unit 995.503169 Unit TRUE 8.64 0.8 18
SEPP1_HUMAN LPTDSELAPR.heavy TRUE 554.797255 Unit 898.450406 Unit TRUE 8.64 0.8 18
SEPP1_HUMAN LPTDSELAPR.heavy TRUE 554.797255 Unit 682.375784 Unit TRUE 8.64 0.8 18
SEPP1_HUMAN LPTDSELAPR.light FALSE 549.79312 Unit 985.4949 Unit TRUE 8.64 0.8 18
SEPP1_HUMAN LPTDSELAPR.light FALSE 549.79312 Unit 888.442137 Unit TRUE 8.64 0.8 18
SEPP1_HUMAN LPTDSELAPR.light FALSE 549.79312 Unit 672.367515 Unit TRUE 8.64 0.8 18
SHBG_HUMAN IALGGLLFPASNLR.heavy TRUE 726.434053 Unit 927.528596 Unit TRUE 19.97 0.8 23.4
SHBG_HUMAN IALGGLLFPASNLR.heavy TRUE 726.434053 Unit 814.444532 Unit TRUE 19.97 0.8 23.4
SHBG_HUMAN IALGGLLFPASNLR.heavy TRUE 726.434053 Unit 667.376118 Unit TRUE 19.97 0.8 23.4
SHBG_HUMAN IALGGLLFPASNLR.light FALSE 721.429918 Unit 917.520327 Unit TRUE 19.97 0.8 23.4
SHBG_HUMAN IALGGLLFPASNLR.light FALSE 721.429918 Unit 804.436263 Unit TRUE 19.97 0.8 23.4
SHBG_HUMAN IALGGLLFPASNLR.light FALSE 721.429918 Unit 657.367849 Unit TRUE 19.97 0.8 23.4
STOM_HUMAN YLQTLTTIAAEK.heavy TRUE 680.384117 Unit 955.554987 Unit TRUE 13.15 0.8 22
STOM_HUMAN YLQTLTTIAAEK.heavy TRUE 680.384117 Unit 854.507309 Unit TRUE 13.15 0.8 22
STOM_HUMAN YLQTLTTIAAEK.heavy TRUE 680.384117 Unit 741.423245 Unit TRUE 13.15 0.8 22
STOM_HUMAN YLQTLTTIAAEK.light FALSE 676.377017 Unit 947.540788 Unit TRUE 13.15 0.8 22
STOM_HUMAN YLQTLTTIAAEK.light FALSE 676.377017 Unit 846.49311 Unit TRUE 13.15 0.8 22
STOM_HUMAN YLQTLTTIAAEK.light FALSE 676.377017 Unit 733.409046 Unit TRUE 13.15 0.8 22
TETN_HUMAN LDTLAQEVALLK.heavy TRUE 661.394484 Unit 879.538943 Unit TRUE 18.06 0.8 21.4
TETN_HUMAN LDTLAQEVALLK.heavy TRUE 661.394484 Unit 808.501829 Unit TRUE 18.06 0.8 21.4
TETN_HUMAN LDTLAQEVALLK.heavy TRUE 661.394484 Unit 330.165962 Unit TRUE 18.06 0.8 21.4
TETN_HUMAN LDTLAQEVALLK.light FALSE 657.387385 Unit 871.524744 Unit TRUE 18.06 0.8 21.4
TETN_HUMAN LDTLAQEVALLK.light FALSE 657.387385 Unit 800.48763 Unit TRUE 18.06 0.8 21.4
TETN_HUMAN LDTLAQEVALLK.light FALSE 657.387385 Unit 330.165962 Unit TRUE 18.06 0.8 21.4
THBG_HUMAN NALALFVLPK.heavy TRUE 547.346609 Unit 908.6059 Unit TRUE 19.92 0.8 17.8
THBG_HUMAN NALALFVLPK.heavy TRUE 547.346609 Unit 795.521836 Unit TRUE 19.92 0.8 17.8
THBG_HUMAN NALALFVLPK.heavy TRUE 547.346609 Unit 724.484723 Unit TRUE 19.92 0.8 17.8
THBG_HUMAN NALALFVLPK.light FALSE 543.339509 Unit 900.591701 Unit TRUE 19.92 0.8 17.8
THBG_HUMAN NALALFVLPK.light FALSE 543.339509 Unit 787.507637 Unit TRUE 19.92 0.8 17.8
THBG_HUMAN NALALFVLPK.light FALSE 543.339509 Unit 716.470524 Unit TRUE 19.92 0.8 17.8
THRB_HUMAN TATSEYQTFFNPR.heavy TRUE 786.371846 Unit 1082.529325 Unit TRUE 13.72 0.8 25.2
THRB_HUMAN TATSEYQTFFNPR.heavy TRUE 786.371846 Unit 919.465996 Unit TRUE 13.72 0.8 25.2
THRB_HUMAN TATSEYQTFFNPR.heavy TRUE 786.371846 Unit 282.18 Unit TRUE 13.72 0.8 25.2
THRB_HUMAN TATSEYQTFFNPR.light FALSE 781.367712 Unit 1072.521056 Unit TRUE 13.72 0.8 25.2
THRB_HUMAN TATSEYQTFFNPR.light FALSE 781.367712 Unit 909.457727 Unit TRUE 13.72 0.8 25.2
THRB_HUMAN TATSEYQTFFNPR.light FALSE 781.367712 Unit 272.1717 Unit TRUE 13.72 0.8 25.2
TotalIGHG DTLMISR.heavy TRUE 423.22488 Unit 629.367862 Unit TRUE 8.74 0.8 14
TotalIGHG DTLMISR.heavy TRUE 423.22488 Unit 516.283798 Unit TRUE 8.74 0.8 14
TotalIGHG DTLMISR.heavy TRUE 423.22488 Unit 385.243313 Unit TRUE 8.74 0.8 14
TotalIGHG DTLMISR.light FALSE 418.220745 Unit 619.359593 Unit TRUE 8.74 0.8 14
TotalIGHG DTLMISR.light FALSE 418.220745 Unit 506.275529 Unit TRUE 8.74 0.8 14
TotalIGHG DTLMISR.light FALSE 418.220745 Unit 375.235044 Unit TRUE 8.74 0.8 14
TRFE_HUMAN EGYYGYTGAFR.heavy TRUE 647.292337 Unit 944.450012 Unit TRUE 11.41 0.8 20.9
TRFE_HUMAN EGYYGYTGAFR.heavy TRUE 647.292337 Unit 781.386683 Unit TRUE 11.41 0.8 20.9
TRFE_HUMAN EGYYGYTGAFR.heavy TRUE 647.292337 Unit 561.301891 Unit TRUE 11.41 0.8 20.9
TRFE_HUMAN EGYYGYTGAFR.light FALSE 642.288202 Unit 934.441743 Unit TRUE 11.41 0.8 20.9
TRFE_HUMAN EGYYGYTGAFR.light FALSE 642.288202 Unit 771.378414 Unit TRUE 11.41 0.8 20.9
TRFE_HUMAN EGYYGYTGAFR.light FALSE 642.288202 Unit 551.293622 Unit TRUE 11.41 0.8 20.9
TTHY_HUMAN GSPAINVAVHVFR.heavy TRUE 459.593939 Unit 738.428488 Unit TRUE 14.1 0.8 20
TTHY_HUMAN GSPAINVAVHVFR.heavy TRUE 459.593939 Unit 568.322961 Unit TRUE 14.1 0.8 20
TTHY_HUMAN GSPAINVAVHVFR.heavy TRUE 459.593939 Unit 284.665118 Unit TRUE 14.1 0.8 20
TTHY_HUMAN GSPAINVAVHVFR.light FALSE 456.257849 Unit 728.420219 Unit TRUE 14.1 0.8 20
TTHY_HUMAN GSPAINVAVHVFR.light FALSE 456.257849 Unit 558.314692 Unit TRUE 14.1 0.8 20
TTHY_HUMAN GSPAINVAVHVFR.light FALSE 456.257849 Unit 279.660984 Unit TRUE 14.1 0.8 20
VTDB_HUMAN HLSLLTTLSNR.heavy TRUE 632.866003 Unit 1127.665818 Unit TRUE 13.38 0.8 20.5
VTDB_HUMAN HLSLLTTLSNR.heavy TRUE 632.866003 Unit 1014.581754 Unit TRUE 13.38 0.8 20.5
VTDB_HUMAN HLSLLTTLSNR.heavy TRUE 632.866003 Unit 701.381598 Unit TRUE 13.38 0.8 20.5
VTDB_HUMAN HLSLLTTLSNR.light FALSE 627.861869 Unit 1117.657549 Unit TRUE 13.38 0.8 20.5
VTDB_HUMAN HLSLLTTLSNR.light FALSE 627.861869 Unit 1004.573485 Unit TRUE 13.38 0.8 20.5
VTDB_HUMAN HLSLLTTLSNR.light FALSE 627.861869 Unit 691.373329 Unit TRUE 13.38 0.8 20.5
VTNC_HUMAN FEDGVLDPDYPR.heavy TRUE 716.834566 Unit 885.434027 Unit TRUE 12.74 0.8 23.1
VTNC_HUMAN FEDGVLDPDYPR.heavy TRUE 716.834566 Unit 772.349963 Unit TRUE 12.74 0.8 23.1
VTNC_HUMAN FEDGVLDPDYPR.heavy TRUE 716.834566 Unit 657.32302 Unit TRUE 12.74 0.8 23.1
VTNC_HUMAN FEDGVLDPDYPR.light FALSE 711.830431 Unit 875.425758 Unit TRUE 12.74 0.8 23.1
VTNC_HUMAN FEDGVLDPDYPR.light FALSE 711.830431 Unit 762.341694 Unit TRUE 12.74 0.8 23.1
VTNC_HUMAN FEDGVLDPDYPR.light FALSE 711.830431 Unit 647.314751 Unit TRUE 12.74 0.8 23.1
ZA2G_HUMAN AYLEEEC[+57.0]PATLR.heavy TRUE 731.349526 Unit 1114.507269 Unit TRUE 10.24 0.8 23.5
ZA2G_HUMAN AYLEEEC[+57.0]PATLR.heavy TRUE 731.349526 Unit 985.464676 Unit TRUE 10.24 0.8 23.5
ZA2G_HUMAN AYLEEEC[+57.0]PATLR.heavy TRUE 731.349526 Unit 567.348841 Unit TRUE 10.24 0.8 23.5
ZA2G_HUMAN AYLEEEC[+57.0]PATLR.light FALSE 726.345391 Unit 1104.499 Unit TRUE 10.24 0.8 23.5
ZA2G_HUMAN AYLEEEC[+57.0]PATLR.light FALSE 726.345391 Unit 975.456407 Unit TRUE 10.24 0.8 23.5
ZA2G_HUMAN AYLEEEC[+57.0]PATLR.light FALSE 726.345391 Unit 557.340572 Unit TRUE 10.24 0.8 23.5
Other	settings:	Fragmentor:	380;	Cell	accelerator	voltage:	4;	Polarity:	positive;		Peptides	highlighted	in	grey	are	not	part	of	the	final	PlasmaDive	kit	(Biognosys,	CH)
SUPPLEMENTAL TABLE 3:
UniProt Entry Name UniProt ID Protein Name Peptide LOD (ug/mL) LOQ (ug/mL) Linear_Range_Start (ug/mL) Linear_Range_End (ug/mL) LOD (ug/mL) LOQ (ug/mL) Linear_Range_Start (ug/mL) Linear_Range_End (ug/mL) LOD (ug/mL) LOQ (ug/mL)
A1AG1_HUMAN P02763 Alpha-1-acid glycoprotein 1 (Orosomucoid-1) SDVVYTDWK 0.226 0.543 1.566 156.610 0.602 1.650 15.661 156.610 0.048 0.134
A1AG2_HUMAN P19652 Alpha-1-acid glycoprotein 2 (Orosomucoid-2) EHVAHLLFLR 0.741 1.652 4.363 436.274 2.843 7.752 43.627 436.274 0.034 0.078
A1AT_HUMAN P01009 Alpha-1-antitrypsin SVLGQLGITK 0.106 0.259 1.472 147.163 0.081 0.203 1.472 147.163 0.162 0.380
A1BG_HUMAN P04217 Alpha-1B-glycoprotein LLELTGPK 0.229 0.439 0.679 67.865 0.356 0.746 6.786 67.865 0.035 0.054
A2AP_HUMAN P08697 Alpha-2-antiplasmin (Serpin F2) LFGPDLK 0.185 0.406 1.171 117.108 0.368 0.899 1.171 117.108 0.070 0.149
A2GL_HUMAN P02750 Leucine-rich alpha-2-glycoprotein (LRG) VAAGAFQGLR 0.127 0.300 1.022 102.199 0.099 0.233 1.022 102.199 0.067 0.175
A2MG_HUMAN P01023 Alpha-2-macroglobulin (Alpha-2-M) AIGYLNTGYQR 0.858 2.300 12.699 1269.924 0.631 1.843 12.699 1269.924 0.781 1.893
AACT_HUMAN P01011 Alpha-1-antichymotrypsin (ACT) EIGELYLPK 0.350 0.774 2.672 267.158 0.111 0.284 2.672 267.158 0.114 0.244
AFAM_HUMAN P43652 Afamin (Alpha-albumin) AESPEVCFNEESPK 0.416 1.139 2.262 2261.951 0.940 2.544 22.620 2261.951 2.844 7.608
ALBU_HUMAN P02768 Serum albumin YLYEIAR 0.527 0.912 1.111 111.100 0.148 0.363 1.111 111.100 0.122 0.323
AMBP_HUMAN P02760 Protein AMBP TVAACNLPIVR 0.061 0.132 0.167 166.982 0.054 0.144 1.670 166.982 0.138 0.356
ANGT_HUMAN P01019 Angiotensinogen (Serpin A8) ALQDQLVLVAAK NA NA NA NA 0.167 0.406 0.646 646.418 0.395 0.712
ANT3_HUMAN P01008 Antithrombin-III (Serpin C1) EVPLNTIIFMGR 0.330 0.801 2.750 275.008 0.947 2.347 27.501 275.008 0.009 0.023
APOA_HUMAN P08519 Apolipoprotein(a) GTYSTTVTGR 8.153 18.704 53.125 5312.484 5.898 10.244 53.125 5312.484 2.980 4.998
APOA1_HUMAN P02647 Apolipoprotein A-I VSFLSALEEYTK 0.055 0.122 0.166 166.494 0.190 0.394 1.665 166.494 0.045 0.125
APOA2_HUMAN P02652 Apolipoprotein A-II EQLTPLIK 0.039 0.059 0.092 9.232 0.106 0.215 0.923 9.232 0.005 0.016
APOA4_HUMAN P06727 Apolipoprotein A-IV LAPLAEDVR 1.164 2.183 1.938 193.807 0.072 0.167 1.938 193.807 0.131 0.317
APOB_HUMAN P04114 Apolipoprotein B-100 FSVPAGIVIPSFQALTAR 0.571 1.079 0.304 3038.832 9.813 22.779 303.883 3038.832 NA NA
APOC1_HUMAN P02654 Apolipoprotein C-I EFGNTLEDK 2.346 5.613 10.646 106.461 0.123 0.229 1.065 106.461 0.163 0.401
APOC2_HUMAN P02655 Apolipoprotein C-II TAAQNLYEK 0.128 0.217 0.782 78.181 0.032 0.072 0.078 78.181 0.034 0.045
APOC3_HUMAN P02656 Apolipoprotein C-III GWVTDGFSSLK 0.540 1.064 0.855 85.466 0.061 0.153 0.855 85.466 0.007 0.017
APOD_HUMAN P05090 Apolipoprotein D NILTSNNIDVK 0.140 0.385 2.334 233.369 0.035 0.090 0.233 233.369 0.161 0.338
APOE_HUMAN P02649 Apolipoprotein E AATVGSLAGQPLQER 0.056 0.121 0.236 236.096 0.254 0.701 2.361 236.096 0.470 1.253
APOH_HUMAN P02749 Apolipoprotein H VCPFAGILENGAVR 0.043 0.112 0.332 332.212 0.241 0.552 3.322 332.212 0.348 0.867
APOL1_HUMAN O14791 Apolipoprotein L1 VTEPISAESGEQVER 0.297 0.763 0.939 938.894 1.532 4.132 9.389 938.894 1.070 2.377
APOM_HUMAN O95445 Apolipoprotein M FLLYNR 0.031 0.058 0.294 29.369 0.036 0.090 0.294 29.369 0.045 0.127
BTD_HUMAN P43251 Biotinidase SHLIIAQVAK 0.361 0.720 2.392 239.183 0.711 1.515 2.392 239.183 0.530 1.496
C1QA_HUMAN P02745 Complement C1q subcomponent subunit A SLGFCDTTNK 0.334 0.714 1.198 119.795 0.100 0.160 1.198 119.795 0.200 0.508
C1QB_HUMAN P02746 Complement C1q subcomponent subunit B GNLCVNLMR 0.180 0.452 1.130 113.040 0.119 0.350 1.130 113.040 0.003 0.006
C1QC_HUMAN P02747 Complement C1q subcomponent subunit C FQSVFTVTR 0.212 0.380 0.429 42.854 0.098 0.240 0.429 42.854 0.063 0.162
C1R_HUMAN P00736 Complement C1r subcomponent GLTLHLK 2.783 4.691 28.483 284.834 0.897 2.135 2.848 284.834 0.607 1.651
C1S_HUMAN P09871 Complement C1s subcomponent TNFDNDIALVR 3.019 5.337 6.390 638.983 3.439 8.845 63.898 638.983 0.942 2.448
C4BPA_HUMAN P04003 C4b-binding protein alpha chain GYILVGQAK 0.567 1.228 4.468 446.815 0.316 0.744 4.468 446.815 0.185 0.417
CBG_HUMAN P08185 Corticosteroid-binding globulin (Serpin A6) GTWTQPFDLASTR 0.303 0.586 2.004 200.422 1.903 3.655 20.042 200.422 0.041 0.107
CD5L_HUMAN O43866 CD5 antigen-like (CT-2) (SP-alpha) IWLDNVR 0.162 0.397 0.450 45.012 0.253 0.494 4.501 45.012 0.015 0.043
CERU_HUMAN P00450 Ceruloplasmin (Ferroxidase) DIASGLIGPLIICK 0.367 0.678 0.903 903.245 0.740 1.712 9.032 903.245 0.262 0.598
CFAB_HUMAN P00751 Complement factor B YGLVTYATYPK 0.557 1.317 0.312 311.592 0.404 0.987 3.116 311.592 0.198 0.476
CFAH_HUMAN P08603 Complement factor H (H factor 1) IDVHLVPDR 5.867 10.403 13.508 1350.785 1.549 4.380 13.508 1350.785 0.584 1.491
CFAI_HUMAN P05156 Complement factor I IVIEYVDR 0.499 1.303 1.365 136.496 0.363 0.707 1.365 136.496 0.111 0.259
CHLE_HUMAN P06276 Cholinesterase (EC 3.1.1.8) IFFPGVSEFGK 1.653 2.196 2.050 205.002 1.376 3.420 20.500 205.002 0.365 0.854
CLUS_HUMAN P10909 Clusterin (Aging-associated gene 4 protein) (Apolipoprotein J) ASSIIDELFQDR 0.114 0.246 0.368 367.879 0.272 0.547 3.679 367.879 0.267 0.665
CO2_HUMAN P06681 Complement C2 AVISPGFDVFAK 0.147 0.297 0.368 368.034 0.147 0.384 3.680 368.034 0.214 0.446
CO3_HUMAN P01024 Complement C3 GYTQQLAFR 0.843 2.104 7.444 744.370 1.398 3.309 7.444 744.370 0.721 2.019
CO4A_HUMAN P0C0L4 Complement C4-A PVAFSVVPTAAAAVSLK 1.384 3.471 1.859 1859.068 1.034 2.376 18.591 1859.068 1.797 4.367
CO5_HUMAN P01031 Complement C5 TDAPDLPEENQAR 0.771 1.993 9.195 919.542 0.749 1.853 9.195 919.542 1.135 2.997
CO8A_HUMAN P07357 Complement component C8 alpha chain HTSLGPLEAK 1.395 3.339 5.993 599.335 4.545 8.725 59.934 599.335 0.433 1.281
CO9_HUMAN P02748 Complement component C9 LSPIYNLVPVK 0.342 0.667 1.760 176.048 0.166 0.378 1.760 176.048 0.161 0.327
CXCL7_HUMAN P02775 Platelet basic protein (C-X-C motif chemokine 7) NIQSLEVIGK 0.362 0.677 1.525 152.528 0.298 0.760 1.525 152.528 0.228 0.576
F13A_HUMAN P00488 Coagulation factor XIII A chain STVLTIPEIIIK 0.470 0.919 0.475 474.596 0.199 0.375 4.746 474.596 0.235 0.399
F13B_HUMAN P05160 Coagulation factor XIII B chain IAQYYYTFK 0.965 2.222 6.941 694.134 0.423 1.144 6.941 694.134 2.524 6.469
FA10_HUMAN P00742 Coagulation factor X ACIPTGPYPCGK 0.136 0.324 0.326 326.053 0.120 0.291 3.261 326.053 0.352 0.788
FA9_HUMAN P00740 Coagulation factor IX SALVLQYLR 0.031 0.078 0.107 106.734 0.127 0.296 1.067 106.734 0.074 0.120
FBLN1_HUMAN P23142 Fibulin-1 TGYYFDGISR 0.636 1.614 3.227 322.717 0.297 0.773 3.227 322.717 0.005 0.012
FETUA_HUMAN P02765 Alpha-2-HS-glycoprotein FSVVYAK 0.129 0.243 0.016 163.393 0.096 0.208 1.634 163.393 0.169 0.375
FETUB_HUMAN Q9UGM5 Fetuin-B LVVLPFPK 0.022 0.056 0.533 53.284 0.013 0.032 0.053 53.284 0.027 0.048
FIBA_HUMAN P02671 Fibrinogen alpha chain GSESGIFTNTK 1.015 2.280 3.973 397.331 0.408 0.691 3.973 397.331 0.445 1.078
FIBG_HUMAN P02679 Fibrinogen gamma chain DNCCILDER 1.127 1.741 0.979 978.581 0.544 1.354 9.786 978.581 2.540 6.830
FINC_HUMAN P02751 Fibronectin (FN) SYTITGLQPGTDYK 1.356 3.728 25.602 2560.181 2.126 4.997 25.602 2560.181 1.948 4.584
GELS_HUMAN P06396 Gelsolin (Actin-depolymerizing factor) AGALNSNDAFVLK 0.352 0.605 0.726 725.669 0.193 0.500 7.257 725.669 0.597 1.462
GPX3_HUMAN P22352 Glutathione peroxidase 3 FLVGPDGIPIMR 0.061 0.110 0.087 87.274 0.158 0.368 0.873 87.274 0.113 0.294
HBB_HUMAN P68871 Hemoglobin subunit beta VNVDEVGGEALGR 0.021 0.050 0.073 72.694 0.020 0.055 0.727 72.694 0.014 0.042
HBD_HUMAN P02042 Hemoglobin subunit delta (Delta-globin) LLGNVLVCVLAR 0.031 0.062 0.043 43.273 0.964 1.892 4.327 43.273 0.062 0.174
HEMO_HUMAN P02790 Hemopexin (Beta-1B-glycoprotein) NFPSPVDAAFR 0.353 0.821 1.419 141.919 3.079 5.998 14.192 141.919 0.202 0.487
HEP2_HUMAN P05546 Heparin cofactor 2 TLEAQLTPR 0.206 0.471 1.423 142.336 0.423 1.024 1.423 142.336 0.194 0.537
HPT_HUMAN P00738 Haptoglobin VTSIQDWVQK 1.257 2.523 2.810 280.985 0.416 1.009 2.810 280.985 0.002 0.005
HPTR_HUMAN P00739 Haptoglobin-related protein VGYVSGWGQSDNFK 0.356 0.897 1.935 193.534 0.167 0.489 1.935 193.534 0.287 0.848
HRG_HUMAN P04196 Histidine-rich glycoprotein GGEGTGYFVDFSVR 0.892 1.874 0.747 746.640 1.913 4.432 7.466 746.640 NA NA
IC1_HUMAN P05155 Plasma protease C1 inhibitor LLDSLPSDTR 0.214 0.430 1.194 119.450 0.016 0.040 0.119 119.450 0.138 0.375
IGHA1_HUMAN P01876 Ig alpha-1 chain C region TPLTATLSK 0.306 0.536 0.902 90.164 0.130 0.294 0.902 90.164 0.204 0.576
IGHA2_HUMAN P01877 Ig alpha-2 chain C region DASGATFTWTPSSGK 0.176 0.416 0.460 459.580 0.596 1.433 4.596 459.580 0.014 0.034
Nanoflow in human plasma digest Standard flow in human plasma digest Standard flow in LC solution
IGHG1_HUMAN P01857 Ig gamma-1 chain C region GPSVFPLAPSSK 0.338 0.534 0.951 95.073 0.079 0.161 0.951 95.073 0.098 0.246
IGHG2_HUMAN P01859 Ig gamma-2 chain C region GLPAPIEK 0.380 0.758 1.208 120.768 0.104 0.262 1.208 120.768 0.072 0.180
IGHG3_HUMAN P01860 Ig gamma-3 chain C region (HDC) WYVDGVEVHNAK 0.559 1.416 1.916 1915.760 19.191 38.241 191.576 1915.760 0.055 0.125
IGHM_HUMAN P01871 Ig mu chain C region YAATSQVLLPSK 0.685 1.353 1.886 188.575 0.254 0.650 1.886 188.575 0.111 0.225
IPSP_HUMAN P05154 Plasma serine protease inhibitor TLYLADTFPTNFR 0.226 0.457 0.442 441.829 0.224 0.587 4.418 441.829 0.333 0.716
ITIH1_HUMAN P19827 Inter-alpha-trypsin inhibitor heavy chain H1 AAISGENAGLVR 0.137 0.341 0.285 285.340 0.588 1.290 2.853 285.340 0.421 1.043
ITIH2_HUMAN P19823 Inter-alpha-trypsin inhibitor heavy chain H2 FYNQVSTPLLR 0.533 1.244 1.279 127.856 0.762 1.920 12.786 127.856 0.121 0.351
ITIH4_HUMAN Q14624 Inter-alpha-trypsin inhibitor heavy chain H4 ILDDLSPR 1.951 3.980 19.220 192.197 0.665 1.474 1.922 192.197 0.130 0.356
KAIN_HUMAN P29622 Kallistatin (Kallikrein inhibitor) LGFTDLFSK 1.599 3.175 3.407 340.747 0.182 0.400 3.407 340.747 0.222 0.485
KLKB1_HUMAN P03952 Plasma kallikrein IAYGTQGSSGYSLR 0.767 1.768 6.996 699.563 2.808 8.323 69.956 699.563 1.358 3.813
KNG1_HUMAN P01042 Kininogen-1 YFIDFVAR 0.342 0.725 0.513 512.520 0.341 0.509 5.125 512.520 0.214 0.460
PEDF_HUMAN P36955 Pigment epithelium-derived factor (PEDF) ELLDTVTAPQK 0.374 0.941 1.680 167.968 0.707 1.842 16.797 167.968 0.486 1.112
PGRP2_HUMAN Q96PD5 N-acetylmuramoyl-L-alanine amidase AGLLRPDYALLGHR 2.527 5.333 21.019 210.192 4.702 12.254 21.019 210.192 0.028 0.078
PLF4_HUMAN P02776 Platelet factor 4 (Oncostatin-A) ICLDLQAPLYK 0.095 0.168 0.093 93.030 0.084 0.210 0.930 93.030 0.048 0.086
PLMN_HUMAN P00747 Plasminogen HSIFTPETNPR 1.162 2.522 13.376 1337.575 3.092 7.606 13.376 1337.575 1.762 4.632
PON1_HUMAN P27169 Serum paraoxonase LLIGTVFHK 2.290 4.871 16.754 167.541 3.225 5.661 16.754 167.541 0.245 0.524
PRG4_HUMAN Q92954 Proteoglycan 4 GLPNVVTSAISLPNIR 1.697 2.759 1.349 1348.583 0.703 1.631 13.486 1348.583 0.903 1.813
RET4_HUMAN P02753 Retinol-binding protein 4 FSGTWYAMAK 0.738 1.440 2.765 276.495 0.262 0.675 2.765 276.495 0.079 0.220
SAA4_HUMAN P35542 Serum amyloid A-4 protein EALQGVGDMGR 0.277 0.508 0.687 68.684 0.143 0.292 0.687 68.684 0.135 0.379
SEPP1_HUMAN P49908 Selenoprotein P LPTDSELAPR 0.316 0.620 2.114 211.412 0.324 0.642 2.114 211.412 0.196 0.477
SHBG_HUMAN P04278 Sex hormone-binding globulin IALGGLLFPASNLR 0.043 0.102 0.094 94.024 0.582 1.441 9.402 94.024 0.059 0.170
TETN_HUMAN P05452 Tetranectin LDTLAQEVALLK 0.122 0.296 1.329 132.863 0.043 0.072 0.133 132.863 0.047 0.099
THBG_HUMAN P05543 Thyroxine-binding globulin (Serpin A7) NALALFVLPK 0.130 0.297 0.232 232.488 0.083 0.204 2.325 232.488 0.193 0.431
THRB_HUMAN P00734 Prothrombin TATSEYQTFFNPR 0.536 1.356 1.477 1476.843 2.370 5.991 14.768 1476.843 3.096 8.583
TRFE_HUMAN P02787 Serotransferrin EGYYGYTGAFR 1.032 2.190 3.144 314.394 2.008 4.891 31.439 314.394 0.823 2.082
TTHY_HUMAN P02766 Transthyretin AADDTWEPFASGK NA NA NA NA 0.689 1.600 5.424 54.236 0.357 0.944
VTDB_HUMAN P02774 Vitamin D-binding protein HLSLLTTLSNR 0.370 0.779 2.021 202.141 0.525 1.455 2.021 202.141 0.443 1.317
VTNC_HUMAN P04004 Vitronectin FEDGVLDPDYPR 0.464 0.968 2.193 219.265 1.494 3.209 21.927 219.265 0.804 1.981
VWF_HUMAN P04275 von Willebrand factor ILAGPAGDSNVVK 0.732 1.711 2.920 2920.271 0.773 2.026 29.203 2920.271 2.336 6.136
ZA2G_HUMAN P25311 Zinc-alpha-2-glycoprotein AYLEEECPATLR 0.209 0.420 0.437 437.112 0.261 0.742 4.371 437.112 0.313 0.847
MEDIAN 0.359 0.768 0.349 0.745 0.195 0.439
AVERAGE 0.721 1.514 1.063 2.409 0.459 1.139
SUPPLEMENTAL TABLE 4:
Proteins Average SD Min Max Average SD Min Max
A1AG1_HUMAN 273.978 97.386 88.176 767.027 289.685 109.295 83.121 820.878
A1AG2_HUMAN 153.128 42.185 54.665 276.891 160.734 48.612 55.326 314.885
A1AT_HUMAN 931.652 236.862 371.225 2102.659 997.558 264.572 369.888 2248.086
A1BG_HUMAN 112.953 22.911 45.416 195.347 103.775 22.689 36.332 180.305
A2AP_HUMAN 21.367 3.218 10.621 32.340 16.839 2.533 8.009 26.412
A2GL_HUMAN 14.400 5.382 4.420 53.817 12.527 4.880 4.035 47.748
A2MG_HUMAN
AACT_HUMAN 191.167 48.326 72.469 730.090 182.711 48.254 69.375 740.588
ABCF1_HUMAN 3.753 1.403 1.038 8.915 2.329 1.084 0.355 10.573
AFAM_HUMAN 116.585 27.288 51.535 264.362 120.085 27.157 50.699 258.232
ALBU_HUMAN 29847.877 3611.924 17521.812 43305.750 35796.752 4732.333 22358.763 50593.131
AMBP_HUMAN 80.284 12.821 36.413 137.023 73.938 12.915 36.530 129.616
ANGT_HUMAN 48.553 13.383 2.384 154.880 40.914 11.542 18.169 136.694
ANT3_HUMAN 261.567 49.219 111.993 465.956 263.320 57.484 121.743 493.690
APOA_HUMAN 250.800 286.845 7.948 1859.563 220.425 266.944 4.794 1801.360
APOA1_HUMAN 2243.625 489.132 1134.769 4235.591 2484.866 608.083 1147.605 5255.154
APOA2_HUMAN 28.420 6.251 13.242 58.098 27.208 6.411 11.797 55.651
APOA4_HUMAN 56.129 15.445 18.127 136.960 52.817 15.021 14.577 136.566
APOB_HUMAN 1151.470 345.354 390.548 2466.532 1103.702 363.772 353.831 2526.697
APOC1_HUMAN 29.898 7.100 12.001 55.689 25.901 6.452 8.419 46.910
APOC2_HUMAN 16.248 6.968 2.795 58.254 13.928 6.307 2.324 52.773
APOC3_HUMAN 64.199 25.232 15.464 218.282 61.870 25.480 13.738 228.689
APOD_HUMAN 32.926 8.516 15.259 76.250 28.750 7.990 14.495 76.757
APOE_HUMAN 28.240 9.194 8.340 82.644 26.683 9.310 7.639 93.999
APOH_HUMAN 163.322 38.532 55.906 281.233
APOL1_HUMAN 16.628 4.562 5.391 36.497 14.743 3.951 4.804 32.756
APOM_HUMAN 13.193 2.681 5.234 23.442 11.269 2.437 5.134 20.091
B3AT_HUMAN 2.613 0.817 0.677 6.269 0.282 0.140 0.050 1.613
C1QB_HUMAN 16.767 2.988 5.649 41.273 16.724 3.077 5.852 30.569
C1QC_HUMAN 27.825 4.823 10.863 45.960 21.536 4.034 8.022 36.660
C1R_HUMAN 24.622 5.033 10.588 44.386 23.419 3.781 13.146 35.836
C1S_HUMAN 34.865 5.840 21.960 58.999 18.992 2.915 10.307 30.548
C4BPA_HUMAN 105.135 25.810 35.994 213.332 98.871 25.504 29.638 195.253
CBG_HUMAN 5.476 1.694 2.265 19.013 4.658 1.570 1.976 20.570
CD5L_HUMAN 15.180 7.886 2.975 78.019 13.800 7.590 2.598 80.200
CERU_HUMAN 1068.045 264.910 461.717 2367.225 1052.695 287.467 392.997 2083.961
CFAB_HUMAN 117.625 25.065 46.638 220.970 110.950 25.266 38.194 214.336
CFAH_HUMAN 161.337 52.426 28.562 456.069 189.738 34.407 111.013 296.185
CFAI_HUMAN 14.404 3.208 5.497 25.471 11.780 2.694 4.126 23.702
CLUS_HUMAN 134.876 21.284 61.655 198.616 127.653 23.121 61.348 203.888
CO2_HUMAN 23.261 4.060 10.222 35.937 16.760 3.035 6.444 28.749
CO3_HUMAN 1240.971 303.537 526.868 2892.228 1263.522 332.920 446.616 3127.835
CO5_HUMAN 58.367 10.732 26.470 105.652 51.658 9.467 21.083 92.208
CO6_HUMAN 26.280 5.965 6.368 44.627 23.130 4.821 8.462 40.623
CO7_HUMAN 56.616 26.515 3.668 369.429 49.430 25.484 2.960 399.596
CO8A_HUMAN 15.139 2.752 5.198 25.233 13.281 2.474 5.076 23.462
CO9_HUMAN 43.024 13.905 8.714 118.699 38.193 13.042 7.666 110.605
CPN2_HUMAN 26.062 6.188 11.870 54.602 21.535 5.364 8.983 43.613
F13A_HUMAN 18.849 5.276 5.071 43.477 15.246 4.349 4.481 36.728
FBLN1_HUMAN 9.912 3.175 1.928 22.797 7.228 2.184 1.989 16.286
FCN3_HUMAN 11.553 3.291 2.887 24.697 6.444 1.917 0.042 14.163
FETUA_HUMAN 175.930 29.978 75.445 276.129 166.563 29.148 69.220 268.305
FIBA_HUMAN 1461.558 371.805 179.064 3374.523 1597.170 424.602 184.489 3587.873
FIBB_HUMAN 1504.306 361.873 163.570 3263.127
FIBG_HUMAN 1085.956 267.720 128.788 2378.050 1153.478 297.871 112.881 2733.730
FINC_HUMAN 343.940 189.990 59.499 2538.839 320.357 195.786 45.230 2913.630
GELS_HUMAN 111.256 16.741 66.008 173.464 80.432 14.779 37.423 140.750




GPX3_HUMAN 4.716 0.956 2.355 7.586 3.723 0.760 1.731 6.822
HBA_HUMAN 22.509 23.172 3.013 271.033 24.906 26.341 3.247 294.509
HBD_HUMAN 2.599 2.301 0.516 24.153 2.153 1.939 0.247 21.033
HBE_HUMAN 0.993 3.186 0.134 31.789 0.525 0.109 0.267 1.105
HEMO_HUMAN 664.943 118.796 259.786 1025.541 646.288 121.821 222.314 1019.497
HEP2_HUMAN 47.783 9.729 18.168 80.693 41.571 9.132 14.822 72.280
HPT_HUMAN 1250.269 562.361 23.080 3855.210 1433.929 676.850 16.530 4985.870
HPTR_HUMAN 40.711 17.940 5.073 250.097 39.316 18.556 4.410 262.325
HRG_HUMAN 189.931 47.869 69.507 407.688 196.549 52.839 70.584 473.516
IC1_HUMAN 277.867 55.000 116.329 520.620 289.834 58.272 115.833 546.196
IGHA1_HUMAN 956.036 456.464 61.592 4339.298 1294.456 656.539 71.237 6705.435
IGHA2_HUMAN 127.000 77.929 13.826 757.461 112.845 79.103 0.766 779.548
IGHG1_HUMAN 5557.499 1886.299 2040.760 25013.172 6254.303 2223.804 2201.105 28236.605
IGHG2_HUMAN 2241.876 872.258 405.498 5345.709 2305.817 954.463 399.473 6083.937
IGHG3_HUMAN 577.374 245.615 166.819 2341.727 545.872 245.723 120.910 2306.035
IGHG4_HUMAN 797.155 686.325 3.363 4997.327 895.961 799.821 7.041 6297.100
IGHM_HUMAN 865.949 632.629 145.548 9182.313 944.944 759.086 156.260 12047.425
IGJ_HUMAN 34.798 18.469 7.294 210.097 33.563 19.134 7.488 230.792
ITIH1_HUMAN 92.540 16.074 1.848 141.905 86.612 16.168 0.378 136.352
ITIH2_HUMAN 248.962 44.436 102.898 408.489 246.662 50.109 84.643 426.426
ITIH4_HUMAN 226.744 71.299 22.076 447.146 223.637 72.469 20.231 458.562
KLKB1_HUMAN 31.731 7.155 6.645 60.502 30.247 6.529 7.100 55.877
KNG1_HUMAN 176.877 29.257 111.625 319.207 166.871 28.358 102.994 332.672
MBL2_HUMAN 0.349 0.220 0.038 1.475 0.267 0.171 0.024 1.193
PEDF_HUMAN 16.531 3.949 6.793 32.835 10.938 2.704 3.855 23.073
PGRP2_HUMAN 54.927 9.489 32.825 94.089 33.701 6.058 18.155 52.141
PLF4_HUMAN 0.612 0.406 0.137 5.556 0.384 0.349 0.056 4.122
PLMN_HUMAN 153.924 25.179 23.527 265.009 154.423 25.607 24.967 253.143
PON1_HUMAN 31.670 9.547 8.318 73.051
RET4_HUMAN 49.548 14.642 17.654 156.953 45.673 13.944 10.879 145.573
SAA4_HUMAN 26.766 7.331 1.074 52.762 25.101 7.271 0.511 56.253
SEPP1_HUMAN 4.365 0.936 1.895 8.316 3.702 0.734 1.388 5.965
SHBG_HUMAN 5.628 2.701 1.071 17.535 5.243 2.472 1.342 18.410
STOM_HUMAN 0.998 0.448 0.259 3.109 0.173 0.138 0.002 1.889
TETN_HUMAN 6.796 1.242 3.062 10.846 6.117 1.137 2.987 9.418
THBG_HUMAN 10.618 2.630 2.640 23.888 8.970 2.210 2.471 17.271
THRB_HUMAN 136.630 27.319 46.466 265.002 145.120 29.609 43.610 259.316
Total IGHG 9050.800 2197.207 2995.452 22761.999 10136.147 2582.882 3398.767 24142.232
TRFE_HUMAN 1686.141 294.745 793.800 2915.196 1793.694 327.922 987.705 3063.628
TTHY_HUMAN 56.336 18.314 15.944 131.699 44.653 15.820 9.640 119.418
VTDB_HUMAN 345.845 66.240 171.631 559.691 368.598 74.985 188.409 662.881
VTNC_HUMAN 154.421 26.624 75.181 254.593 149.864 27.323 73.685 269.201
ZA2G_HUMAN 32.305 6.274 15.506 76.090 28.541 6.000 12.947 71.777
wrong RT window
